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Abstract	
Energy	 balance,	 when	 energy	 intake	 (EI)	 equals	 energy	 expenditure	 (EE),	 is	 key	 in	 the	
maintenance	 of	 body	weight	 and	 composition.	 Pre-menopausal	women	 seem	 to	 experience	
fluctuations	 on	 both	 sides	 of	 the	 energy	 balance	 equation	 and	 this	 seems	 to	 respond	 to	
changes	in	the	ovarian	hormones,	estradiol	(E2)	and	progesterone	(P4)	within	a	menstrual	cycle	
(MC).	 In	 light	of	the	current	prevalence	of	overweight	and	obese	 in	the	female	population,	 it	
seems	imperative	to	have	a	better	understanding	of	the	influence	of	the	ovarian	hormones	on	
energy	regulation	in	pre-menopausal	women.	
This	thesis	aimed	to:	examine	the	fluctuations	in	salivary	and	plasma	ovarian	hormones	within	
a	 MC	 in	 naturally	 cycling	 (NC)	 women	 and	 hormonal	 contraceptive	 (HC)	 users;	 investigate	
whether	resting	metabolic	rate	(RMR)	significantly	changed	throughout	the	MC	in	NC	women	
and	 in	 HC	 users;	 explore	 the	 association	 between	 RMR	 and	 the	 ovarian	 hormones;	 and	
investigate	 whether	 appetite	 responses	 to	 the	 same	 breakfast	 changed	 throughout	 the	MC	
phases.	
Ovarian	hormones	in	plasma	experienced	a	greater	fluctuation	than	in	saliva	within	a	MC	and	
this	affected	the	correlation	and	the	ratio	between	the	two	collection	specimens.	Increases	in	
RMR	in	the	 luteal	 (LPh)	compared	to	the	other	MC	phases	 in	NC	women	were	observed,	but	
were	not	statistically	significant	despite	showing	clinically	meaningful	fluctuations.	Salivary	P4	
contributed	to	the	variance	of	RMR	seen	in	the	LPh.	Finally,	gastric	emptying	(GE)	time	and	PYY	
response	 to	 a	 standardized	 breakfast	 changed	 significantly	 across	 the	MC;	 the	 LPh	 had	 the	
fastest	 GE	 time	 and	 the	 smallest	 PYY	 response	 of	 all	 the	 phases.	 P4	 and	 E2-P4	 ratio	 were	
significantly	correlated	to	GE	time.	
The	 findings	 suggest	 that	 NC	women	might	 experience	 changes	 in	 their	 inherent	 regulatory	
mechanisms	by	which	energy	homeostasis	is	achieved	within	a	MC.	Whether	these	regulatory	
changes	 are	 beneficial	 or	 not	 in	 the	maintenance	 of	 body	weight	 in	 the	 long	 term	 remains	
unknown.	
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1. Literature	review	
1.1. The	menstrual	cycle:	overview	
From	the	age	of	12-13	years	when	the	menarche,	 i.e.	 the	first	menstrual	period	occurs,	until	
the	 age	 of	 45-55	 years	 when	 menopause	 begins,	 healthy	 women	 experience	 an	 ordered	
sequence	 of	 hormonal	 and	morphological	 events	 that	 repeat	 every	 month	 with	 the	 aim	 to	
promote	human	reproduction;	this	is	the	menstrual	cycle	(MC).	
The	 coordination	 of	 these	 events	 relies	 on	 a	 hypothalamic-pituitary-ovarian/gonadal	 (HPG)	
close	 relationship	 perfectly	 synchronised.	 As	menstruation	 ceases	 at	 the	 beginning	 of	 a	MC,	
the	 hypothalamus	 releases	 the	 gonadotropin	 releasing	 hormone	 (GnRH)	 to	 stimulate	 the	
anterior-pituitary	 to	 synthesise	 the	 luteinising	 hormone	 (LH)	 and	 the	 follicle-stimulant	
hormone	(FSH).	These	two	gonadotropins	will	induce	the	progressive	production	of	oestrogen	
in	 the	ovary	which	 is	 the	hormone	 responsible	 for	 the	growth	and	maturation	of	 the	 follicle	
containing	the	oocyte,	hence	why	this	is	called	the	follicular	phase	(FPh).	It	can	also	be	called	
the	proliferative	phase	as	it	represents	the	time	of	repair	and	growth	of	the	endometrium	of	
the	uterus	post-menstruation.	As	estradiol	concentrations	reach	the	first	peak	during	the	MC	
they	will	 induce	 a	 sudden	 and	 sharp	 rise	 in	 LH	 that	will	 stimulate	 the	 release	 of	 the	 oocyte	
from	 the	 ovary	 to	 the	 fallopian	 tube,	 i.e.	 ovulation,	 within	 24-48h.	 From	what	 is	 left	 of	 the	
follicle	in	the	ovary,	i.e.	the	corpus	luteum,	the	other	ovarian	hormone	i.e.	progesterone,	along	
with	oestrogen,	 is	synthesised.	Progesterone	will	be	 in	charge	of	finalising	the	preparation	of	
the	endometrium	by	increasing	the	surface	area	of	the	endometrial	glands	and	by	stimulating	
the	 secretion	 of	 different	 nutrients	 that	 will	 allow	 the	 implantation	 and	 survival	 of	 the	
fertilised	egg	 in	 the	uterus;	 thus	 the	post-ovulatory	phase	 is	 called	 the	 luteal	phase	 (LPh)	or	
secretory	phase.	 If	 the	oocyte	does	not	get	 fertilised,	 the	cycle	will	 finish	by	the	cessation	of	
the	 production	 of	 the	 ovarian	 hormones	 and	 the	 shedding	 of	 the	 endometrium	 (menses)	
which	will	subsequently	stimulate	the	secretion	of	GnRH	to	begin	with	a	new	cycle	(Ferin	et	al	
1993).	
		
1.1.1. The	ovarian	hormones:	estradiol	and	progesterone	
Each	MC	will	 last	for	approximately	28	days	(usually	between	22	and	36	days)	and,	according	
to	the	changes	that	occur	 in	 the	ovarian	hormones,	 it	can	be	divided	 in	three	MC	phases	 (1)	
the	menstrual	phase	(MPh)	when	oestrogen	and	progesterone	are	at	very	low	concentrations,	
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(2)	the	FPh	when	oestrogen	levels	gradually	increase	until	a	peak	after	which	ovulation	occurs	
and	 (3)	 the	 LPh	 in	which	oestrogen	 and	progesterone	progressively	 increase	until	 they	peak	
and	then	drop,	provided	the	egg	has	not	been	fertilised.	
Oestrogen	 and	 progesterone,	 (along	 with	 the	 other	 steroid	 hormones,	 such	 as	 androgens,	
glucocorticoids	 and	mineralocorticoids),	 are	 the	 product	 of	 the	 different	 enzymatic	 changes	
originated	 from	 the	 27	 carbons	 (C)	 steroid	 hormone	 cholesterol.	 As	 shown	 in	 Fig	 1.1,	
progestagens	are	derived	from	the	first	step	in	the	conversion	of	cholesterol	which	results	 in	
21C	hormones	 from	which	the	most	predominant	 is	progesterone	 (P4).	To	obtain	androgens,	
the	conversion	from	progestogens	by	losing	two	carbons	is	required,	thus	androgens	are	made	
of	19C.	Of	all	the	androgens,	testosterone	(T)		is	the	most	potent	but	only	androstenedione	is	
found	at	similar,	rather	than	lower,	concentrations	in	women	and	men	to	serve	as	a	precursor	
of	 oestrogens	 via	 direct	 aromatisation	 to	 oestrone	 (E1)	 or	 through	 the	 conversion	 to	
testosterone	first	and	then	to	estradiol	(E2)	(Heffner	and	Schust	2014).	Oestrogens	are	formed	
of	18C	and	E2	is	the	most	potent	of	all,	hence	its	research	interest.	Although	the	gonad	organs,	
i.e.	the	ovaries	for	women,	are	the	main	producers	of	the	sex	steroid	hormones	(progestogens,	
androgens	and	oestrogens)	 the	adrenal	gland	also	contributes	 in	 the	production,	mainly	as	a	
result	of	the	synthesis	of	the	corticoids	(nevertheless,	their	function	becomes	more	significant	
during	pregnancy	or	at	menopause).	
Fig	1.1.	Steroid	hormone	biosynthesis	from	(Hu	et	al	2010).	
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The	synthesis	of	oestrogens	in	the	ovary	is	regulated	by	the	response	of	the	theca	cells	to	the	
presence	of	LH,	which	will	facilitate	the	conversion	of	cholesterol	to	androstenedione,	as	well	
as	the	aromatisation	from	androstenedione	to	oestrogen	induced	by	the	FSH	in	the	granulosa	
cells.	
The	 sex	 steroid	hormones	E2	 and	T	 are	 transported	 in	 the	bloodstream	by	 the	 same	carrier,	
namely	 the	 sex	hormone-binding	globulin	 (SHBG).	 In	 fact	~70%	of	 the	 total	of	each	of	 these	
hormones	are	bound	to	this	globulin	while	30%	are	carried	in	a	weaker	bond	to	albumin,	thus	
allowing	 only	 1-2%	of	 the	 total	 concentrations	 free	 and	 ready	 to	 access	 to	 the	 target	 tissue	
(Tenovuo	1989).	Similar	relative	concentrations	of	free	P4	are	found	in	blood.	Moreover,	P4	can	
also	be	weakly	bound	to	albumin.	However,	about	half	of	the	conjugated-P4	in	blood	is	carried	
more	strongly	with	another	protein,	namely	the	cortisol	binding	globulin	(CBG),	which	 is	also	
used	by	cortisol	(Bentley	1980).	
	
1.1.2. Hormonal	contraceptives	(HC)	
Since	the	late	1940’s	when	Dr	Carl	Djerassi	synthesized	for	the	first	time	“the	pill”	that	could	
“arrest	ovulation”	in	women,	many	different	approaches	to	women’s	birth	control	have	been	
proposed	and	its	acceptance	and	use	within	the	society	has	changed	enormously.	In	fact,	the	
advances	 in	technology	have	not	only	allowed	the	dose	of	the	oral	contraceptives	(OC)	to	be	
less	 than	 a	 third	 of	 the	 original	 content,	 but	 also	 new	 hormone	 delivery	 systems	 e.g.	
contraceptive	 vaginal	 rings,	 patches,	 injections	 and	 implants,	 have	 been	 launched	 into	 the	
world	market	 (Liao	 and	Dollin	 2012).	 Therefore,	 in	 2006-07	 76%	of	 the	women	of	 16-49y	 in	
Great	Britain	were	using	at	least	one	form	of	contraception,	of	which	43%	were	some	type	of	
hormonal	contraceptives	(HC)	(FPA	2007).	
HC	can	be	classified	 in	 two	groups	according	 to	 their	 composition.	 Firstly,	 the	combined	HC,	
which	 is	 the	 most	 commonly	 used	 and	 includes	 a	 portion	 of	 synthetic	 oestrogen	 (mainly	
ethinlyestradiol)	 and	another	of	 a	progestogen	 (which	 can	be	of	many	different	 forms).	 This	
category	 can	 be	 further	 categorised	 depending	 on	 the	 release	 pattern	 of	 the	 contained	
hormones	throughout	the	MC:	monophasic,	biphasic	and	triphasic	combinations.	Monophasic	
combinations	supply	both	hormones	constantly	at	the	same	concentrations,	whereas	biphasic	
and	triphasic	combinations	(less	popular)	provide	two	and	three	different	dosages	of	the	two	
hormones,	 respectively,	 throughout	 the	MC.	 Finally,	 the	progesterone-only	HC	 is	 formulated	
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only	 by	 progestagens	 and	 it	 is	 less	 used,	 being	 mainly	 prescribed	 to	 women	 of	 a	 higher	
cardiovascular	risk	(Frye	2006).	
HC	action	is	primarily	based	on	preventing	the	development	of	the	follicle	and	thus	ovulation	
by	the	 induced	inhibition	of	the	FSH	and	LH	secretion	by	the	 intake	of	exogenous	hormones.	
Furthermore,	they	enhance	their	function	by	targeting	peripheral	parts	of	the	ovaries	such	as	
the	 endometrium	 and	 the	 cervix	 by	 making	 the	 entry	 and	 implantation	 environment	 more	
hostile	 for	 the	sperm	(Monga	and	Dobbs	2011).	As	 the	 two	gonadotropins	are	 inhibited,	 the	
synthesis	 of	 ovarian	 hormones	 is	 expected	 to	 be	 affected.	 The	 effect	 of	HC	on	 testosterone	
levels	was	examined	in	a	systematic	review	and	it	was	concluded	that	HC	induced	alterations	
in	the	free-	and	bound-testosterone	levels,	which	were	significantly	reduced	while	their	carrier	
i.e.	 SHGB,	 was	 significantly	 increased	 (Zimmerman	 et	 al	 2014).	 Furthermore,	 significant	
increases	in	CBG	have	also	been	observed	(Granger	et	al	2009),	thus	suggesting	an	impact	on	
total	and	free	ovarian	concentrations.	
	
1.1.3. Methods	for	monitoring	the	MC	phases	
Natural	MC	can	vary	widely	from	the	typical	“28-days”	cycle	described	in	text	books	in	which	
ovulation	 occurs	 in	 day	 14	 and	 the	 FPh	 and	 LPh	 are	 equally	 distributed	 around	 this	 event.	
Indeed,	 the	MC	 and	 its	 phases	 not	 only	 vary	 in	 length	 between	 individuals,	 but	 also	within	
individuals.	A	study	by	Fehring	et	al	(2006)	demonstrated	how	~43%	of	141	women	that	were	
followed	 during	 ~5.2	MCs	 displayed	 an	 intra-cycle	 length	 variation	 of	 7-14	 days.	Moreover,	
they	showed	that	the	variability	of	the	length	was	mainly	dependant	on	the	length	of	the	FPh	
rather	 than	the	LPh	 (34	vs.	9	%	of	 the	participants	had	a	 longer	 than	seven	day	 intra-phases	
variability	 for	 the	FPh	and	LPh,	respectively).	These	natural	variations	will	have	an	 impact	on	
the	design	of	any	MC	related	study	as	these	are	indicating	differences	in	the	time	exposure	of	
each	of	the	ovarian	hormones	per	MC.	
For	 the	 last	 decades,	 saliva	 samples	 have	 progressively	 become	 a	 common	method	used	by	
researchers	and	clinicians	to	measure	and	monitor	levels	of	hormones	such	as	cortisol	and	sex	
steroids	(Gröschl	2008).	The	benefits	of	this	technique	versus	the	traditional	vein-puncture	are	
the	 non-invasive,	 stress-free	 and	 easy	 to	 collect	 and	 store	 characteristics	 that	 define	 this	
method.	Moreover,	 the	salivary	hormone	 levels	solely	provide	 the	unbound	 (free	of	protein)	
portion	of	the	total	volume	(Bellem	et	al	2011),	these	have	shown	a	high	correlation	with	the	
total	or	a	portion	(i.e.	free	or	bound)	of	the	hormone	levels	measured	in	blood	(Hofman	2001).	
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For	example,	Bolaji	 (1994)	showed	that	P4	concentrations	assessed	 in	saliva	and	serum	were	
highly	correlated	(r	=	0.974,	p	<	0.0001)	in	a	population	of	23	healthy	regular	menstrual	cycling	
women.	 Both	 samples	 were	 collected	 on	 a	 single	 day	 within	 15	min	 at	 7.00-10.00	 am	 in	 a	
fasted	state.	Saliva	was	analysed	using	a	non-isotopic	solid-phase	EIA	(enzyme	immunoassay).	
Although	the	results	of	this	study	showed	the	natural	change	of	P4	 levels	 in	saliva	during	the	
different	phases	of	the	MC	(i.e.	≤250	and	251-885	pmol/l	in	the	FPh	and	LPh,	respectively),	the	
author	of	the	study	failed	to	fully	specify	how	the	MC	phases	were	assessed	and	the	number	of	
participants	included	in	each	phase.	In	addition,	the	findings	might	have	been	more	persuasive	
if	 two	 measurements	 had	 been	 taken	 from	 the	 same	 participants,	 i.e.	 one	 in	 each	 of	 the	
phases	of	the	MC.		
In	fact	this	is	what	De	Boever	et	al	(1986)	did	in	their	study	in	which	seven	women	provided	a	
saliva	 sample	 every	 two	 or	 three	 days	 throughout	 their	 MC.	 In	 this	 study,	 the	 researchers	
employed	a	direct	solid-phase	chemiluminescence	immunoassay	(CIA)	to	measure	P4	in	saliva.	
The	results	confirmed	that	P4	concentrations	vary	across	the	MC,	 i.e.	178	±	46,	313	±	90	and	
658	±	166	pmol/l	in	the	FPh	(days	-11	to	-3),	periovulatory	period	(days	-2	to	+1)	and	LPh	(days	
+2	 to	 +11),	 respectively,	 although	 they	 failed	 to	 state	 whether	 these	 differences	 were	
significant.	Moreover,	they	also	measured	serum	samples	in	two	occasions	during	the	FPh,	and	
three	times	in	the	periovulatory	and	LPh.	Similarly,	they	found	a	positive	correlation	between	
the	96	serum	and	saliva	samples	across	the	MC	(r	=	0.88	p	<	0.001).	Furthermore,	 this	study	
showed	that	depending	on	the	phase	of	the	MC	there	was	a	different	serum-to-saliva	ratio,	i.e.	
5.1,	 16	 and	 56	 in	 the	 FPh,	 periovulation	 and	 LPh,	 respectively.	 However,	 the	 two	 different	
specimens	were	not	taken	simultaneously	thus	the	values	compared	might	have	not	taken	into	
account	 possible	 diurnal	 differences	 and	might	 have	 been	 biased	 by	 the	 averages	 obtained	
from	every	phase.	Nevertheless,	 their	 findings	 concurred	with	Cedard	et	 al’s	 (1984)	 study	 in	
which	14	women	simultaneously	provided	a	pair	of	specimens,	 i.e.	saliva	and	blood	samples,	
every	 two	 days	 throughout	 their	 MC.	 In	 this	 case,	 the	 researchers	 employed	 a	
radioimmunoassay	(RIA)	for	the	analysis	of	the	saliva	samples.	Their	results	showed	that	in	the	
FPh	P4	levels	in	saliva	were	significantly	lower	than	in	the	mid-LPh	(48-254	and	184-566	pmol/l,	
respectively	 ranges).	 Furthermore,	 there	 was	 a	 positive	 correlation	 between	 salivary	 and	
plasma	P4	during	the	mid-LPh	(r	=	0.63)	(n	=	39)	(p<0.001).	In	agreement	with	De	Boever	et	al	
(1986),	 this	 study	 showed	 that	 the	 saliva:plasma	 ratio	 changed	 substantially	 during	 the	
different	phases	of	the	MC	i.e.	0.0532	and	0.0112	in	the	FPh	and	LPh.	
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Nevertheless,	 that	 is	 not	 in	 complete	 agreement	 with	 some	 other	 studies.	 In	 fact,	 a	 recent	
investigation	by	Konishi	and	colleagues	(2012)	demonstrated	that	this	correlation	is	altered	by	
an	 individual	saliva-to-blood	ratio.	 In	this	case,	they	compared	cortisol	and	P4	concentrations	
of	saliva	against	serum	obtained	from	finger	pricks	once	a	week	for	4	consecutive	weeks	(n	=	
48)	 or	 daily	 for	 40	 consecutive	 days	 (n	 =	 10)	 (a	 validation	 study	 of	 the	 finger	 prick	 blood	
samples	 had	 previously	 been	 conducted).	 The	 participants	 self-took	 both	 specimens	
simultaneously	 at	 the	 time	of	 the	 day	 that	 suited	 them	best	 (between	 5.00am-6.00pm)	 and	
they	 stored	 the	 samples	 at	 home.	 Dried	 blood	 spot	 samples	 from	 the	 finger	 pricks	 were	
collected	in	a	filter	paper	and	analysed	by	EIA	and	saliva	samples	were	collected	from	passive	
drool	 and	 analysed	 using	 EIA	 (by	 Salimetrics	 Salivary	 Assay	 kits).	 Both	 techniques	 showed	 a	
positive,	 but	 weaker	 correlation	 (r	 =	 0.345,	 p	 <	 0.001)	 compared	 to	 the	 serum-saliva	
relationships	 in	 the	 abovementioned	 studies.	 This	may	have	been	due	 to	 the	 type	of	 assays	
employed	in	the	different	studies.	Moreover,	the	correlation	became	stronger	when	studied	in	
subgroups	 of	 high,	 medium	 and	 low-	 saliva-to-blood	 ratio	 (r	 =	 0.695,	 0.652	 and	 0.533,	
respectively)	(p<0.001	for	all).	Finally,	it	is	interesting	to	mention	that	saliva,	but	not	plasma,	P4	
levels	were	 significantly	higher	early	 in	 the	morning	 (5.00-9.00	am)	 than	 late	 in	 the	morning	
(9.00am-12.00pm)	or	in	the	afternoon	(12.00-6pm).		
Similarly	to	P4,	other	research	has	been	done	on	salivary	oestrogen	with	the	aim	of	monitoring	
the	MC.	For	example,	Worthman	et	al	(1990)	studied	saliva	E2	levels	intermittently	during	early	
to	mid-FPh	and	then	twice	a	day	(at	9.00	and	21.00	h)	at	the	late	FPh	until	concentrations	of	E2	
peaked	and	ovulation	was	detected	by	ultrasound	in	15	healthy	women.	Their	results	from	RIA	
showed	 that	 E2	 peaked	on	day	 14.4	 (i.e.	 1.2	 days	before	ovulation)	 and	 this	 occurred	on	 an	
individual	time	relative	to	ovulation.	In	addition,	they	also	measured	E2	in	saliva	and	plasma	in	
a	group	of	18	women	who	were	under	ovulation-induction	therapy	 in	which	both	specimens	
showed	a	strong	linear	relationship	with	a	saliva-to-serum	ratio	of	0.005	±	0.003.	Nevertheless,	
they	suggested	that	the	fraction	of	free	E2	in	plasma	(assuming	it	was	equivalent	to	salivary	E2)	
was	not	directly	altered	by	the	amount	of	total	E2	found	in	blood	as	there	was	no	correlation	
between	the	saliva-to-serum	ratio	and	total	plasma	E2.		
Other	findings	by	Lu	et	al	(1999)	showed	that	saliva	E2	peaked	from	17	pmol/l	(on	day	-10)	to	
45	pmol/l	(on	day	-1)	in	seven	women	and	that	serum	to	saliva	was	positively	correlated	in	all	
but	 one	 subject.	 However,	 results	 were	 solely	 statistically	 significant	 in	 five	 of	 the	 positive	
correlations.	 This	 agrees	 with	 the	 idea	 that	 remarkable	 individual	 differences	 can	 be	
encountered.	However,	 it	 is	worth	bearing	 in	mind	 that	 the	 serum	 samples	were	 taken	 in	 a	
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fasted	state	in	the	morning	whereas	saliva	samples	were	collected	from	unstimulated	saliva	at	
night	to	be	finally	analysed	by	double-antibody	RIA	with	[125I]E2.	This	may	have	influenced	the	
results	 as	 Bao	 and	 co-workers	 (2003)	 showed	 that	 free	 E2,	 likewise	 P4,	 suffers	 diurnal	 and	
ultradian	rhythms.	In	this	study	15	healthy	Chinese	women	provided	a	saliva	sample	every	2h	
for	 four	days	 (one	day	 in	each	of	 the	MC	phases:	MPh,	 late	FPh,	mid-LPh	and	 late	LPh)	 from	
20:00-06:00	 of	 the	 following	 morning.	 The	 collection	 method	 consisted	 of	 soaking	 a	 small	
polyester	 tampon	with	 saliva	 and	 the	 analyses	was	 performed	 by	 RIA.	 Their	 results	 showed	
that	 E2	 followed	 a	 rhythm	with	 circadian	 and	 ultradian	 constituents	 that	 were	 fairly	 similar	
throughout	 the	 phases	 of	 the	 MC	 despite	 the	 differences	 observed	 between	 individuals.	
Nevertheless,	the	daily	peak	in	oestrogen	appeared	to	be	later	 in	the	day	in	the	MPh	than	in	
the	 late-FPh	 and,	 unexpectedly,	 no	 significant	 differences	 in	 the	 mesors	 (“average	 around	
which	a	variable	oscillates”)	between	phases	were	observed.	This	might	be	due	to	the	fact	that	
the	 saliva	 samples	were	 taken	 solely	one	day	 in	each	of	 the	MC	phases	and	 these	were	not	
correctly	 assigned,	 yet	 an	 ovary	 ultrasonic	 examination	 was	 performed	 and	 changes	 in	 the	
body	 temperature	 were	 monitored	 to	 ensure	 the	 phase	 of	 the	 MC,	 thus	 insignificant	
differences	could	not	be	explained.		
Another	 important	feature	to	take	 into	account	when	measuring	saliva	E2	and	P4	 is	that	they	
may	exhibit	a	similar	effect	to	that	observed	in	cortisol	after	waking	up	(“the	cortisol	awaking	
response”),	i.e.	awaking	produces	a	neuroendocrine	activation	of	the	hypothalamus-pituitary-
adrenal	 (HPA)	 and	 the	 suprachiasmatic	 nucleus	 (SN)	 that	 will	 cause	 an	 increase	 in	 cortisol	
levels	after	30	and	60	min	of	waking	up.	 Interestingly,	and	differently	 to	what	happens	with	
cortisol,	the	rise	in	salivary	P4	and	E2	concentrations	after	awaking	was	only	observed	in	natural	
regular	 cycling	women	whereas	postmenopausal	women	showed	no	effect	 (Ahn	et	al	2011).	
Moreover,	 this	 response	 occurred	 simultaneously	 in	 the	 two	 hormones	 and	 with	 no	
differences	 throughout	 the	MC	phases.	These	 findings	may	suggest	 that	 the	diurnal	patterns	
showed	by	Bao	et	al	(2003)	might	have	been	confounded	by	alterations	in	the	HPA	and	SN	as	
participants	were	awaken	every	2h	during	the	sleeping	time.	
When	reviewing	the	findings	of	the	literature,	it	is	crucial	to	determine	whether	salivary	E2	and	
P4	concentrations	are	compared	/	correlated	to	the	free	portion	in	plasma	(Cedard	et	al	1984,	
Evans	1986),	or	the	total	concentrations	in	serum	(De	Boever	et	al	1986,	Bolaji	1994,	Konishi	et	
al	2012,	Worthman	et	al	1990).	Trying	to	correlate	levels	of	unbound	sex	hormones	(measured	
in	 saliva)	 against	 total	 concentrations	 (measured	 in	 plasma)	 might	 seem	 inappropriate,	
however,	Evans	(1986)	found	that	the	proportion	of	unbound	P4	in	saliva	and	plasma	was	kept	
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constant	throughout	the	phases	of	the	MC	(i.e.			̴2	and			̴90	%,	respectively),	and	that	there	was	
a	 high	 positive	 correlation	 between	 the	 two.	 Conversely,	 he	 also	 showed	 that	 the	 ratio	
between	these	two	changed	depending	on	the	phase	of	 the	MC	 i.e.	47.1	and	115	 in	the	FPh	
and	 the	 LPh,	 respectively	 (Evans	 1986),	 as	 previously	 shown	 with	 serum-to-saliva	 ratio	 (De	
Boever	 et	 al	 1986).	 Therefore,	 he	 concluded	 that	 the	 alterations	 in	 this	 ratio	 between	
specimens	 might	 be	 due	 to	 a	 change	 in	 the	 ability	 of	 the	 steroids	 to	 cross	 the	 capillary	
membranes,	rather	than	a	change	in	the	proportion	of	unbound	hormones	in	blood.	
In	 conjunction,	 these	 studies	 support	 the	 idea	 of	 using	 saliva	 sampling	 for	 E2	 and	 P4	 as	 a	
monitoring	method	of	 an	 individual’s	MC.	However,	more	 controversy	 exists	when	 trying	 to	
extrapolate	 these	 values	 into	 plasma	 or	 serum	 concentrations.	 Not	 only	might	 there	 be	 an	
individual	saliva-to-blood	ratio,	but	also	this	is	affected	by	the	phase	of	the	MC.	Moreover,	the	
use	 of	 different	 techniques	 for	 the	 collection	 and	 analyses	 amongst	 these	 studies	 has	
contributed	to	the	wide	range	of	results	regarding	the	concentrations	of	these	hormones	and	
their	correlations	in	blood.	
Nevertheless,	saliva	seems	to	be	a	reliable	method	of	monitoring	the	ovarian	function	that	also	
confers	 some	 advantages	 to	 other	 non-invasive	 techniques	 employed.	 For	 instance,	 when	
comparing	daily	saliva	samples	against	early	morning	urine	samples	throughout	the	MC,	peak	
P4	concentrations	in	the	LPh	appeared	in	urine	as	pregnanediol-3-α-glucuronide	(Pd-3-α-G)	1.8	
days	 delayed	 compared	 to	 saliva	 peak	 P4	 (Adekunle	 et	 al	 1989).	 This	 delay	 occurred	 as	 a	
consequence	of	the	metabolic	process	that	Pd-3-α-G	needs	to	go	through	before	appearing	in	
urine,	 whereas	 blood	 hormones	 passively	 diffuse	 to	 the	 saliva	 matrix	 without	 having	 to	 be	
metabolised.	However,	concentrations	of	both	specimens	were	significantly	correlated.		
Another	 non-invasive	 technique	 employed	 is	 the	 body	 basal	 temperature	 (BBT)	 which	
increases	when	P4	 is	 raised	during	 the	LPh.	This	was	demonstrated	by	 	 Lee	 (1988)’s	 study	 in	
which	 13	 naturally-cycling	 women	 and	 three	 using	 HC	 provided	 BBT	 (from	 rectal	
measurements)	during	33h	in	each	of	the	MC	phases.	The	study	revealed	that	BBT	increased	~	
0.36°C	in	the	LPh	compared	to	the	FPh	in	the	naturally-cycling	women,	whereas	no	differences	
were	observed	in	the	HC	users.	Moreover,	the	change	in	BBT	was	simultaneous	to	a	significant	
increase	in	the	levels	of	salivary	P4	in	the	LPh	compared	to	the	FPh	(526.4	±	183.78	vs.	216.0	±	
70.57	 pmol/l).	 Nevertheless,	 not	 all	 women	 experience	 an	 increase	 in	 BBT,	 even	 when	
ovulation	has	occurred	(Moghissi	1976).	
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Therefore,	 in	summary	saliva	collection	seems	to	be	not	only	a	comfortable	and	non-invasive	
technique	 for	 the	 measurement	 of	 the	 ovarian	 hormones,	 but	 also	 it	 may	 offer	 a	 reliable	
method	for	distinguishing	the	different	phases	of	the	MC.	Finally,	to	our	knowledge,	only	a	few	
studies	have	measured	 salivary	P4	 and	E2	 in	women	 taking	HC	and	none	have	examined	 the	
correlations	between	these	and	plasma	concentrations.	
	
1.2. Energy	balance:	overview	
It	is	well	known	that	metabolic	diseases	are	a	major	public	health	concern	due	to	their	impact	
on	 society’s	 life	 and	 economic	 cost	 (Yach	 et	 al	 2006).	 Of	 the	 metabolic	 diseases,	 a	 main	
concern	is	the	increasing	epidemic	of	overweight	and	obesity	present	in	the	global	population	
for	 the	 last	 decades.	 Recent	 estimated	 figures	 of	 the	 World	 Health	 Organization	 (WHO)	
showed	that	in	2014	1.9	billion	adults	aged	≥18	y	were	overweight,	i.e.	with	a	body	mass	index	
(BMI)	 of	 25-30	 kg/m2,	 and	 11	 and	 15%	 of	 the	 male	 and	 female	 adults,	 respectively,	 were	
obese,	 i.e.	 BMI	 ≥	 30	 kg/m2	 (WHO	 2015).	 As	 the	 overweight	 population	 has	 increased,	 the	
amount	 of	 people	 dieting,	 i.e.	 to	 restrict	 food	 intake	 and	 control	 eating	 patterns,	 has	 been	
simultaneously	 raised.	 In	 1998	 it	 was	 estimated	 that	 53%	 of	 the	 U.S	 overweight	 and	 obese	
women	of	≥18	years	attempted	 to	 lose	body	weight	 (BW)	 (Kruger	et	al	2004).	Nevertheless,	
attempts	to	lose	BW	are	not	always	achieved.	
Energy	balance,	namely	when	energy	expended	equals	energy	 intake,	 is	 the	key	 to	maintain	
metabolism	 in	harmony	and	BW	stable.	 In	 contrast,	 continuous	 imbalances	between	what	 is	
metabolised	 and	 what	 is	 ingested	 can	 induce	 changes	 in	 BW	 and	 body	 composition.	 It	 is	
suggested	 that	 women’s	 metabolism	 can	 vary	 across	 the	 phases	 of	 the	 MC	 as	 their	
metabolomic	profile	 of	 different	metabolites	 (e.g.	 glutamine,	 lysine)	 in	 plasma	 is	 changed	 in	
the	LPh	compared	to	the	MPh	of	the	MC	(Wallace	et	al	2010).	Having	a	better	understanding	
on	how	energy	balance	is	achieved	throughout	the	MC	might	aid	the	understanding	on	energy	
regulation	in	women.		
	
1.2.1. Energy	expenditure:	resting	metabolic	rate	
Energy	expenditure	(EE)	 is	the	sum	of	the	resting	metabolic	rate	(RMR),	physical	activity	(PA)	
and	the	thermogenic	effect	of	food	(EFSA	2013).	Of	all	these	components,	RMR	(occasionally	
referred	as	basal	metabolic	rate	-BMR-),	i.e.	the	energy	required	by	the	body	cells	to	maintain	
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postabsorptive	 homeostatic	 functions	 in	 resting	 subjects	 (Wang	 et	 al	 2001),	 is	 the	 most	
important	component	of	total	EE	(TEE)	(i.e.	~70%	TEE)	(Payne	and	Waterlow	1971).	Therefore,	
its	 determination	 is	 crucial	 in	 order	 to	 assess	 the	 daily	 individual	 energetic	 requirements,	
particularly	 in	 overweight	 and	 obese	 populations	 whose	 estimated	 RMR	 by	 prediction	
equations	can	be	remarkably	inaccurate	in	some	cases	(i.e.	>10%	difference	to	the	actual	RMR)	
(Frankenfield	et	al	2003).	Consequently,	measuring	RMR	using	indirect	calorimetry	may	enable	
us	 to	 have	 a	 better	 understanding	 of	 an	 individual’s	 requirements.	 Differences	 in	 RMR	 are	
attributed	to	age,	gender,	race,	PA	and	body	composition	(Arciero	et	al	1993,	Speakman	and	
Westerterp	2010).		
Van	 Pelt	 et	 al	 (1997)	 studied	 RMR	 in	 pre-	 and	 postmenopausal	 women	 with	 the	 aim	 to	
demonstrate	an	age	effect	on	RMR	when	adjusted	by	fat	mass	(FM)	and	fat	free	mass	(FFM).	
Moreover,	due	to	the	potential	influence	of	fitness	on	this	parameter,	the	authors	investigated	
this	 phenomenon	 by	 subdividing	 participants	 into	 sedentary	 and	 endurance	 trained	 groups.	
Aerobic	fitness	was	assessed	by	measuring	their	maximal	oxygen	uptake	(VO2max).	The	MC	was	
controlled	by	having	the	premenopausal	women	studied	at	the	early	FPh	(days	1-10)	and	none	
of	them	was	taking	HC.	Of	the	post-menopausal	women,	eight	out	of	15	in	each	subgroup	was	
under	 oestrogen-based	 hormone	 supplements.	 Their	 results	 showed	 that	 adjusted	 RMR	
(RMRadj)	decreased	by	10%	 in	sedentary	postmenopausal	women	compared	to	 their	younger	
counterparts.	 Conversely,	 there	 was	 no	 difference	 between	 pre-	 and	 postmenopausal	
endurance	trained	women.	This	suggests	that	PA	status	may	modulate	changes	in	RMR	caused	
by	aging.	 In	fact,	a	significant	correlation	was	found	not	only	between	RMRadj	and	VO2max	(r	=	
0.48),	but	also	VO2max	accounted	for	35	%	of	the	RMRadj	variance	in	women.	This	indicated	that	
a	 higher	 VO2max	 accomplished	 by	 long-term	 endurance	 training	 could	 potentially	 impair	 the	
age-decreasing	 effect	 on	 RMRadj	 observed	 in	 sedentary	 women.	 Nevertheless,	 the	 authors	
failed	 to	 report	 whether	 there	 were	 any	 differences	 in	 RMR	 between	 the	 sedentary	 and	
endurance	trained	populations.	Despite	expecting	significant	differences	between	trained	pre-	
and	 sedentary	 postmenopausal	 women,	 this	 might	 not	 have	 happened	 when	 comparing	
sedentary	pre-	against	 trained	postmenopausal	women.	Therefore,	although	being	physically	
active	during	youth	and	adulthood	might	be	a	good	method	to	maintain	a	high	RMRadj,	starting	
PA	at	a	later	stage,	e.g.	mid-thirties,	might	also	have	a	positive	impact	on	RMRadj	at	later	stages	
of	life,	thus	it	should	be	recommended	to	all	women	regardless	their	age.		
Arciero	 et	 al	 (1993)	 demonstrated	 that	 women	 had	 23%	 lower	 RMR	 than	 men	 in	 general,	
regardless	of	the	age	subgroup	(i.e.	pre-	or	postmenopausal	women	against	younger	or	older	
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men).	Moreover,	when	adjusting	RMR	with	FFM,	FM	and	aerobic	fitness	the	differences	were	
maintained,	 yet	 reduced	 due	 to	 their	 high	 contribution	 to	 RMR.	 Young	men	 had	 4%	 higher	
RMRadj	 than	 premenopausal	 women	 and	 older	 men	 had	 5%	 higher	 RMRadj	 than	
postmenopausal	women.	The	reason	behind	the	gender	difference	despite	controlling	for	body	
composition	 and	 fitness	 could	 not	 be	 explained	 by	 the	 study;	 however,	 the	 same	 group	 of	
researchers	had	previously	demonstrated	that	Na+-K+-ATPase	activity,	which	is	related	to	RMR,	
was	 reduced	 in	women,	 thus	potentially	 accounting	 for	 the	difference.	 Finally,	 in	agreement	
with	Van	Pelt	 et	 al	 (1997)’s	 results	 in	 the	 subset	of	 endurance	 trained	women,	Arciero	et	 al		
(1993)	 found	 no	 differences	 in	 RMRadj	 between	 pre-	 and	 post-menopausal	 women.	
Nevertheless,	this	sample	included	women	of	a	wide	range	of	aerobic	fitness	levels,	compared	
to	endurance	trained	women	in	Van	Pelt’s	study,	although	Arciero	adjusted	RMR	with	VO2peak	
thus	confirming	the	impact	of	age	and	physical	fitness	on	RMR.	
Forman	 et	 al	 	 (1998)	 investigated	 RMR	 in	 inactive	 obese	 African-American	 and	 Caucasian	
women	and	found	that	the	former	had	a	9%	lower	RMR	compared	to	the	latter.	The	authors	
controlled	 age,	 body	mass	 index	 (BMI),	 habitual	 PA,	 fitness	 status,	 and	MC,	 thus	 it	 seemed	
conclusive	 that	 race	 could	 therefore	 make	 a	 difference	 in	 RMR,	 namely,	 obese	 sedentary	
African-American	 women	 appeared	 to	 be	 more	 energetically	 efficient	 than	 their	 Caucasian	
counterparts.	Moreover,	when	RMR	was	controlled	by	FFM,	the	difference	between	the	two	
increased	 to	 12%,	 making	 evident	 the	 race-effect	 and	 this	 was	 attributed	 to	 metabolic	
differences	between	obese	African-American	and	Caucasian	women.	
As	 aforementioned,	 understanding	 and	 calculating	 RMR	 in	 overweight	 and	 obese	 people	 is	
crucial	to	accurately	address	their	enhanced	energetic	needs.	Although	one	could	assume	that	
their	higher	BW	would	explain	the	greater	RMR	in	adults,	actually,	FFM	has	been	shown	to	be	
more	 strongly	 correlated	 to	RMR	 than	BW	 (Ravussin	et	 al	 1982).	 Therefore,	on	basis	of	 a	2-
compartment	model	of	body	composition	with	FM	and	FFM	as	parts	of	the	total	BW,	different	
authors	 have	 tried	 to	 find	 an	 equation	 that	 better	 defines	 RMR.	 Nelson	 et	 al	 (1992)	 tested	
different	mathematical	models	in	a	large	population	of	adult	men	and	women	that	were	non-
obese	and	obese	(i.e.	with	a	%FM	>	20%	in	men	and	>30%	in	women)	and	demonstrated	that	
FFM	 accounted	 for	 the	 majority	 of	 variance	 in	 RMR.	 Conversely,	 after	 controlling	 for	 FFM,	
differences	 in	 FM	would	 have	 a	 minor	 effect	 on	 RMR.	 That	 was	 due	 to	 the	 higher	 relative	
metabolic	 rate	 of	 FFM	 over	 FM.	 However,	 yet	 the	 best	 predictive	 model	 contained	 both	
covariates	because	although	FM	might	not	have	a	great	impact	on	RMR	after	controlling	FFM	
in	lean	individuals,	RMR	differences	between	lean	and	obese	stop	being	significant	solely	when	
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FM	 (36%	 difference	 between	 groups)	 was	 added	 into	 the	 equation.	 Nevertheless,	 that	
equation	 just	 accounted	 for	 the	 74%	 of	 the	 RMR	 variance,	 thus,	 other	 possible	 parameters	
needed	to	be	studied	to	fully	predict	RMR.	
Supporting	 the	 impact	of	FM	on	RMR,	Bosy-Westphal	and	colleagues	 (2008)	demonstrated	a	
concomitant	 increase	 of	 RMR	 in	 women	 with	 differing	 %FM.	 Nonetheless,	 it	 is	 worthwhile	
mentioning	 that	 differences	 in	 RMR	between	%FM	 categories	within	 >10-≤50	%FM	were	 no	
longer	observed	after	controlling	 for	age,	FFM	and	FM.	Furthermore,	 this	study	showed	that	
FM	impact	in	RMR	increased	with	adiposity	in	agreement	with	Nelson	et	al	(1992).	However,	in	
severely	obese	(>	40	%FM)	and	severely	lean	women	(≤	10	%FM),	RMR	did	not	relatively	relay	
further	 on	 FM.	 Authors	 could	 not	 explain	 the	 reason	 behind	 the	 alterations	 on	 the	 relative	
impact	of	each	body	composition	component	in	RMR.	
Recently,	 Javed	 et	 al	 (2010)	 aimed	 to	 improve	 these	 predictive	 models	 by	 including	 the	
abovementioned	variables	(i.e.	age,	gender,	race,	BW	and	body	composition)	and	adding	FFM	
in	 its	 components,	 thus,	 the	 liver,	 kidney,	 spleen,	 heart	 and	 brain	 (i.e.	 high	 metabolic	 rate	
organs	–HMRO-)	 in	their	specific	relative	metabolic	rates	into	the	predictive	equation.	Firstly,	
their	results	predicted	~68%	of	the	RMR	variance	after	including	age,	sex,	race,	BW	and	height.	
By	 changing	 BW	and	 height	 to	 FM	 and	 FFM,	 the	model	 improved	 to	 ~70%	of	 the	 predicted	
RMR	variance	and	sex	became	an	insignificant	variable.	Moreover,	by	adding	the	HMRO	of	the	
trunk	 (thus,	 excluding	 the	 brain	 of	 HMRO)	 the	 model	 enhanced	 another	 3%	 of	 the	 RMR	
variance	 and	 dismissed	 the	 statistical	 significance	 of	 race	 contribution	 to	 the	 predictive	
equation.	Finally,	the	inclusion	of	the	brain	improved	the	predicted	variance	of	RMR	to	~75%.	
This	suggested	that	sex,	race	and	age	impact	on	RMR	actually	responded	to	the	differences	in	
HMRO	that	occur	with	age	and	between	sexes	and	races.	Nevertheless,	the	last	model	still	did	
not	resolve	the	25%	remaining	variance	of	RMR.	Different	possibilities	could	underlie	this	such	
as	 an	 individual	 RMR	 for	 each	 organ	 or	 the	 need	 to	 add	 other	 HMRO	 to	 the	 equation.	
Therefore,	other	studies	are	required	to	further	understand	the	variables	affecting	RMR.	
	
1.2.1.1. RMR	during	the	MC	
Although	all	the	abovementioned	factors	that	determine	the	RMR	of	a	person	are	rather	stable	
on	a	day-to-day	basis,	whether	RMR	is	kept	constant	daily	and	more	specific,	throughout	the	
course	of	a	MC	is	the	question	that	has	brought	discrepancies	between	studies	for	many	years.	
Daily	variability	of	RMR	has	been	measured	by	looking	at	its	coefficient	of	variance	(CV)	from	
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repeated	measurements	on	the	same	subject.	Despite	the	low	values	found	in	men	i.e.	2.5-4.0	
%	(Henry	et	al	1989),	wider	ranges	1.7-12.0	%	(Curtis	et	al	1996,	Diffey	et	al	1997,	Henry	et	al	
2003)	have	been	found	in	women	which	may	be	due	to	the	potential	effect	that	the	MC	may	
have	on	energy	balance	during	phases	of	the	MC.		
In	1982,	Solomon	et	al	 showed	that	BMR,	collected	 for	10	min	every	other	day	during	 three	
MCs,	was	 suppressed	 from	menstruation	 to	a	week	before	ovulation	but	 raised	again	 in	 the	
LPh	in	five	out	of	six	women.	The	average	CV	between	women	was	12%	with	an	individual	CV	
ranging	 from	6-9	%,	 thus	making	 evident	 the	 greater	 variance	 in	women	 compared	 to	men.	
Nevertheless,	 the	authors	did	not	provide	the	average	values	for	each	of	the	phases	and	the	
sample	size	was	small	(n	=	6),	thus	making	it	challenging	to	assume	that	this	occurs	in	the	vast	
majority	of	women.	Moreover,	diet	and	PA	were	controlled	and	therefore	whether	these	two	
components	would	have	been	altered	 in	normal	conditions	 throughout	 the	MC	and	whether	
that	would	have	affected	their	BMR	patterns	remain	unknown.	
In	 fact,	 this	 partly	 disagrees	 with	 Howe	 et	 al	 (1993)’s	 research	 as	 their	 first	 experiment	
revealed	that	1h	of	indirect	calorimetry	showed	no	differences	in	RMR	amongst	the	three	MC	
phases	 in	 a	 healthy	 but	 within	 a	 wide	 range	 of	 BMI	 (17.0-46.6	 kg/m2)	 population	 of	 14	
premenopausal	 women	 under	 free-style	 conditions.	 Moreover,	 this	 lack	 of	 change	 was	 still	
present	when	 controlling	 for	 BW	 or	 BMI.	 However,	 in	 the	 second	 experiment	with	 another	
group	 of	 12	 women	 the	 authors	 found	 that	 TEE	 (24h	 collection)	 was	 decreased	 in	 the	 FPh	
compared	to	the	other	phases.	Again	BMI	or	BW	adjustments	had	no	effect	on	the	MC	phase	
differences.	Nevertheless,	the	estimated	BMR	(extrapolated	from	sleeping	EE)	was	significantly	
higher	in	the	LPh	compared	to	the	others.		
Furthermore,	Howe	et	 al	 (1993)	 studied	exercise	EE	and	 they	 found	 that	when	exercise	was	
performed	in	the	morning	(10:30-11:00),	it	tended	to	induce	a	lower	EE	in	the	FPh	than	the	LPh	
and	MPh.	 This	 outcome	was	 quite	 surprising	 as	 no	 differences	were	 found	when	 looking	 at	
exercise	 EE	 performed	 in	 the	 afternoon	 (15:00-15:30)	 or	 the	 total	 of	 both.	 Changes	 in	
substrate	oxidation	might	have	prompted	 the	nearly	 significant	differences	 in	EE	of	morning	
exercise;	however,	the	authors	did	not	report	respiratory	exchange	ratio	(RER)	of	the	exercise	
bouts.	 Yet,	 they	 found	 similar	 values	 for	 RER	 as	 a	 24h	measurement	 across	 the	MC	phases.	
Finally,	 they	 showed	 how	 P4	 had	 an	 impact	 on	 sleeping	metabolic	 rate	 and	 24h-EE	while	 E2	
showed	no	 association	with	 these.	Whether	 these	 findings	 are	 the	 appropriate	 reflection	 of	
each	phase	still	remains	uncertain	as	these	values	were	taken	solely	on	one	day	of	each	of	the	
phases	that	had	been	selected	according	to	the	length	of	the	MC	of	each	participant.		
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In	agreement	with	Howe	et	al’s	findings,	Matsuo	et	al	(1999)	showed	that	EE	was	similar	while	
cycling	60	min	at	 a	moderate	exercise	 intensity	 (i.e.	 60	%	VO2max)	during	 the	FPh	and	 LPh	 in	
seven	Japanese	women,	without	differences	 in	RER.	However,	they	also	observed	that	EE	for	
the	6h	following	exercise	was	significantly	 increased	in	the	LPh	compared	to	the	FPh	with	an	
RER	being	significantly	lower	in	the	LPh	(i.e.	there	was	a	greater	contribution	of	carbohydrates	
(CHO)	 to	 EE	 during	 the	 FPh	 than	 the	 LPh).	 Finally,	 RMR	was	 also	measured	 for	 30	min	 in	 a	
fasted	 state	 before	 exercising	 on	 the	 testing	 day	 in	 each	 MC	 phase	 (designated	 by	 body	
temperature	 monitoring).	 Their	 results	 showed	 once	 again	 that	 RMR	 was	 significantly	
increased	in	the	LPh	compared	to	the	FPh.	Despite	not	measuring	the	ovarian	hormones,	the	
authors	associated	these	differences	in	metabolism	to	the	changes	in	oestrogen	and	P4	levels	
throughout	 the	 MC.	 In	 fact,	 another	 study	 conducted	 by	 the	 same	 group	 of	 researchers	
showed	that	RMR	and	P4	levels	were	significantly	higher	in	the	LPh	than	the	FPh	(Matsuo	et	al	
1998).	
To	 further	 support	 this	notion,	Day	et	al	 (2005)	 investigated	whether	 inducing	a	decrease	 in	
oestrogens	 (E1	 and	 E2)	 and	 P4	 levels	 by	 providing	 an	 antagonist	 of	 GnRH	 would	 cause	 a	
decrease	in	RMR.	Their	findings	showed	that	when	women	exhibited	significantly	lower	levels	
of	 oestrogens	 and	 P4	 as	 a	 response	 to	 the	 decreased	 FSH	 and	 LH,	 they	 also	 displayed	 a	
significantly	lower	RMR	compared	to	the	mid-LPh	(7-9	days	after	ovulation)	of	a	natural	cycle.	
Moreover,	they	also	showed	a	significant	reduction	in	RMR	in	the	MPh	(days	2-6)	compared	to	
the	 LPh	of	 the	natural	MC.	 It	 is	worthwhile	mentioning	 that	 the	energy	 intake	estimated	by	
food	 diaries	 and	 the	 PA	 assessed	 by	 step	 counts	 during	 three	 days	 in	 each	 phase,	 was	
maintained	during	the	different	phases.	Furthermore,	their	findings	revealed	that	despite	the	
differences	in	RMR,	substrates	metabolism	at	rest	(i.e.	RER)	did	not	exhibit	any	changes	by	the	
decrease	 of	 the	 ovarian	 hormones.	 Despite	 showing	 strong	 evidence	 for	 how	 RMR	 can	 be	
affected	 by	 significant	 reductions	 in	 the	 ovarian	 hormones	 (induced	 by	 alterations	 in	 the	
sympathetic	 nervous	 system),	 this	 study	 did	 not	 examine	 the	 impact	 that	 high	 levels	 of	
oestrogens	together	with	low	concentrations	in	P4	might	have	on	RMR;	this	is	of	relevance	as	
this	occurs	during	the	FPh.			
However,	not	all	studies	have	found	differences	in	RMR	throughout	the	MC.	For	example,	an	
investigation	 in	 which	 19	 healthy,	 premenopausal	 naturally	 cycling	 (NC)	 women	 were	
monitored	for	RMR,	BW	and	body	composition	for	at	least	three	days	a	week	for	a	MC	showed	
that	there	were	no	significant	differences	in	RMR	or	anthropometric	measurements	between	
phases	 (Henry	 et	 al	 2003).	 Nevertheless,	 this	 study	 revealed	 that	 the	 intra-individual	 CV	 for	
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RMR	 varied	 widely	 in	 women	 i.e.	 range	 of	 1.7-10.4	 %,	 therefore,	 it	 might	 be	 that	 RMR	
throughout	phases	of	 the	MC	was	 significantly	modified	 in	 some	but	not	all	 individuals.	This	
agrees	with	Curtis	et	al	(1996)	who	showed	a	CV%	range	2.93-12.0%	in	a	sample	of	19	healthy	
women,	 although	 they	 did	 find	 a	 significantly	 greater	 BMR	 in	 the	 late	 LPh	 compared	 to	 the	
early	FPh,	in	contrast	to	the	Henry	et	al	(2003)	observations.	Another	study	reporting	the	CV	of	
RMR	in	16	healthy	 Indian	women,	showed	an	average	of	7.6%	CV	which	 is	again	higher	than	
that	observed	in	men	(Piers	et	al	1995).	However,	likewise	Henry	et	al	(2003),	they	showed	no	
differences	 between	 phases	 of	 the	 same	 MC	 in	 RMR,	 although	 Piers	 et	 al	 (1995)	 solely	
measured	RMR	twice	in	each	phase.	
Moreover,	it	needs	to	be	noticed	that	in	the	Curtis	et	al	(1996)	and	Henry	et	al	(2003)	studies	
the	 phases	 of	 the	MC	 were	 estimated	 by	 self-reporting	 the	 starting	 and	 ending	 day	 of	 the	
cycle,	thus	the	assignation	of	the	phases	might	have	been	inaccurate	and	therefore	the	values	
appointed	to	each	phase	as	well.	Monitoring	the	phases	of	the	MC	by	a	reliable	method,	e.g.	
measuring	 the	ovarian	hormones,	would	have	provided	more	persuasive	 results.	 Finally,	 it	 is	
worthwhile	mentioning	that	Henry	et	al	(2003)	extended	their	study	for	a	subsequent	cycle	in	
nine	participants	and	found	no	significant	differences	in	RMR	CV%	between	MCs.		
Considering	 the	 above	 studies	 and	 assuming	 that	 changing	 levels	 in	 the	 ovarian	 hormones	
throughout	the	MC	induce	alterations	in	energy	metabolism	in	NC	women,	it	seems	rational	to	
suggest	 that	women	 taking	HC	may	 have	 a	 different	 energetic	metabolism	 as	 the	 hormonal	
patterns	are	exogenously	altered.		
	
1.2.1.2. RMR	in	women	using	HC	
Diffey	and	colleagues	(1997)	tested	whether	there	were	any	variances	in	fasting	BMR	between	
22	 NC	 women	 and	 24	 women	 taking	 OC	 (OCW).	 Their	 results	 showed	 that	 there	 were	 no	
significant	differences;	however,	when	analysing	 the	 results	 taking	 into	account	BW	or	body	
composition	(i.e.	FFM	+	FM)	OCW	appeared	to	have	~	5%	significantly	greater	BMR	than	NC.	
Moreover,	 excluding	 eight	 participants	 who	 were	 unsure	 of	 the	 day	 of	 their	 MC	 and	
maintaining	BW	and	body	composition	as	covariates,	the	comparison	between	the	two	groups	
again	 showed	 a	 significantly	 higher	 BMR	 in	 OCW	 (n	 =	 23)	 than	 in	 NC	 (n	 =	 15).	 However,	
regarding	the	MC	phase,	there	were	similar	values	for	BMR	in	the	FPh	(n	=	18)	and	LPh	(n	=	20).	
Moreover,	there	was	no	interaction	effect	between	OC	and	the	MC	phase	despite	the	greater	
BMR	observed	 in	OCW.	Nevertheless,	 these	 results	would	have	been	more	persuasive	 if	 the	
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same	 participants	were	 followed	 throughout	 the	 phases,	 rather	 than	 assessing	 BMR	 in	 only	
one	phase	as	 they	do	not	 take	 into	account	 individual	differences,	 therefore	challenging	any	
fluctuations	throughout	the	phases	of	the	MC	within	subjects.	
A	study	that	monitored	RMR	in	five	healthy	women	taking	a	monophasic	combined	OC	~5	days		
week	for	an	entire	MC	showed	no	differences	between	phases	nor	between	the	days	of	taking	
the	pill	and	the	7	days	without	the	pill	 (Curtis,	Henry	and	Ghusain-Choueiri	1996).	Moreover,	
the	range	of	the	CV%	was	lower	than	the	one	observed	in	NC	women	(Curtis	et	al	1996).	This	
would	suggest	a	better	maintenance	of	the	energy	balance	throughout	the	MC	and	therefore	a	
decreased	 risk	 on	 losing	 control	 on	 BW.	 Nevertheless,	 the	 sample	 size	 of	 the	 study	 was	
potentially	not	large	enough	to	find	possible	differences.		
Pelkman	 et	 al	 (2001)	 studied	 whether	 an	 injected	 progestin-only	 HC	 (Depo-Provera)	 could	
induce	energy	imbalances	in	a	population	of	young	healthy	women	who	had	not	taken	any	HC	
during	 the	 last	 year.	 For	 this	 purpose,	 20	 women	 were	 randomly	 assigned	 in	 one	 of	 the	
following	 groups:	 placebo	 or	 Depo-Provera	 and	 their	 RMR	 and	 food	 intake	 was	 assessed	
before	and	after	receiving	the	treatment.	There	were	four	testing	sessions	(one	in	the	FPh	and	
another	 in	 the	 LPh	 of	 two	 different	 cycles)	 before	 and	 after	 the	 intervention.	 Each	 testing	
session	included	the	measurement	of	RMR	on	the	first	day	and	the	measurement	of	24h-food	
intake	during	 three	days.	Their	 results	 showed	 that	 the	Depo-Provera	had	no	effect	on	 food	
intake,	macronutrient	intake,	BW	and	RMR.	However,	when	examining	the	phases	separately,	
there	was	a	2	%	(30	kcal/d)	increase	post-treatment	in	RMR	compared	to	the	FPh.	Conversely,	
no	 differences	 were	 observed	 compared	 to	 the	 LPh	 pre-treatment.	 Finally,	 it	 is	 worthwhile	
mentioning	 that	 data	 pre-	 treatment	 showed	 that	 energy	 intake	 and	 RMR	 were	 4.3	 %	
significantly	greater	in	the	LPh	compared	to	the	FPh.	These	results	corresponded	to	101	and	48	
kcal/d	 increase	 in	 energy	 intake	 and	 RMR,	 respectively,	 which	 could	 ultimately	 explain	 the	
significant	 rise	 in	BW	 in	 the	 LPh	 compared	 to	 the	 FPh	 (0.3	 kg).	Nevertheless,	whether	 these	
small	fluctuations	in	body	balance	might	have	an	impact	on	BW	management	in	the	long-term	
in	 NC	 women,	 remains	 uncertain.	 Nonetheless,	 only	 the	 placebo	 group	 experienced	 a	
significant	increase	in	BW	(+	0.7	kg),	therefore,	HC	may	facilitate	BW	management	as	they	may	
provide	a	more	stable	RMR	and	a	more	controlled	energy	intake.	
Caution	 is	 required	 when	 generalising	 this	 outcome	 as	 many	 different	 types	 of	 HC	 exist.	
Moreover,	 McNeill	 et	 al	 (1988)	 showed	 that	 averaged	 BMR	 significantly	 decreased	 (~170	
kcal/d	difference)	in	five	young	healthy	women	after	taking	an	OC,	causing	an	increase	in	BW	
(~0.8kg),	 albeit	 not	 significant.	 Although	 both	 studies	 were	 using	 a	 progesterone-only	 HC,	
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Pelkman	 et	 al	 (2001)	 employed	 an	 injected	 HC	 containing	 depot	 medroxyprogesterone	
acetate,	whereas	McNeill’s	HC	was	 taken	orally	 in	 a	daily	bases	 and	was	 containing	 another	
progestin,	 i.e.	 levonorgestrel.	 However,	 a	 recent	 review	 looking	 at	 BW	 and	 the	 use	 of	
progesterone-only	 HC	 found	 little	 evidence	 on	 BW	 gain	 when	 comparing	 subtypes	 of	
progesterone-only	HC	(based	on	doses,	regimens	and	formulations)	or	vs.	non-using	HC	(Lopez	
et	al	2011).	Nevertheless,	 it	was	concluded	that	more	controlled	studies	focusing	on	BW	and	
HC	should	be	conducted,	thus,	whether	HC	help	or	not	on	energy	balance	is	still	unknown.		
In	 summary,	 RMR,	 the	 most	 important	 component	 of	 TEE,	 depends	 on	 several	 individual	
factors,	e.g.	age,	 sex,	body	composition,	 that	have	not	been	 fully	elucidated.	Although	many	
studies	 have	 aimed	 to	 understand	whether	 the	MC	 can	 also	modify	 this	 part	 of	 the	 energy	
balance	equation,	it	still	remains	ambiguous.	Possible	reasons	behind	the	controversial	results	
include	incorrect	assignation	of	the	MC	phase	and	taking	measurements	solely	one	day	in	the	
MC	or	of	each	phase	which	might	not	fully	depict	the	whole	story	of	what	is	happening.		
	
1.2.2. Energy	intake	and	appetite	regulation	
It	 is	 well	 known	 that	 multiple	 body	 regulators,	 e.g.	 brain,	 blood	 glucose	 levels,	 appetite	
hormones,	 gastric	 emptying	 velocity,	 control	 our	 food	 consumption	 in	 terms	 of	what,	when	
and	how	much	do	we	eat	(Coll	et	al	2007).	However,	other	external	aspects	such	as	religion,	
food	 availability,	 hedonic	 eating	 and	 lifestyle	 can	 also	 determine	 human	 eating	 patterns	
(Näslund	and	Hellström	2013).	 In	addition,	women	might	have	an	added	aspect	which	 is	 the	
influence	of	the	MC	hormones,	precisely,	the	effect	of	the	ovarian	hormones	E2	and	P4.	These	
fluctuate	 considerably	 throughout	 the	MC	 and	 that	might	 have	 a	 final	 effect	 on	 energy	 and	
macronutrient	intake	(Dye	and	Blundell	1997).		
	
1.2.2.1. Central	and	peripheral	regulation	of	food	intake	
It	is	well	known	that	the	hypothalamus	is	the	part	of	the	brain	and	the	central	nervous	system	
(CNS)	that	is	constantly	receiving	hormonal	and	chemical	messages	regarding	the	energy	state	
of	 the	organism	to	be	able	 to	maintain	 it	 in	homeostasis	 (Schwartz	et	al	2000).	 In	particular,	
the	 arcuate	 nucleus	 (ARC)	 along	 with	 the	 paraventricular	 nucleus	 (PVN),	 the	 lateral	
hypothalamic	area	 (LHA)	and	 the	ventromedial	hypothalamic	nucleus	 (VHN)	are	 the	areas	of	
the	 hypothalamus	 that	 contain	 neurons	 that	 express	 the	 receptors	 for	 the	 hormonal	 and	
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metabolic	factors	e.g.	leptin,	ghrelin,	that	will	induce	an	orexigenic	or	anorexigenic	effect	(i.e.	
inducing	or	 inhibiting	food	intake,	respectively)	to	our	feeding	system	(Hirschberg	2012).	The	
orexigenic	 neurons	 co-express	 the	 neuropeptide	 Y	 (NPY)	 and	 the	 agouti-related	 peptide	
(AgRP),	 whereas	 the	 anorexigenic	 neurons	 co-express	 cocaine-amphetamine	 regulated	
transcript	 (CART)	 and	 pro-opiomelanocortin	 (POMC)	 and	 its	 derivate	 α-	 melanocyte-
stimulating	 hormone	 (α-MSH)	 (Schwartz	 et	 al	 2000).	 Therefore,	 for	 example,	 during	 fasting,	
leptin	 levels	 are	 decreased	 and	 CART	 will	 be	 inhibited,	 whereas	 if	 leptin	 is	 injected,	 CART	
expression	will	recovered	(Gortari	and	Joseph-Bravo	2006).	
Despite	 having	 what	 looks	 like	 a	 very	 controlled	 and	 autonomous	 feeding	 mechanism	 that	
should	 strictly	 respond	 to	 the	 physiological	 stimulus	 dictated	 by	 the	 peripheral	 hormones,	
there	exist	cortical	and	subcortical	 regions	of	 the	brain	 that	 regulate	“hedonic	eating”	which	
can	overwrite	the	hypothalamus	commands.	For	instance,	these	areas	(e.g.	anterior	cingulate,	
insula,	 amygdala,	 nucleus	 accumbens)	 can	 stimulate	 food	 consumption	 despite	 receiving	 a	
positive	 feedback	of	 the	energy	status	 in	 the	hypothalamus	(Van	Vugt	2010).	This	 is	possible	
due	 to	 the	 projections	 of	 the	 abovementioned	 neuropeptides	 into	 these	 areas	 of	 the	 brain,	
thus	both	areas	together	have	an	impact	on	EI.	 In	fact,	Frank	et	al	(2010)	demonstrated	how	
different	 areas	 of	 the	 corticolimbic	 brain	 responded	 differently	 when	 high	 and	 low	 caloric	
foods	are	presented	 in	 front	of	women	at	 the	different	phases	of	 the	MC.	More	specifically,	
they	 found	 that	 in	 the	 LPh	 certain	 reward	 areas	 of	 the	 brain	 (e.g.	 nucleus	 accumbens,	
amygdala,	 hippocampus)	 were	 only	 activated	 when	 participants	 were	 shown	 high-calorie	
foods,	whereas	in	the	FPh,	the	same	brain	areas	were	activated	by	high-,	but	also	low-calorie	
foods.	 The	 authors	 related	 these	 changes	 to	 alterations	 in	 food	 preferences	 that	 could	
ultimately	affect	food	intake.	Furthermore,	they	suggested	that	the	lack	of	activation	in	these	
areas	of	the	brain	might	have	responded	to	an	impairment	in	the	dopamine	signalling	similar	
to	what	 is	 seen	 in	obesity	 induced	hyperphagia	due	 to	 the	modulatory	action	of	 the	ovarian	
hormones	on	dopamine’s	regulation.		
As	abovementioned,	the	changes	in	the	expression	of	the	orexigenic	or	anorexigenic	neurons	
are	 dependent	 on	 the	 action	 of	 the	 peripheral	 hormones	 of	 which	 some	 will	 be	 outlined	
below:	
Leptin	 is	 a	 cytokine	 synthesised	 by	 the	 adipose	 tissue	 that	 has	 been	 shown	 to	 suppress	
appetite	 and	 re-establish	 normal	 BW	 if	 injected	 in	 those	who	 naturally	 cannot	 synthesise	 it	
because	 of	 a	 genetic	 mutation	 (Farooqi	 and	 O’Rahilly	 2009).	 Its	 concentration	 in	 blood	 has	
been	 correlated	 with	 adiposity,	 therefore	 high	 concentrations	 are	 found	 in	 obese	 people	
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because	 of	 an	 induced-leptin	 resistance	 whereas	 low	 levels	 have	 been	 reported	 in	 patients	
with	 anorexia	 nervosa	 as	 an	 attempt	 of	 the	 body	 to	 stimulate	 food	 intake	 and	 achieve	 a	
healthy	 BW	 (Germain	 et	 al	 2007).	 Interestingly	 a	 study	 in	which	 obese	 subjects	 successfully	
achieved	a	reduction	in	their	BW,	showed	that	the	provision	of	exogenous	leptin	could	reverse	
the	reduction	 in	energy	metabolism	and	satiety	 induced	by	the	BW	loss	(Kissileff	et	al	2012).	
This	 suggests	 that	 the	concomitant	and	disproportional	decrease	 in	EE	and	satiation	 induced	
by	a	reduction	in	BW	is	regulated	by	leptin.	Therefore,	leptin	is	regulated	by	the	amount	of	fat	
stores	 and	 its	 main	 role	 in	 the	 short-	 and	 long-term	 energy	 regulation	 is	 to	 ensure	 the	
availability	 of	 sufficient	 energy	 stores	 that	 can	 guarantee	 the	 survival	 of	 the	 species	
(Rosenbaum	and	Leibel	2014).	This	 is	 corroborated	by	 the	 fact	 that	 low	 leptin	 levels	cause	a	
delay	 in	 the	 physical	 maturation	 during	 puberty	 in	 children	 and	 a	 paralysation	 of	 the	
reproductive	system	in	women	(i.e.	MCs	are	annovulatory	and	amenorrheic),	which	both	can	
be	restored	by	the	provision	of	exogenous	leptin	(Farooqi	and	O’Rahilly	2009,	Mantzoros	et	al	
2011).	Furthermore,	it	has	been	shown	that	other	organs	such	as	the	ovaries	and	the	placenta,	
can	also	synthesise	leptin	(Margetic	et	al	2002).		
Ghrelin	 is	 the	only	appetite-stimulating	hormone	currently	known	and	 this	 is	 secreted	 in	 the	
fundus	 of	 the	 stomach.	 Its	 concentration	 is	 abruptly	 increased	 before	 a	 meal	 whereas	 it	 is	
suppressed	 post	 food	 consumption	 (Yin	 et	 al	 2009).	 Of	 note,	 if	 fasting	 for	 24h	 its	 secretion	
pattern	will	 be	maintained	around	usual	 eating	hours,	 i.e.	 ghrelin	 levels	decrease	after	meal	
habitual	 times	 despite	 not	 having	 ingested	 any	 food	 (Natalucci	 et	 al	 2005).	 Moreover,	 this	
hormone	 has	 the	 capacity	 of	 stimulating	 the	 release	 of	 the	 growth	 hormone	 (Messini	 et	 al	
2013).	Nevertheless,	this	will	not	occur	in	fasting	conditions	when	the	secretion	pattern	of	the	
two	hormones	differs	(Natalucci	et	al	2005).	Decreased	levels	of	ghrelin	have	been	reported	in	
obese	 humans	 (Tschop	 et	 al	 2001),	 whereas	 elevated	 concentrations	 have	 been	 found	 in	
anorexia	nervosa	patients	(Germain	et	al	2007).	After	normalizing	BW	ghrelin	levels	change	to	
healthy	 levels.	 In	 addition,	 ghrelin	 presents	 different	 isoforms,	 acyl	 ghrelin	 (with	 an	
esterification	with	n-octanoic	acid),	des-acyl	ghrelin	(without	the	esterification)	and	obestatin.	
Initially,	 it	was	 thought	 that	 the	only	 active	 form	was	 the	acyl	 ghrelin,	 however,	 it	 has	been	
recently	shown	that	the	dea-acyl	form	has	also	an	important	role	interacting	and	counteracting	
the	acyl	form	actions	(Delhanty	et	al	2012).	
Peptide	tyrosine-tyrosine	 (PYY)	 is	an	appetite	suppressor	 released	 from	the	L-cells	of	 the	gut	
that	controls	meal	size	and	termination	by	suppressing	gut	motility	(Onaga	et	al	2002).	 It	has	
been	found	in	two	different	forms:	PYY1-36	which	is	the	main	form	at	a	fasted	state	and	PYY3-36	
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which	 is	 predominant	 after	 a	 meal	 (Grandt	 et	 al	 1994).	 There	 has	 been	 found	 a	 negative	
correlation	 between	 body	 fat	 and	 PYY	 and	 its	 release	 after	 a	 meal	 is	 diminished	 in	 obese	
humans,	 however	 its	 administration	 exogenously	 can	 reduce	 food	 consumption	 in	 this	
particular	population	(Batterham	et	al	2003).	Although	the	few	studies	that	have	looked	at	the	
impact	of	 exogenous	PYY	on	EI	 did	not	differentiate	 the	effect	between	men	and	women,	 a	
study	 in	female	monkeys	showed	that,	similarly	to	male	monkeys,	the	 injection	of	PYY	 in	the	
lateral	ventricle	of	the	brain	caused	a	suppression	in	EI	that	might	be	altered	in	the	LPh	of	the	
MC	(Papadimitriou	et	al	2007).	
Glucagon-like	peptide	1	(GLP-1)	 is	another	appetite	suppressor	synthesised	by	processing	the	
proglucagon	peptide	in	the	L-cells	of	the	gut.	Its	action	is	to	inhibit	food	ingestion	by	reducing	
the	gastric	emptying	rate	of	the	stomach	after	a	meal	(Deane	et	al	2010).	Moreover,	it	has	the	
capacity	of	 lowering	blood	glucose	by	increasing	insulin	secretion	in	a	dose-manner	response	
in	healthy	and	type2	diabetics	(Kjems	et	al	2003).	Humans	suffering	from	obesity	or	anorexia	
nervosa	present	 low	 levels	of	GLP-I	 compared	 to	normal	weight	counterparts	 (Germain	et	al	
2007).		
Cholecystokinin	(CCK)	is	another	gut	hormone	produced	in	the	L-cells	of	the	gut	affecting	the	
emptying	 rate	 of	 the	 stomach	 causing	 a	 reduction	 in	 food	 intake.	 Its	 actions	 comprise	 the	
contraction	of	the	gall-bladder	and	the	stimulation	of	pancreatic	enzyme	secretion	(Hameed	et	
al	2009).	CCK	levels	increase	3-5-fold	after	the	ingestion	of	a	fat	and	protein	rich	meal	(Crawley	
and	Corwin	1994).	
To	 summarise,	 appetite	 regulation	 conforms	many	different	 internal	 and	external	 aspects	 to	
the	individual	that	make	difficult	the	prediction	of	the	nature	of	his/her	food	intake.	
	
1.2.2.2. Ovarian	hormones	and	appetite	regulation	
Animal	studies	have	shown	cyclical	changes	in	EI	throughout	the	oestrus	cycle	in	rodents	and	
throughout	 the	MC	 in	 primates;	 in	 particular,	 EI	 is	 reduced	when	 high	 oestrogen	 levels	 are	
present,	whereas	it	is	increased	when	P4	levels	are	high	(Dye	and	Blundell	1997).	Furthermore,	
the	removal	of	 their	ovaries	 results	 in	an	 increase	 in	BW	due	to	an	 increment	 in	 food	 intake	
and	reduction	in	EE	that	can	be	reversed	with	the	provision	of	oestrogens	(Mauvais-Jarvis	et	al	
2013).	
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Likewise,	 NC	 women	 undergo	 different	 eating	 patterns	 according	 to	 the	 MC	 phase.	 Many	
studies	 have	 shown	 that	women	 have	 higher	 EI	 in	 the	 LPh	 compared	 to	 the	 FPh	 of	 the	MC	
(Chung	et	al	2010,	Johnson	et	al	1994,	Li	et	al	1999,	Lyons	et	al	1989);	however,	not	all	have	
found	 significant	differences	and	 this	 could	be	due	 in	part	 to	annovulatory	 cycles	 (Barr	et	 al	
1995)	or	unconfirmed	ovulation	(Bryant	et	al	2006).	Nevertheless,	the	general	consensus	from	
different	reviews	is	that	food	intake	varies	throughout	the	MC	(Buffenstein	et	al	1995,	Dye	and	
Blundell	1997,	McNeil	and	Doucet	2012).			
In	 fact	 a	 recent	 review	 on	 the	 topic,	 showed	 that	 increases	 in	 EI	 during	 the	 LPh	 are	 of	 a	
magnitude	 of	 87-500	 kcal/d	 when	 comparing	 it	 to	 the	 FPh	 of	 the	 MC	 (McNeil	 and	 Doucet	
2012).	For	example,	Gil	and	coworkers	(2009)	showed	a	significant	increase	in	EI	(+	2182	kJ/d),	
that	 was	 achieved	 through	 a	 higher	 intake	 of	 carbohydrates	 (CHO)	 (+	 67	 g/d)	 and	 lipids	 (+	
55g/d)	during	the	LPh	compared	to	the	FPh.	Food	diaries	were	collected	during	three	days	in	
each	phase	(two	weekdays	and	one	weekend	day)	and	blood	samples	were	taken	on	a	single	
occasion	 in	 each	 phase	 to	 measure	 P4,	 oestrogen	 and	 leptin	 levels.	 As	 expected,	 P4	 and	 E2	
levels	were	 significantly	 greater	 in	 the	mid-LPh	 than	 in	 the	FPh.	Moreover,	 leptin	 levels	 also	
increased	in	LPh	compared	to	FPh	(~12%	difference).	This	is	of	relevance	as	it	suggests	that	not	
only	the	EI	(and	potentially	appetite)	fluctuates	along	with	the	ovarian	steroids	of	the	MC,	but	
also	 leptin	 levels	 appear	 to	 be	 altered	 throughout	 the	 phases	 of	 the	 MC.	 In	 addition,	 this	
seemed	to	be	the	opposite	of	what	would	be	expected,	as	above-mentioned,	the	provision	of	
leptin	causes	a	restriction	in	food	consumption	(Farooqi	et	al	2001).		
Therefore,	it	could	be	suggested	that	during	the	LPh	there	might	be	a	leptin	resistance	similar	
to	what	 is	 observed	 in	 obese	 populations	 (Kolaczynski	 et	 al	 1996)	 or	 rather,	 that	 leptin	 it	 is	
actually	 increased	 to	 comply	 its	 reproduction	 functions,	 e.g.	 prepare	 a	 women’s	 body	 to	
become	pregnant	(Moschos	et	al	2002).	Nonetheless,	the	only	hormone	that	was	significantly	
correlated	with	EI	and	CHO	intake	was	P4.	Riad-Gabriel	et	al	(1998)	also	observed	an	increase	
in	 leptin	 levels	 in	nine	healthy	NC	women	during	 the	 late	FPh	and	 the	 LPh	compared	 to	 the	
early	FPh,	and	this	was	in	contrast	to	a	lack	of	variation	in	post-menopausal	women	and	men	
within	29	days.	
Similar	findings	have	been	reported	by	Brennan	et	al	(2009)	who	assessed	food	intake	from	a	
buffet	90	min	after	providing	a	load	of	50g	of	glucose	in	300ml	of	water	to	nine	healthy	women	
on	three	days	of	the	MC:	two	in	the	FPh	and	one	in	the	LPh.	Their	results	indicated	an	increase	
in	 the	 amount	 of	 food	 and	 EI	 during	 LPh	 compared	 to	 FPh	 (~50	 g	 and	 ~700	 kJ	 difference,	
respectively).	 This	 was	 related	 to	 a	 faster	 emptying	 of	 the	 stomach,	 in	 particular,	 the	 time	
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needed	 for	emptying	50%	of	 the	gastric	glucose	during	LPh	was	15	min	 less	 than	during	 the	
FPh.	This	was	corroborated	by	a	higher	post-meal	release	of	GLP-1	during	the	LPh.	Moreover,	
gastric	 emptying	 time	 was	 negatively	 correlated	 with	 P4	 levels	 which	 suggests	 that	 gastric	
emptying	may	be	sensitive	to	the	alterations	in	the	ovarian	steroids	levels	throughout	the	MC.	
However,	 it	 did	 not	 show	 any	 relation	with	 E2	 concentration.	 Furthermore,	 it	 is	 worthwhile	
mentioning	 that	 due	 to	 the	 slower	 gastric	 emptying	 during	 the	 FPh,	 post-ingesting	 blood	
glucose	 and	 plasma	 insulin	 levels	 were	 also	 significantly	 lower	 than	 in	 the	 LPh,	 thus	 the	
glycaemia	response	was	improved	when	P4	was	low	in	the	FPh.	Finally,	CCK	levels	showed	no	
differences	during	the	90min	post-	glucose	 ingestion	despite	the	differences	found	in	hunger	
and	EI	between	phases.	Nevertheless	this	was	not	entirely	unexpected	as	CCK	secretion	seems	
to	be	more	affected	by	fat	and	protein	intake	rather	than	glucose	(Liddle	et	al	1985).	Similarly,	
no	differences	were	found	at	baseline.		
Lundberg	 et	 al	 (2010)	 also	 found	 no	 differences	 in	 CCK	 levels	 either	 in	 plasma	 or	 in	 the	
cerebrospinal	 fluid	when	 fasted.	 This	 contradicts	with	 Frick	 et	 al	 (1990)’s	 findings	 showing	 a	
significant	rise	in	basal	CCK	levels	in	the	LPh	compared	to	the	FPh	in	eight	NC	women	(5.2	±	0.6	
and	7.1	±	0.9	pM,	respectively).	This	is	somewhat	surprising	considering	that	CCK	reduces	food	
intake.	Thus,	more	studies	are	required	to	determine	whether	there	exist	changes	in	CCK	levels	
at	fasting	levels	and	post-prandially	across	the	MC.		
Dafopoulos	et	al	(2009)	studied	whether	fasting	ghrelin	(acylated	and	unacylated),	resistin	and	
adiponectin	 levels	 varied	 significantly	 throughout	 the	 MC	 in	 eight	 healthy	 and	 NC	 women.	
Serum	 acylated	 and	 unacylated	 ghrelin	 were	 kept	 constantly	 at	 ~100	 and	 250	 pg/ml,	
respectively	during	the	MC.	Likewise,	adiponectin	and	resistin	showed	no	significant	changes.	
Nevertheless,	E2	and	the	two	isoforms	of	ghrelin	showed	to	be	significantly	correlated	in	some	
of	 the	 days	 of	 the	MC	 (the	 authors	 did	 not	 indicate	which	 days	 neither	 the	 strength	 of	 this	
correlation).	Therefore,	similarly	to	what	has	been	shown	in	rodent	studies,	ghrelin	could	be	at	
least	partly	regulated	by	E2,	yet	there	is	no	evidence	of	such	association	in	humans,	thus	how	
E2	modulates	food	intake	remains	uncertain	(Asarian	and	Geary	2013).	
Pannacciulli	et	al	(2006)	reported	that	fasting	GLP-1	levels	were	positively	correlated	with	RMR	
(adjusted	 for	 sex,	 age,	 FFM	 and	 FM)	 in	 a	 population	 of	 men	 and	 women	 at	 their	 FPh.	
Therefore,	 it	 could	 be	 speculated	 that	 an	 increase	 in	 GLP-1	 during	 the	 LPh	 observed	 by	
Brennan	et	al	(2009)	could	partly	explain	the	increase	in	RMR	and	food	intake	as	an	approach	
to	 maintain	 energy	 balance	 within	 the	 MC.	 Nevertheless,	 the	 differences	 between	 phases	
observed	by	Brennan	et	al	(2009)	were	encountered	after	meal	ingestion,	whereas	no	changes	
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were	 found	 at	 fasting	 levels.	 Therefore,	 it	would	be	 interesting	 to	 study	whether	GLP-1	 and	
RMR	 change	 simultaneously	 throughout	 the	 different	 phases	 of	 the	 MC.	 Pannacciulli	 et	 al	
(2006)’s	results	would	have	been	more	persuasive	if	reported	separately	the	two	sexes	and	in	
the	different	phases	of	the	MC.		
Along	the	same	line	of	Pannacciulli	et	al,	Guo	et	al	(2006)	studied	how	PYY	levels	might	affect	
not	only	EI	but	also	EE.	In	their	study,	29	adults	(21	men	and	eight	women)	were	admitted	into	
the	metabolic	ward	to	measure	PYY,	glucose	and	insulin	concentrations	in	a	fasted	state,	after	
a	providing	a	standardized	breakfast	and	every	30	min	 for	 the	 three	 following	hours.	On	the	
day	 after,	 23h-EE	 was	measured	 in	 a	 calorimetric	 chamber	 and	mean	 RMR	 was	 calculated.	
Their	 results	showed	that	 fasting	PYY	was	negatively	correlated	to	BMI,	waist	circumference,	
fasting	triglyceride,	postprandial	insulin	area	under	the	curve	(AUC)	and	15h	RMR.	which	might	
reveal	a	connection	between	this	peptide	and	its	role	in	BW	regulation	from	the	EE	side	of	the	
energy	balance	equation.	In	fact,	there	was	no	significant	correlation	between	the	feelings	of	
hunger	and	satiety	with	fasting	PYY,	nor	postprandial	PYY	peak	or	PYY	AUC	except	from	latter	
one	with	satiety	AUC.	One	of	the	drawbacks	of	this	investigation	was	not	separating	the	results	
based	on	participants’	sex,	despite	controlling	the	MC	by	testing	all	women	during	their	FPh.	In	
fact,	Hill	et	al	(2011)	studied	PYY	secretion	pattern	over	24-h	in	normal-women	during	the	FPh	
and	 found	 that	 RMR	 was,	 on	 the	 contrary	 to	 Guo	 et	 al’s	 outcome,	 positively	 correlated	 to	
fasting	PYY,	24h-PYY	AUC	and	24h	PYY	levels	(only	the	last	two	were	significantly	correlated).	
Although	 the	 discrepancies	 could	 be	 attributed	 to	 the	 inclusion	 criteria,	 both	 investigations	
ensured	 the	 potential	 effect	 of	 the	MC,	 despite	 the	 fact	 that,	 to	 our	 knowledge,	 no	 studies	
have	 looked	 at	 fasting	 and	 postprandial	 PYY	 throughout	 the	 MC	 in	 humans	 and	 that	 no	
fluctuations	have	been	observed	in	rhesus	monkeys	(Van	Vugt	2010).		
Therefore,	it	seems	evident	that	there	is	a	lack	of	knowledge	in	the	area	of	appetite	responses	
in	 fertile-aged	 women.	 This	 is	 somehow	 concerning	 since	 there	 are	 multiple	 studies	
investigating	 appetite	 hormones	 with	 the	 objective	 of	 having	 a	 better	 understanding	 of	
appetite	 regulation	 and	 aiming	 to	 find	 a	 strategy	 to	 target	 the	 current	 obesity	 epidemic.	 In	
fact,	 in	the	majority	of	studies,	the	MC	phase	and/or	the	use	of	HC	is	not	even	mentioned	or	
taken	into	account	(Karl	et	al	2013,	Nieuwenhuizen	et	al	2009).	When	studies	have	attempted	
to	 control	 the	potential	 effects	 that	 the	phases	of	 the	MC	might	have	on	appetite	 and	 food	
regulation,	women	have	been	tested	at	the	same	MC	phase	(Guo	et	al	2006)	or	once	they	have	
reached	menopause	(Pasman	et	al	2008).	Although	these	methods	of	controlling	the	potential	
influence	of	 the	 fluctuations	 in	 the	ovarian	hormones	within	 the	MC	are	easy	approaches	 to	
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manage	this	 issue,	 it	would	not	be	appropriate	to	assume	that	the	research	outcome	of	that	
particular	study	is	the	real	and	complete	picture	of	any	possible	effect	(e.g.	increased	satiety,	
decreased	food	intake)	a	food/diet	might	have	in	this	group	of	the	population.	
In	summary,	it	 is	well	known	that	numerous	factors	modify	our	food	consumption	during	the	
day;	 however,	 how	 these	 respond	 and	 interact	 with	 the	 changes	 that	 oestrogen	 and	 P4	
experience	during	the	MC	is	still	uncertain.	Future	research	should	look	at	food	intake	and	how	
this	 might	 be	 related	 to	 the	 appetite	 hormones	 in	 the	 different	 phases	 of	 the	 MC	 in	 NC	
women.	
	
1.3. Summary	and	aims	
To	conclude,	it	seems	plausible	that	the	fluctuations	experienced	by	the	sex	steroids,	E2	and	P4,	
throughout	the	MC	might	have	an	effect	on	both	sides	of	the	energy	balance	equation.	On	the	
one	hand,	RMR	seems	to	increase	TEE	in	the	LPh,	and	on	the	other	hand,	EI	and	appetite	might	
be	physiologically	 increased	 in	 response	 to	 this	 potential	 increase	 in	 energy	demands	 in	 the	
LPh.	
Therefore,	this	thesis	aims	to:	
• Study	the	changes	and	the	correlations	between	salivary	and	plasma	E2	and	P4	 in	the	
MC	in	a	group	of	NC	women	and	HC	users.	
• Investigate	whether	 RMR	 is	 significantly	 increased	 in	 the	 LPh	 compared	 to	 the	MPh	
and	FPh	in	a	group	of	NC	women,	while	no	changes	are	expected	in	HC	users.	
• Explore	the	association	between	RMR	and	the	ovarian	hormones	in	plasma	and	saliva	
as	possible	determiners	of	RMR.	
• Investigate	 whether	 appetite	 responses	 (gastric	 emptying,	 PYY	 levels,	 appetite	
sensations	and	food	intake)	to	the	same	breakfast	vary	according	to	the	phase	of	the	
MC.
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2. Methods	
This	chapter	aimed	to	cover	in	depth	the	different	methods	used	during	the	conduction	of	the	
three	studies	included	in	this	thesis.	Firstly,	the	common	methods	employed	in	all	the	studies	
(e.g.	 ethical	 approval,	 recruitment	 of	 participants)	 were	 explained	 and	 later,	 the	 specific	
techniques	 used	 in	 each	 study	 were	 also	 described.	 The	 specific	 protocols	 and	 statistical	
techniques	used	in	each	study	were	covered	in	the	relevant	chapters	of	the	thesis.	
	
2.1. Ethical	approval	
Prior	 to	 the	 start	 of	 all	 studies,	 ethical	 approval	 was	 applied	 for	 and	 obtained	 from	 the	
University	Research	Ethics	Committee	(UREC)	at	Oxford	Brookes	University	(UREC	Registration	
No:	130697	 for	Studies	1	and	2,	and	140854	 for	Study	3	 (Appendices).	 	All	participants	were	
given	full	details	of	study	protocols	and	the	opportunity	to	ask	questions.	All	participants	gave	
written	informed	consent	prior	to	participation	(Appendices).	
	
2.2. Participant	recruitment	and	screening	
Initially,	 the	recruitment	of	participants	was	made	through	posters	placed	 in	Oxford	Brookes	
University	facilities	e.g.	library,	sport	centre,	student	accommodation,	and	also	in	local	libraries	
or	 gyms	 (e.g.	 The	 Athlete	 Centre)	 as	 well	 as	 in	 the	 social	 media	 (e.g.	 Facebook).	 Previous	
experience	within	 the	 Functional	 Food	 Centre	 at	Oxford	 Brookes	University	 had	 shown	 that	
advertising	 through	 posters	 can	 be	 ineffective	 in	 recruiting	 participants,	 therefore	
announcements	 in	 under-graduate	 and	 post-graduate	 lectures	 and	 informal	 recruitment	
through	personal	networks	was	also	used.	Moreover,	the	study	was	advertised	 in	the	Oxford	
Brookes	University	Research	Activity	Group,	on	the	Functional	Food	Centre	website	and	in	the	
volunteers	section	of	a	local	website	(http://www.dailyinfo.co.uk/).	
Interested	participants	were	provided	with	further	information	on	the	study	in	the	form	of	an	
information	 sheet	 (Appendices),	 sent	 by	 email.	 After	 at	 least	 24	 hours	 of	 having	 read	 the	
information	sheet	participants	came	to	the	Functional	Food	Centre	to	discuss	any	queries	they	
had	with	the	researcher	and	to	sign	the	consent	form.	Finally,	a	screening	questionnaire	was	
completed	to	ensure	eligibility	of	the	participant	in	the	study.	
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During	 the	 screening	 session,	 participants	 completed	 a	 questionnaire	 (Appendices)	 to	 verify	
that	they	were	healthy	women	of	18-40	years	of	age,	with	regular	menstrual	cycles	(i.e.	cycle	
length	 of	 25-35	 days)	 and	 not	 lactating	 or	 pregnant	 for	 the	 previous	 six	 months	 at	 least.	
Participants	 were	 excluded	 if	 their	 BMI	 >30	 kg/m2	 or	 they	 were	 suffering	 from	 any	
metabolic/genetic	diseases	or	taking	any	medications	known	to	interfere	with	metabolism,	e.g.	
hypothyroidism.	 Finally,	 those	who	 showed	 to	 be	 restrictive	 eaters	were	 also	 excluded.	 This	
was	assessed	by	the	combination	of	two	adapted	restrictive	eating	questionnaires:	the	Dutch	
Eating	 Behaviour	 Questionnaire	 (DEBQ)	 (van	 Strien	 et	 al	 1986)	 and	 the	 Three-factor	 eating	
questionnaire	–	restraint	eating	(TFEQ)	(Stunkard	and	Messick	1985)	(Appendices).	Participants	
with	a	TFEQ	score	of	>10	and	a	DEBQ	>2.5	were	 considered	 restrictive	eaters	and	 therefore	
they	were	excluded	from	participating	in	the	study.	
In	 addition	 to	 the	 above	 general	 inclusion/exclusion	 criteria,	 in	 Study	 3	 HC	 users	 were	 not	
eligible	 to	 participate	 because	 the	 aim	 of	 the	 investigation	 was	 to	 look	 at	 the	 appetite	
responses	 of	 women	 whose	 sex	 hormones	 fluctuate	 naturally	 over	 the	 course	 of	 a	 MC.	
Moreover,	participants	suffering	from	anaemia	were	excluded	from	participating	in	the	second	
study	due	to	any	potential	harm	caused	by	the	increased	amount	of	blood	drawn	throughout	
the	MC.	 In	addition,	participants	who	had	an	allergy/intolerance	to	any	of	the	foods	given	 in	
the	study,	did	not	consume	breakfast	and	lunch	habitually	or	were	attempting	to	lose	weight	
were	also	excluded.	Finally,	smokers	and	participants	with	a	disease	(e.g.	Gilbert's	syndrome)	
or	taking	medication	known	to	interfere	with	appetite	(e.g.	codeine)	were	excluded	from	the	
study.	
At	the	end	of	each	study,	participants	were	compensated	with	a	£50	Amazon	voucher	as	well	
as	a	full	report	detailing	their	personal	results	including	their	individual	RMR,	menstrual	cycle	
profile,	body	composition,	PA	and	eating	patterns,	depending	on	the	study	they	participated	
in.	
	
2.3. Baseline	characteristics	
2.3.1. Lifestyle	questionnaire	
During	 the	 first	 visit	 to	 the	 Functional	 Food	 Centre,	 participants	 completed	 a	 lifestyle	
questionnaire	that	encompassed	the	Physical	Activity	Questionnaire	(PAQ)	(Baecke	et	al	1982)	
and	 the	 Premenstrual	 Syndrome	 Screening	 Tool	 (PSST)	 (Steiner	 et	 al	 2003)	 to	 have	 a	 better	
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characterisation	of	population	being	studied.	The	PAQ	(Appendices)	consists	of	three	different	
indexes,	i.e.	work,	sport	and	leisure	that	were	summed	and	to	obtain	an	overall	PA	index	(PAI)	
with	higher	scores	indicating	greater	PA	levels.	The	PSST	(Appendices)	is	a	validated	screening	
tool	that	can	aid	in	the	diagnosis	of	the	premenstrual	syndrome	(PMS)	and	the	premenstrual	
dysphoric	disorder	(PMDD)	by	rating	the	premenstrual	symptoms	in	a	four-levels	scale	i.e.	‘not	
at	all’,	‘mild’,	‘moderate’	and	‘severe’	(Steiner	et	al	2003).	
	
2.3.2. Body	composition	assessment	
All	 anthropometric	measurements	were	made	 in	 the	 fasting	 state.	 	Height	was	measured	 to	
the	 nearest	 0.1	 cm	 using	 a	 stadiometer	 (Seca	 Ltd,	 Birmingham,	 UK),	 with	 subjects	 standing	
upright	and	without	shoes.		BW	(to	the	nearest	0.1	kg)	and	body	composition,	i.e.	FM,	FFM	and	
body	 water	 (BW),	 were	 measured	 with	 the	 Tanita	 Body	 Composition	 Analyzer	 BC-418MA	
(Tanita	 Ltd,	West	Drayton,	UK).	 Finally,	waist	 and	hip	 circumferences	were	measured	 to	 the	
nearest	 0.1cm	 with	 an	 anthropometric	 tape	 (Lufkin	W606PM	 flexible	 steel	 tape,	 Maryland,	
USA).	These	were	determined	as	the	narrowest	and	widest	circumference	of	the	waist	and	hip,	
respectively	(Stewart	et	al	2011).	
	
2.4. Blood	sample	collection	and	analyses	
2.4.1. Blood	collection	and	storage	
Blood	 samples	 were	 collected	 from	 a	 large	 vein	 of	 the	 anti-cubital	 fosse	 of	 the	 arm	 of	 the	
participants	 with	 K2E-EDTA	 tubes	 (BD	 Vacutainer,	 Becton	 Dickinson,	 UK)	 by	 a	 trained	
phlebotomist.	When	only	one	blood	sample	was	required	during	the	visit	to	the	lab	(studies	1,	
and	2)	this	was	withdrawn	into	a	6	ml	tube	via	venepuncture	using	a	21G	multi	sample	needle	
(BD	Vacutainer,	PrecisionGlide).	In	Study	3,	repeated	blood	sampling	during	the	same	visit	was	
required,	thus	plasma	samples	were	obtained	from	an	inserted	cannula	(BD	Venflon	Pro	Safety	
20GA,	 Becton	 Dickinson	 Induction	 Therapy,	 Singapore).	 The	 cannulation	 technique	 involves	
flushing	3ml	of	 0.9%	 sodium	chloride	 into	 the	 system	with	 a	needle-free	 syringe	before	 and	
after	collecting	each	sample	to	ensure	that	the	cannula	is	still	patent	and	to	remove	any	blood	
from	the	cannula	to	avoid	clotting.	Before	disconnecting	the	syringe	to	collect	the	blood,	a	3	ml	
sample	was	withdrawn	with	 the	 same	 syringe	 to	 ensure	 the	 sample	was	 clean	 from	 sodium	
chloride	(Fig.	2.1).	A	4ml	blood	sample	was	withdrawn	from	the	cannula	for	every	time	point,	
CHAPTER	2	 Methods	
	
28	
except	 for	 the	 baseline	 when	 8ml	 were	 colected	 to	 measure	 the	 ovarian	 hormones.	 After	
colection,	blood	samples	were	kept	in	ice	until	they	were	centrifuged	at	4°C	for	10	minutes	at	
4000	rpm	(MC-6,	Sarstedt	Ltd,	Leicester,	UK)	to	extract	the	plasma.	This	was	then	frozen	at	-
80°C	in	diferent	aliquots	until	analysis.	
	
2.4.2. Plasma	E2	and	P4	measurement	(Study	1,	2	and	4)	
Plasma	 samples	 were	 thawed	 to	 measure	 E2	and	 P4	by	 an	 ElectroChemiLuminescense	
immunoassay	(ECLIA)	with	a	Cobas	e411	semi-automated	analyser	(Roche	diagnostics	Burgess	
Hil,	UK).	The	ECLIA	employs	the	competitive	test	principle	to	quantify	the	concentrations	of	E2	
and	P4	in	plasma	(Roche	2009a,	b).	In	preparation	for	the	analyses,	al	reagents	and	samples	
were	 brought	 to	 room	 temperature.	 Firstly,	 the	 reagent	kits	 were	 calibrated	 using	 their	
respective	 CalSets.	 Once	 plasma	 samples	 were	 completely	 thawed,	 these	 were	 vortexed	 and	
centrifuged	at	4000	rpm	for	one	minute.	Then,	300	µl	of	plasma	was	added	into	a	sample	cup	
in	 order	 to	 be	 analysed	 by	 the	 semi-automated	 analyser.	 The	 analyser	 executed	 two	
incubations:	(1)	the	sample	was	incubated	with	the	specific	biotinylated	antibodies	for	E2	and	
P4	and	 also	 E2/P4	labeled	 with	 a	 ruthenium	 complex	 (Tris(2,2’bipyridyl)ruthenium(I)	 was	
added;	(2)	streptavidin	was	added	to	interact	with	the	biotin	of	the	antibodies.	The	amount	of	
labeled	 antigen	 was	 inversely	 proportional	 to	 the	 concentrations	 of	 E2/P4	of	 the	 plasma	
samples.	The	reaction	mixture	was	aspirated	into	the	measuring	cel	where	the	microparticles	
were	magneticaly	captured	into	the	surface	of	the	electrode.	Unbound	particles	were	washed	
out	 and	 a	 voltage	 was	 applied	 to	 the	 electrode	 which	 induced	 a	 chemiluminescent	 emission	
that	 was	 measured	 by	 a	 photomultiplier.	 Results	 were	 automaticaly	 determined	 with	a	
calibration	curve	(Roche	2009a,	b).	
	 	
Fig	2.1.	Colection	of	a	blood	sample	from	a	cannula:	(A)	Flushing	sodium	chloride	into	the	system	with	
to	ensure	patency	of	the	cannula	(B)	Extraction	of	a	sample	with	the	syringe	to	ensure	the	colection	of	a	
blood	sample	clean	of	sodium	chloride	(C)	Extraction	of	the	blood	sample	with	a	tube	(D)	Flushing	into	
the	system	to	maintain	the	cannula	patent	until	the	colection	of	the	subsequent	sample.	
A	 C	B	 D	
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Fig	2.2.	Plate	layout	for	PYY	assay	
2.4.3. PYY	(total)	measurement	(Study	3)	
Plasma	total	PYY	(both	1-36	and	3-36)	concentrations	were	measured	using	a	direct	sandwich	
enzyme-linked-immunosorbent	assay	(ELISA)	kit	(EMD	Milipore).	The	testing	principal	of	this	
assay	 is	 to	 measure	 the	 levels	 of	 total	 PYY	 in	 plasma	 by	 capturing	 the	 antigen	 with	 two	
diferent	 antibodies	 (the	capture	and	 the	detection	antibodies)	 that	 bind	 to	 two	 diferent	
epitopes	of	the	PYY	molecule	(EMD	Milipore	Corporation	2014).	The	capture	antibody	is	the	
one	 coating	 the	 microtiter	 plate	 that	 wil	 bind	 to	 the	 PYY	 of	 the	 plasma	 samples	 and	 the	
detection	antibody	is	the	one	measuring	the	concentrations	of	antigen	by	being	conjugated	to	
an	enzyme	(R&D	Systems	(n.d.).	This	enzyme	wil	bind	to	a	detection	reagent	that	reacts	with	
a	substrate	solution	to	develop	colour	and	its	optical	density	wil	be	used	to	measure	the	levels	
of	PYY	in	each	sample.	Since	the	increase	in	absorbency	is	directly	proportional	to	the	amount	
of	PYY	present	in	the	samples,	the	latter	can	be	delivered	by	interpolation	from	the	reference	
curve	generated	by	the	standards	containing	known	PYY	concentrations.		
Assay	 protocol	 was	 executed	 folowing	 manufacturer’s	 instructions	(EMD	 Milipore	
Corporation	 2014).	 The	 layout	 of	 the	 wels	 of	 the	 plate	 was	 designed	 with	 duplicates	 of	
unknowns	 (UNK)	 i.e.	 plasma	 sample,	 standards	 (ST),	 quality	 controls	 (QC),	 and	 blanks,	 as	
shown	in	Fig	2.2.		
For	the	preparation	of	the	assays,	al	reagents	and	samples	were	brought	to	room	temperature	
and	 once	 plasma	 samples	 were	 completely	 thawed,	 these	 were	 vortexed	 and	 centrifuged	 at	
3000	rpm	for	1	minute.	Before	proceeding	with	the	assay,	preparation	of	the	STs	and	the	QCs	
was	required.	First,	the	vials	containing	PYY	standard	and	the	two	QCs	(their	concentration	was	
dependent	and	indicated	on	each	individual	lot)	were	mixed	with	500	µl	deionized	water	each	
and	left	to	sit	for	~5	minutes	to	completely	dissolve.	Six	tubes	were	labeled	(ST1-6)	and	200	µl	
assay	bufer	(borate	saline)	was	added	in	each	tube.	Then	200	µl	reconstituted	PYY	standard	
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was	added	into	PYY	ST1	to	be	serialy	diluted	two-fold	by	pipetting	200	µl	from	tube	1	to	tube	
2,	from	tube	2	to	tube	3	and	so	on	until	tube	6	was	made	up	with	a	final	concentration	of	64-
fold	 less	 than	 the	 reconstituted	 PYY	 standard	 (Fig	 2.3).	 Before	 aspirating	 from	 one	 standard,	
the	tube	was	mixed	wel	and	a	new	pipette	tip	was	used	to	pipette	to	the	next	next	tube.	
The	first	step	was	to	add	300	µl	diluted	wash	bufer	(bufered	saline)	into	each	wel.	This	was	
decanted	 and	 tapped	 into	 absorbent	 paper	 towels	 three	 times	 and	 20	 µl	 matrix	 solution	
(contains	 DPP	 IV	 inhibitor)	 was	 added	 into	 the	 blank,	 STs	 and	 QC	 wels.	 Subsequently,	 20	 µl	
plasma,	 ST,	 QC,	 and	 assay	 bufer	 (in	 the	 blank	 wels)	 was	 added	 in	 the	 designated	 wels	 in	
duplicate.	Finaly,	20	µl	blocking	solution	was	added	into	each	wel	and	left	to	incubate	for	30	
minutes	 at	 room	 temperature	 in	 a	 plate	 shaker	 (MicroPlate	 Shaker	 PMS-1000i,	 Grant	 bio,	
Grant	Instruments,	Cambridge,	UK)	at	450	rpm.		
Folowing	this,	50	µl	mixture	of	the	capture	(rabbit	antihuman	PYY)	and	detection	(biotinylated	
antihuman	 PYY)	 antibodies	 was	 added	 into	 each	 wel	 and	 the	 plate	 was	left	 to	 incubate	 at	
room	temperature	for	1.5	hours	to	enable	the	PYY	of	the	samples	to	bind	to	the	antibodies.	Al	
the	unbound	particles	were	washed	away	by	decanting	plus	tapping	the	plate	three	times	as	
previously	done.	Subsequently,	100	µl	enzyme	solution	(Streptavidin-HRP	Conjugate	in	Bufer)	
was	added	into	each	wel	to	bind	to	the	biotin	of	the	detection	antibody	while	shaking	at	400	
rpm	during	30	minutes	at	room	temperature.	Residual	liquid	was	decanted	from	the	plate	and	
this	 was	 washed	 six	 times	 as	previously	 done.	 Then,	 100	 µl	 of	 TMB	 substrate	 solution	 was	
added	into	each	wel	to	react	with	the	HRP	bound	to	the	detection	antibody	which	produced	a	
blue	 colour	 while	 the	 plate	 was	 shaken	 for	 5-20	 minutes	 at	 450	 rpm.	 Finaly,	 100	 µl	 stop	
200µl	assay	diluent	
Reconstituted	PYY	standard	(32pg/ml)	
Fig	2.3.	Serial	dilution	for	PYY	standards	
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solution	containing	sulphuric	acid	was	added	to	end	the	colour	development	and	the	plate	was	
shaken	by	hand	until	the	wells	turned	into	a	yellow	colour.	
Within	 five	minutes,	 the	plate	was	 read	 in	a	plate	 reader	 (LT-4500	Microplate	ELISA	Reader,	
Labtech	International	Ltd,	UK)	at	a	wavelength	of	450	nm	and	590	nm	to	obtain	two	different	
optical	 densities	 (OD)	 of	 all	 the	wells.	 The	 two	 readings	were	 subtracted	 and	 the	 an	 online	
software	 (My	 Assays	 Ltd)	 computed	 the	 concentrations	 of	 total	 PYY	 of	 each	 plasma	 sample	
using	an	equation	derived	from	a	4-parameter	logistic	equation	curve	obtained	by	plotting	PYY	
levels	of	the	standards	on	the	x-axis	(pg/ml)	and	their	absorbance	(nm)	y-axis	(Fig	2.4).		
The	assay	was	accepted	 if	one	of	 the	 two	QC	was	±2SD	of	 the	applicable	mean	of	 the	range	
given	 by	 the	 supplier.	 Average	 concentrations	 between	 duplicates	 were	 accepted	 provided	
that	 the	 CV%	between	 duplicates	was	 <15%.	 The	minimal	 concentration	 of	 PYY	 that	 can	 be	
distinguished	 from	0	 is	 6.5pg/ml.	 To	minimize	 error	within	 participant,	 each	 participant	 had	
their	PYY	of	the	three	visits	measured	in	the	same	microplate.	
Concentrations	of	PYY	were	used	to	calculate	the	total	area	under	the	curve	(AUC)	using	the	
trapezoidal	method	at	min	60,	120,	180,	210	and	240	from	baseline	(before	breakfast).	When	
time	point	samples	were	not	available	due	to	collection	procedure	issues,	an	average	between	
the	previous	and	subsequent	collection	time	points	was	made	to	estimate	the	concentration	of	
the	missing	sample	a	an	obtain	a	representative	PYY	AUC.		
	
	
Fig	2.4.	Example	PYY	4parameter	curve	fit	
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2.5. Saliva	sample	collection	and	analyses	(Study	1)	
2.5.1. Saliva	collection	and	storage	
Saliva	 samples	 were	 collected	 using	 the	 unstimulated	 passive	 drool	 technique	 (Salimetrics	
2008)	 	under	 standardised	conditions:	early	 in	 the	morning,	 in	a	 fasted	 state	without	having	
consumed	alcohol	for	the	previous	12	hours	and	after	rinsing	thoroughly	the	mouth	with	water	
10	minutes	before	a	~2	ml	sample	was	collected	.	Participants	were	asked	to	allow	the	saliva	to	
pool	in	their	mouth	and	then	with	the	head	tilted	forward	they	self-collected	a	saliva	sample	in	
a	 polypropylene	 tube	 (Sarstedt,	 Nümbrecht,	 Germany).	 Participants	 were	 instructed	 to	
imagine	eating	their	favourite	food	to	stimulate	saliva	secretion.	Samples	were	kept	in	ice	until	
they	were	distributed	in	different	aliquots	to	be	stored	at	-40°C	within	four	hours	of	collection.	
	
2.5.2. Salivary	E2	and	P4	measurement	
Free	 E2	 and	 P4	 concentrations	 in	 saliva	 were	measured	 by	 an	 EIA	 kit	 (Salimetrics).	 The	 test	
principle	 of	 these	 assays	 is	 a	 competitive	 EIA	 in	 which	 the	 antigen	 (i.e.	 E2/P4)	 of	 the	 saliva	
sample	competes	against	a	reagent	containing	enzyme-conjugated	E2/P4	to	bind	to	the	antigen	
antibody.	 The	 more	 enzyme-conjugated	 E2/P4	 bound	 to	 the	 antibodies,	 the	 less	 antigen	 is	
present	 in	 our	 saliva	 samples	 and	 the	 more	 colour	 is	 produced	 by	 the	 enzyme-conjugated	
E2/P4,	 i.e.	 the	optical	density/colour	of	the	sample	 is	 inversely	proportional	to	the	amount	of	
E2/P4	in	the	sample	(Sino	Biological	Inc.	(n.d.)).	
Assay	protocols	were	performed	following	manufacturer’s	 instructions	(Salimetrics	2012a,	b).	
The	 layout	 of	 the	wells	 of	 the	plate	with	unknowns	 (UNK)	 i.e.	 saliva	 sample,	 standards	 (ST),	
quality	 controls	 (QC)	 high	 and	 low,	 zeros	 and	 non-specific	 binding	 (NSB)	 wells	 (i.e.	 wells	
without	anti-E2	antibody)	was	designed	as	shown	in	Fig.	2.5.	For	the	preparation	of	the	assays,	
all	 reagents	and	 samples	were	brought	 to	 room	 temperature	and,	once	 saliva	 samples	were	
completely	thawed,	these	were	vortexed	and	centrifuged	at	3000	rpm	for	15	minutes.		
	 	
Fig	2.5.	Plate	layout	for	saliva	E2	an	P4	assays	
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2.5.2.1. Salivary	E2	EIA	protocol		
The	first	step	was	the	preparation	of	the	STs.	Five	tubes	were	labeled	corresponding	to	STs	2	
to	6	in	which	300	µl	E2	assay	diluent	was	added.	Then	E2	ST1	(32	pg/ml)	was	serialy	diluted	2	
fold	by	pipetting	300	µl	from	tube	1	to	tube	2,	from	tube	2	to	tube	3	and	so	on	until	tube	6	was	
made	up	with	a	final	concentration	of	1	pg/ml	(Fig	2.6).	(Before	aspirating	from	one	standard,	
the	tube	was	mixed	wel	and	a	new	pipette	tip	was	used	to	pipette	to	the	next	tube).	
Folowing	this,	100	µl	each	ST,	UNK	and	QC	was	pipetted	into	the	corresponding	wels	and	100	
µl	E2	assay	diluent	was	pipetted	into	the	zero	and	the	NSB	wels	of	the	plate	coated	with	rabbit	
antibodies	for	E2.	Subsequently,	the	HRP-conjugated	E2	was	diluted	1:800	by	adding	15	µl	into	
12	ml	of	E2	assay	diluent.	This	solution	was	mixed	and	100	µl	was	added	into	each	wel	using	a	
multichannel	 pipette.	 The	 plate	 was	 covered	 and	 left	 to	 incubate	 at	 room	 temperature	 in	 a	
plate	shaker	for	5	minutes	and	then	115	minutes	more	out	of	the	plate	shaker.	This	alowed	
the	 E2	from	 each	 saliva	 sample	 to	 compete	 against	 the	 HRP-conjugated	 E2	to	 bind	 to	 the	
antibodies	 of	 the	 plate.	 Once	 the	 incubation	 was	 completed,	 the	 plate	 was	 washed	 out	 to	
remove	 any	 unbound	 components	 by	 adding	 300	 µl	 pre-diluted	 wash	 bufer	 containing	
phosphate	into	each	wel	with	a	multichannel	pipette.	The	plate	was	decanted	into	a	sink	to	
finaly	be	blotted	onto	paper	towels	to	ensure	there	was	no	wash	left	in	the	wels.	The	washing	
process	was	repeated	three	times	to	ensure	complete	wash	out	of	unbound	particles	and	then	
200	µl	TMB	substrate	solution	was	added	into	each	of	the	wels	which	reacted	with	the	HRP	of	
the	E2	conjugated	producing	a	blue	colour	while	the	plate	was	being	shaken	for	five	minutes	at	
500	 rpm.	 Subsequently,	 the	 plate	 was	 incubated	 in	 the	 dark	 at	 room	 temperature	 for	 25	
minutes	to	further	alow	the	colour	reaction	to	occur	and	then	50	µl	stop	solution	containing	
	 300µl	estradiol	assay	diluent	
Estradiol	ST1	(32pg/ml)		
Fig	2.6.	Serial	dilution	for	E2	standards	
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sulphuric	acid	was	added	to	end	the	colour	development.	The	plate	was	shaken	at	500	rpm	for	
three	minutes	so	that	the	wells	turned	into	a	yellow	colour	and	then	the	plate	was	read	in	a	
plate	 reader	 at	 a	 wavelength	 of	 450	 nm	 within	 10	 minutes	 of	 adding	 the	 stop	 solution	 to	
obtain	the	OD	of	all	the	wells.	
	
The	plate	reader	software	(Gen5,	BioTek	Instruments,	Inc)	calculated	the	concentrations	of	E2	
of	 each	 saliva	 sample	 using	 an	 equation	 derived	 from	 a	 4-parameter	 non-linear	 regression	
curve	 obtained	 by	 plotting	 E2	 levels	 of	 the	 standards	 on	 the	 x-axis	 and	 their	 percentage	 of	
bound	E2	in	the	y-axis	(Fig.	2.7).	
Percentage	of	bound	E2	of	each	duplicate	of	standards,	saliva	samples,	zeros	and	controls	were	
calculated	as	follows:		
	
	
High	 and	 low	 QC	 were	 checked	 to	 be	 within	 limits	 and	 average	 concentrations	 between	
duplicates	were	accepted	provided	that	the	CV%	between	duplicates	was	<15%.	The	minimal	
concentration	of	E2	that	can	be	distinguished	from	0	is	0.1	pg/ml.	
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Fig	2.7.	Example	estradiol	4-parameter	curve	fit	
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2.5.2.2. Salivary	P4	EIA	protocol	
The	 measurement	 of	 P4	in	 saliva	 by	 EIA	 folowed	 the	same	 protocol	 as	 the	 salivary	 E2	with	
some	obvious	changes	in	the	reagents	as	wel	as	the	quantities	of	some.	
In	preparation	of	the	STs,	five	tubes	were	labeled	corresponding	to	STs	2	to	6	in	which	200	µl	
of	P4	assay	diluent	was	added.	P4	ST1	(2430pg/ml)	was	serialy	diluted	three-fold	by	pipetting	
200	µl	from	tube	1	to	tube	2,	from	tube	2	to	tube	3	and	so	on	until	tube	6	was	made	up	with	a	
final	concentration	of	10	pg/ml	(Fig.	2.8).	(Before	aspirating	from	one	standard,	the	tube	was	
mixed	wel	and	a	new	pipette	tip	was	used	to	pipette	to	the	next	tube).	
Folowing	this,	50	µl	ST,	UNK	and	QC	were	pipetted	into	the	corresponding	wels	and	50	µl	P4	
assay	 diluent	 were	 pipetted	 into	 the	 zero	 and	 the	NSB	 wels	 of	 the	 plate	 coated	 with	 rabbit	
antibodies	 for	 P4.	 Subsequently,	 the	 HRP-conjugated	 P4	was	 diluted	 1:800	 by	 adding	 22.5	 µl	
into	18	ml	P4	assay	diluent.	This	solution	was	mixed	and	150	µl	was	added	into	each	wel	using	
a	multichannel	pipette.	The	plate	was	covered	and	left	to	incubate	at	room	temperature	while	
shaking	in	a	plate	shaker	60	minutes.	This	alowed	the	P4	from	each	saliva	sample	to	compete	
against	the	HRP-conjugated	P4	to	bind	to	the	antibodies	of	the	plate.	Once	the	incubation	was	
complete,	 the	 plate	 was	 washed	 out	 to	 remove	 any	 unbound	 components	 by	 adding	 300	 µl	
pre-diluted	wash	bufer	containing	phosphate	into	each	wel	with	a	multichannel	pipette.	Then	
the	plate	was	decanted	into	a	sink	to	finaly	be	blotted	onto	paper	towels	to	ensure	there	was	
no	wash	left	in	the	wels.	The	washing	process	was	repeated	three	times	and	then	200	µl	TMB	
substrate	 solution	 was	 added	 into	 each	 of	 the	 wels.	 This	 reacted	 with	 the	 HRP	 of	 the	 P4	
conjugated	producing	a	blue	colour	while	the	plate	was	being	shaken	for	five	minutes	at	500	
	 200µl	progesterone	assay	diluent	
Progesterone	ST1	(2430pg/ml)		
Fig	2.8.	Serial	dilution	for	P4	standards	
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rpm.	Subsequently,	the	plate	was	incubated	in	the	dark	at	room	temperature	for	25	minutes	to	
further	 alow	 the	 colour	 reaction	 to	 occur	 and	 then	 50	 µl	 stop	 solution	 containing	 sulphuric	
acid	 was	 added	 to	 end	 the	 colour	 development.	 The	 plate	 was	 shaken	 at	 500	 rpm	 for	 three	
minutes	 so	 that	 the	 wels	 turned	 into	 a	 yelow	 colour.	 Finaly,	 the	 plate	 was	 read	 in	 a	 plate	
reader	at	a	wavelength	of	450	nm	within	10	minutes	of	adding	the	stop	solution	to	obtain	OD	
of	al	the	wels.	
Once	more,	P4	concentrations	of	each	saliva	sample	were	calculated	using	the	equation	of	the	
4-parameter	non-linear	regression	curve	obtained	by	plotting	P4	levels	of	the	standards	on	the	
x-axis	and	their	percentage	of	bound	P4	in	the	y-axis	(Fig.	2.9).	Percentage	of	bound	P4	of	each	
duplicate	of	standards,	saliva	samples,	zeros	and	controls	were	calculated	as	abovementioned	
in	the	EIA	protocol.	
	
High	 and	 low	 QC	 were	 checked	to	 be	 within	 limits	 and	 average	 concentrations	 between	
duplicates	were	accepted	provided	that	the	CV%	between	duplicates	was	<15%.	The	minimal	
concentration	of	P4	that	can	be	distinguished	from	0	is	5	pg/ml.	
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Fig	2.9.	Example	progesterone	4-parameter	curve	fit	
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2.6. RMR	and	substrate	metabolism	assessment	(Study	2)	
2.6.1. RMR	measurement	
RMR	was	measured	by	the	hooded	open	circuit	 indirect	calorimeter	GEM	(GEMNutrition	Ltd,	
Daresbury,	 UK).	 Previous	 research	 in	 our	 laboratory	 has	 shown	 that	 the	 GEMNutrition	 is	 a	
reliable	 tool	 for	 repeated	 measures	 of	 RMR	 (CV%	 <5%)	 (Kennedy	 et	 al	 2014).	 The	 testing	
principle	of	any	indirect	calorimeter	is	that	by	measuring	the	volumes	of	oxygen	consumption	
(VO2)	 (ml/min)	and	the	carbon	dioxide	production	 (VCO2)	 (ml/min)	 from	breath	samples,	 the	
heat	(energy)	produced	by	the	metabolic	oxidative	processes	can	be	calculated	(in	kcal/d).	To	
facilitate	 this,	 the	 GEM	 applies	 the	 adapted	 version	 of	 the	Weir	 equation	 in	 which	 protein	
oxidation	is	considered	negligible	(Weir	1949):	
!"! !"#$/! =  3.9 !!! + 1.1 !!"! ×1.44	
Where	1.44	computes	the	kcal	requirements	per	day.	
On	the	testing	day	participants	attended	the	laboratory	in	the	morning	(between	07:00-10:00)	
after	a	10-12	hour	overnight	fast	and	rested	for	30	minutes	to	achieve	a	state	of	stabilization	
after	their	commute	to	the	laboratory.	RMR	was	measured	with	the	GEM	for	30	minutes	under	
the	following	standardized	conditions	(Compher	et	al	2006)	(Fig.	2.10):	lying	down	in	a	supine	
position	 in	 a	 thermoneutral	 environment	 (20–25°C)	 and	 without	 having	 practised	 any	
strenuous	or	non-habitual	physical	exercise	as	well	as	not	having	consumed	alcohol	or	caffeine	
the	 evening	 before.	 The	 first	 five	minutes	 of	measurement	were	 automatically	 discarded	 so	
that	 the	participants	had	enough	 time	 to	adapt	 to	 the	hood.	Moreover,	of	 the	 remaining	25	
minutes	measurement,	the	first	 five	minutes	were	used	to	ascertain	that	the	participant	was	
stable	by	achieving	≤10	%	CV	for	VO2	and	VCO2	(Compher	et	al	2006).	Thus,	the	average	of	the	
respiratory	gas	exchange	data	of	the	25	minutes	measurement	was	used	to	calculate	the	RMR	
A	 B	
Fig	10.	Measurement	of	RMR.	(A)	First	30	min	lying	down	for	stabilisation	(B)	Last	30	min	
under	the	canopy	to	measure	RMR	
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after	applying	 the	modified	Weir	equation.	When	the	%	CV	 for	VO2	and	VCO2	was	 indicating	
the	participant	was	unstable,	that	day	was	removed	from	the	averaged	RMR	measurements	of	
the	cycle	and	phase	of	that	participant.	RMR	was	calculated	as	absolute	RMR	(i.e.	per	day)	and	
relative	 RMR	 (i.e.	 per	 kg	 of	 BW).	 During	 the	 entire	 time	 lying	 down	 (resting	 or	 under	 the	
canopy),	participants	were	allowed	to	 read,	watch	 films	or	 listen	 to	music	while	being	quiet.	
These	conditions	were	kept	constant	between	visits	within	participants.		
The	calorimeter	was	calibrated	before	every	measurement	with	two	gas	bottles	(1%	CO2/20%	
O2/N2	 and	 Nitrogen	 Zero	 grade)	 and	 alcohol	 checks	 were	 performed	 monthly	 for	 further	
calibration.	
	
2.6.2. RMR	measured	vs.	RMR	predicted	
Averaged	measured	RMR	(RMRm)	of	the	entire	MC	and	per	phase	were	compared	to	predicted	
RMR	 (RMRp)	 from	 ten	 different	 equations	 valid	 for	 adult	 females	 according	 to	 the	 latest	
published	 scientific	 opinion	 on	 dietary	 reference	 values	 for	 energy	 by	 the	 European	 Food	
Safety	 Authority	 (EFSA	 2013)	 (Table	 2.1).	 Bias	 was	 determined	 as	 the	 mean	 percentage	
difference	between	RMRm	and	RMRp	and	accuracy	as	the	percentage	of	participants	with	an	
RMRp	within	±10%	of	RMRm.	
	
2.6.3. Substrates	metabolism	measurement	
From	the	volumes	of	O2	consumed	and	CO2	produced	(l/min),	oxidation	rates	of	the	substrates	
were	 calculated	 using	 the	 adapted	 Frayn	 stoichiometric	 equations	 where	 negligible	 protein	
oxidation	is	assumed	(Frayn	1983):	
Fat oxidation rates ! !"# =  1.67×!!! −  1.67×!!"!	
Carbohydrate oxidation rates ! !!" = 4.55×!!! −  3.21×!!"!	
The	 average	 rate	 during	 the	 25	minutes	measurement	was	 used	 as	 the	 substrate	 oxidation	
value	 of	 the	 visit.	 Moreover,	 each	 substrate	 was	 converted	 to	 kcal/min	 using	 the	 Awater	
Factors	(1g	fat	=	9kcal	and	1g	carbohydrates	=	4kcal)	(Feher	2012)	to	further	calculate	each	of	
the	substrate’s	contribution	as	a	percentage	of	the	total	energy	oxidised.		
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Table	2.1.	Validated	predictive	equations	for	female	adults	(EFSA	2013)	
	 	 Predictive	equation	 Units	
(1) 	 Harris	Benedict	 !"×9.5634 + !"(!")×1.8496 − !"#×4.6756 + 655.0955	 (kcal/d)	
(2) 	 Schofield_1	
	
Age	18	–	30	y:
	
 0.062 ×!" +  2.036	
Age	30	-	60	y:	0.034 ×!" +   3.538	
(MJ/d)	
(3) 	 Schofield_2	 Age	18	–	30	y:	
	
0.057 × BW +  1.184 × HT(m)  +  0.411		
Age	30	-	60	y:	0.034 ! !" +  0.006 × !"(!)  + 3.53	
(MJ/d)	
(4) 	 Mifflin	 9.99 × !" +  6.25 × !"(!")  −  4.92 × !"# –  161		 (kcal/d)	
(5) 	 Muller_1	 0.47 × !" −  0.01452 × !"# +  1.009 × !"# +  3.21		 (MJ/d)	
(6) 	 Muller_2	 BMI	>	18.5	to	25:	0.02219 × !" +  0.02118 × !"(!")  −  0.01191 × !"# +  0.884 × !"# +  1.233 	
BMI	>	25	to	<30:	0.04507×!" − 0.01553× !"# +  1.006 × !"# +  3.407	
BMI	>30:	0.05 × !" −  0.0158 × !"# +  1.103 × !"# +  2.924	
(MJ/d)	
(7) 	 Muller_3		 0.5192×!" +  0.04036× !" + 0.869 × !"# − 0.01181 × !"# +  2.992		 (MJ/d)	
(8) 	 Muller_4	 BMI	>	18.5	to	25:	0.0455 × !!" +  0.0278 × !" +  0.879 × !"# −  0.0129 × !"# +  3.634	
BMI	>	25	to	<30:	
	
0.03776 × FFM +  0.03013× FM +  0.93 × Sex - 0.01196×Age +  3.928		
BMI	>	30:	
	
0.05685 × FFM + 0.04022 × FM +  0.808 × Sex - 0.01402 × Age +  2.818		
(MJ/d)	
(9) 	 Henry_1	 Age	18-30	y:	
	
0.0546 × BW +  2.33		
Age	30-60	y:	
	
0.0407 × BW +  2.90		
(MJ/d)	
(10) 	 Henry_2	 Age	18-30	y:	0.0433×!" + 2.57×!"(!)  −  1.18	
Age	30-60	y:	0.0342×!" + 2.10×!"(!)  −  0.0486	
(MJ/d)	
Where	BW	=	body	weight	(kg);	HT	=	height;	FM	=	fat	mass	(kg);	FFM	=	fat	free	mass	(kg);	Sex	=	0.	
	
CHAPTER	2	 Methods	
	
40	
2.7. Gastric	emptying	assessment	(Study	3)	
2.7.1. Breakfast	characteristics	
In	Study	3,	potential	changes	in	the	gastric	emptying	(GE)	throughout	the	MC	were	examined	
after	consuming	the	same	breakfast	on	a	single	day	in	each	of	the	three	phases	of	the	MC.	
A	breakfast	containing	scrambled	eggs	on	toast,	fruit	(pineapple)	and	a	drink	(i.e.	coffee,	tea	or	
water)	 was	 given	 to	 participants	 between	 07:30-09:30.	 The	 breakfast	 was	 standardised	
amongst	participants	and	provided	375-395	kcal	of	which	35%,	38%	and	23%	were	in	the	form	
of	 fat,	 carbohydrates	 and	 protein,	 respectively.	 The	 energy	 provided	 by	 the	 breakfast	
accounted	 for	17-18	%	of	 the	 total	daily	energy	 requirements	 for	 an	average	woman	 (19-44	
years)	 with	 median	 PA	 level	 of	 1.63	 i.e.	 2103-2175	 kcal/d	 (SACN	 2011).	 The	 nutritional	
composition	of	the	breakfast	is	shown	in	Table	2.2.	
The	preparation	of	the	breakfast	was	as	following:	
● Two	 slices	 of	 frozen	 wholemeal	 bread	 (Tesco	 Everyday	 Value	 Medium	 Sliced	
Wholemeal	 Bread)	 were	 defrosted	 at	 room	 temperature	 and	 then	 grilled	 for	 three	
minutes	on	each	side	and	spread	with	15	g	olive	spread	(Tesco).	
● For	the	scrambled	eggs,	two	free-range	eggs	were	beaten	and	100	µg	13C	octanoic	acid	
(see	section	2.7.3)	was	added	for	the	measurement	of	gastric	emptying.	The	eggs	were	
cooked	in	the	microwave	for	30s	+	30s	+	15s	+	15s	while	stirring	between	bouts.		
● Drained	pineapple	chunks	(Tesco)	were	weighed	into	a	bowl.	
● The	 drink	 was	 chosen	 by	 each	 participant	 with	 the	 aim	 of	 replicating	 their	 usual	
breakfast.	 This	 could	 be	 tea,	 coffee	 or	 water	 with/out	 milk	 and	 sugar.	 The	 total	
amount	 of	 liquid	 was	 250	 ml,	 thus	 if	 taking	 coffee	 (2g	 of	 Nescafe	 Original	 Instant	
Coffee)	or	 tea	 (1	bag	of	Yorkshire	Tea)	with	milk	 (British	 semi	 skimmed	milk,	Tesco),	
the	hot	beverages	were	prepared	with	210	ml	of	 hot	water	plus	 40	 g	of	milk.	 If	 the	
participant	wanted	 sugar,	 on	 the	 first	 visit	 she	 served	herself	ad	 libitum	 from	a	pre-
weighed	bowl	and	then	the	amount	was	replicated	for	the	next	two	visits.	
Participants	were	asked	to	 finish	the	whole	breakfast	within	15	minutes.	After	 finishing	their	
breakfast,	participants	were	 instructed	not	 to	eat	or	drink	anything	else	until	 lunch	with	 the	
exception	 of	 a	 330	ml	 bottle	 of	water	 provided	 by	 the	 researcher.	Water	 consumption	was	
calculated	by	weighing	 the	bottle	before	 and	after;	 the	 same	amount	was	 replicated	on	 the	
subsequent	visits.	
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Fig.	2.11.	Breath	sample	collection	
Fig	 2.12.	 Octanoic	 acid	 structure	
(PubChem	(n.d.))	
	
2.7.2. Breath	samples	collection	
Breath	 samples	 were	 collected	 by	 blowing	 into	 a	 small	 glass	 tube	 (Labco	 Exetainer,	 Labco	
Limited,	 UK)	 through	 a	 straw	 while	 having	 the	 nose	 blocked	 with	 a	 nose-clip	 (Fig.	 2.11).	
Participants	blew	into	the	tube	while	removing	the	straw	to	 immediately	cap	the	tube	which	
was	 then	 stored	 at	 room	 temperature	 for	 analysis.	 Breath	 samples	 containing	 the	 oxidised	
octanoic	 acid	 (i.e.	 CO2)	 were	 analysed	 using	 an	
isotope	 ratio	 mass	 spectrometer	 (ABCA,	 Sercon	 Ltd,	
Chesire	UK).	The	atomic	mass	of	13CO2	present	 in	the	
sample	 was	 quantified	 by	 the	 deflection	 that	 the	
isotope	 (13C)	 labelling	 the	 ingested	 octanoic	 acid	
created	through	a	magnetic	field.	The	mass	of	13C	was	
expressed	 in	 Vienna	 Pee	 Dee	 Belemnite	 (V-PDB)	 (an	
international	standard	for	known	13C	composition).	
	
2.7.3. Gastric	emptying	measurement	
As	mentioned	in	section	2.7.1,	100	µg	13C	octanoic	
acid	 (octanoic	 acid	 1-13C	 99%13C,	 Euriso-Top,	
France)	was	pipetted	 into	the	eggs	before	cooking	
to	determine	GE	time.	Octanoic	acid	(C8H16O2)	 is	a	
medium-chain	 triglyceride	 (MCT)	 formed	by	eight	
carbons	 (Fig.	 2.12)	 that	 can	be	naturally	 found	 in	
foods	such	as	coconut	oil	(PubChem	(n.d.)).	During	
digestion,	once	MCTs	reach	the	small	intestine,	they	do	not	go	into	the	lymphatic	system	as	a	
chylomicron	to	get	access	into	the	venous	system	like	long-chain	triglycerides,	rather	they	are	
Table	2.2.	Food	composition	of	the	breakfast	(with	milk)	
Food	
Serv	
(g)	
Energy	
(kJ)	
Energy	
(kcal)	
Fat	
(g)	
Sat	fat	
(g)	
Carbs	
(g)	
Sugars	
(g)	
Fibre	
(g)	
Prot	
(g)	
Wholemeal	bread	 64	 620	 147	 2	 0	 24	 3	 5	 7	
Free	range	eggs	 110	 602	 144	 10	 3	 <0.1	 <0.1	 0	 14	
Olive	light	spread	 15	 115	 28	 3	 1	 0	 0	 0	 0	
Pineapple	 125	 238	 56	 0	 <0.1	 12	 12	 2	 1	
Semi	skimmed	milk	 40	 84	 20	 1	 0	 2	 2	 0	 1	
Total	 357	 1658	 395	 16	 4	 38	 17	 7	 23	
	Serv,	serving;	Sat,	saturated;	Carbs,	carbohydrates;	Prot,	protein	
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directly	transported	to	the	liver	to	be	rapidly	oxidised	via	the	portal	venous	system	(Bloom	et	
al	1951).	Thus,	CO2	appears	almost	immediately	in	the	breath	once	the	octanoic	acid	reaches	
the	 stomach	 from	 the	 duodenum.	 Therefore	 if	 octanoic	 acid	 is	 labelled	with	 an	 isotope,	 for	
example	13C,	the	GE	time	can	be	estimated	by	the	appearance	of	13CO2	in	the	breath.	Despite	
not	being	 a	direct	measurement	of	 gastric	 emptying,	 breath	 collection	 is	 a	 less	 invasive	 and	
expensive	method	than	the	γ	scintigraphy	technique,	requires	 little	training	for	the	measurer	
and	shows	a	low	intra-individual	variability	(Perri	et	al	2006).	
GE	time	can	be	expressed	as	four	different	parameters	(Fig.	2.13):	
a. half	 time	 (thalf)	 which	 represents	 the	 time	 (min)	 that	 requires	 half	 of	 the	 given	
amount	of	13C	to	be	excreted	by	breath;		
b. lag	 phase	 (tlag)	 which	
represents	 the	 time	 (min)	
needed	 to	 reach	 the	 highest	
excretion	 rate	 of	 13C	 which	
coincides	 with	 the	 inflection	
point;	
c. latency	 phase	 (tlat)	 which	
signifies	 the	 initial	delay	 in	 the	
excretion	 curve	 and	 is	 located	
at	 the	 point	 of	 intersection	
between	 the	 tangent	 at	 the	
inflection	 point	 of	 the	
cumulative	 percentage	 of	 the	
dose	recovered	(PDR)	curve	and	the	x-axis	(min);	
d. and	 ascension	 time	 (tasc)	 which	 is	 the	 time	 period	 between	 the	 !!"#	 and	 the	 !!!"#	
representing	the	phase	of	high	13CO2	excretion	rates	(min).	
	
To	 obtain	 these	 four	 parameters,	 the	 first	 step	 was	 to	 convert	 the	 V-PDB	 of	 13CO2	 of	 each	
sample	 into	moles	and	calculate	the	excess	of	CO2	produced	 in	each	sample	(13Ctx)	 from	the	
measurement	taken	at	baseline	(13Ct0)	when	the	participant	was	still	fasted:	
!"#$%% !" !"! !"#$%&'$  !!"# = (13C !x − 13C !0) × !"! !"#$%&'$ 	
	
Fig	 2.13.	 GE	 time	 points	 (Clegg	 and	 Shafat	
2010)	
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Table	 2.3.	 Equations	 used	 to	 calculate	 the	 different	 GE	 parameters	 (Ghoos	 et	 al	 1993,	
Schommartz	et	al	1997)	
GE	parameter	 Equation	
!!"#$	 = !60 !− 1!!×!" !1 − 2
!!!! − 66! /1.12	
!!"#	 = ⌈60×(!"#/!)− 60⌉/0.94	
!!"#	 =
1
!× !!"(!)+
1
! − 1!	
!!"#	 = −
1
!× !!" !1 − 2
!!!! + !"(!) + 1! − 1!	
	
where	CO2 produced equals the normal endogenous production of 300	mmol	 CO2	 per	m2	 of	
body	surface	area	(BSA)	per	h	(Shreeve	et	al	1970).	Participants’	BSA	was	calculated	as	follows	
(Haycock	et	al	1978):	
!"# !! = !"#$ℎ! !" !.!"#$×ℎ!"#ℎ! !" !.!"#$×0.024265	
The	 amount	 of	 13CO2	 produced	 that	 was	 formed	 only	 from	 the	 octanoic	 acid	 given	 was	
calculated:	
!"#$%% !"!!"#$%$&'(!')"(!!"#) = MF!"#!$%&$' −MF!" ×
!
! ×!	
Where	MFsubstrate	=	molar	fraction	of	13C	(0.99);	m	=	the	administered	dose	of	13C	(99mg);	M	=	
the	molar	mass	of	the	13C	(145mg/mmol);	n	=	number	of	labelled	positions	in	the	substrate	(1).	
Finally,	excess	CO2	produced	was	expressed	as	the	PDR	from	that	given	in	the	breakfast:		
!"# = !"#!$$ !"! !"#$%&'$!"#!$$ !"! !"#$%$&'(!')"
×100	
This	 was	 fitted	 into	 the	model	 created	 by	 Ghoos	 et	 al.	 (1993)	 with	 a	 non-linear	 regression	
analyses	using	the	“solver”	tool	of	Excel	(Microsoft	Office,	2013):	
! = !"#×!!!"× (1 − !!!")!!!	
Where	!	equals	the	cumulative	PDR;	!	is	the	time	(h);	and	!, ! !"# ! are	constants.	To	ensure	
the	validity	of	 the	model,	 r2	 coefficient	between	the	 raw	data	and	 the	model	was	calculated	
and	that	equalled	>0.95.	
Finally,	 thalf	 (Ghoos	 et	 al	 1993)	 tlag,	 tasc	 and	 tlat	 (Schommartz	 et	 al	 1997)	were	 determined	 as	
follows:		(Table	2.3):	
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2.8. Food	intake	assessment	(Study	3)	
2.8.1. Food	diaries	
During	the	screening	session,	a	3-day	food	diary	(Appendices)	along	with	a	food	weighing	scale	
(Arc	Electronic	Kitchen	Scale,	HoMedics	Group	Ltd.	Salter,	Kent,	UK)	were	handed	out	 to	 the	
participants	 with	 instructions	 on	 how	 to	 complete	 the	 food	 diary	 and	 use	 the	 food	 weight	
scale.	 Food	 diaries	 are	 representative	 of	 a	 participant’s	 food	 choice	 and	 eating	 patterns;	
however,	 errors	 can	 be	made	when	 recording	meals,	 especially	 during	 the	measurement	 of	
quantities,	 as	 participants	 tend	 to	 underreport	 (Livingstone	 and	 Black	 2003).	 Thus,	 the	
averaged	EI	of	the	total	of	9	days	record	(3-days	x	3-MC	phases)	was	compared	to	the	average	
EE	measured	by	the	PA	monitor	to	ensure	the	validity	of	the	food	diaries.	
Although	 a	 7-days	 food	 record	 is	 considered	 to	 be	 the	 gold	 standard	 of	 food	 intake	
assessment,	 it	has	been	shown	that	as	more	consecutive	days	are	asked	to	be	recorded,	 the	
measurement	error	is	magnified	(Willett	2012).	Therefore,	a	3-day	food	diary	(2	weekdays	+	1	
weekend	day)	is	generally	recommended	for	this	practice	(Rachel	K	Johnson	2002).			
Participants	were	asked	to	weigh	out	and	record	all	the	foods	and	beverages	consumed	with	as	
much	detail	as	possible	(e.g.	brand,	cooking	process)	for	three	days	in	each	phase	of	the	MC.	If	
participants	 could	 not	weigh	 out	 a	meal,	 they	were	 asked	 to	 provide	 portion	 sizes	 by	 using	
household	measures	 (e.g.	 cups)	 and/or	 by	 taking	 pictures	 of	 the	 foods	 eaten.	 The	 selected	
days	 of	 each	 phase	 included	 one	 of	 the	 visits	 to	 the	 laboratory	 (on	 day	 2	 of	 the	 3-days),	
therefore	participants	had	to	only	record	anything	consumed	after	leaving	the	testing	facilities	
on	the	test	day.	Before	participants	left	the	testing	facilities,	a	new	food	diary	was	given	for	the	
next	MC	phase	and	participants	were	reminded	to	 fill	 them	in	closer	to	the	following	testing	
day.	 Food	 intake	 was	 entered	 into	 nutrition	 analyses	 software	 (Nutritics	 V3.74	 Professional	
Edition)	 and	 intakes	 of	 energy,	 carbohydrates,	 sugars,	 protein,	 fats,	 saturated	 fat,	 fibre	 and	
sodium	were	determined	per	day	and	per	phase	of	the	MC	for	each	participant.		
	
2.8.2. Ad	libitum	food	intake	
After	the	four	hours	of	testing,	a	buffet	lunch	was	provided	to	be	consumed	within	30	minutes	
(Fig.	2.14).	This	 lunch	was	used	 to	measure	participants’	 food	 intake	covertly	and	separately	
from	their	food	diary	as	awareness	of	having	their	food	intake	assessed	may	change	or	restrain	
their	food	intake	(Stubbs	et	al	1998).	Thus,	participants	were	told	to	“eat	as	much	as	you	want	
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Fig	2.14.	Buffet	lunch	(non-vegetarian)	
until	you	feel	comfortably	full”.	Nevertheless,	 it	may	have	been	obvious	that	food	intake	was	
measured	because	they	did	not	have	to	recall	this	meal	nor	the	breakfast	of	that	day	in	their	
food	diaries.	The	researcher	weighed	out	all	the	foods	before	and	after	the	participant	had	her	
lunch	 and	 then	 food	 intake	 was	 analysed	 using	 an	 excel	 spreadsheet	 designed	 from	 the	
manufacture’s	food	information	provided	in	the	food	label.	Ad-libitum	food	intake	assessment	
included	the	measurement	of	energy,	carbohydrates,	protein,	sugars,	fats,	saturated	fat,	fibre	
and	 sodium.	The	 foods	offered	 in	 the	buffet	were	a	 variety	of	pre-cooked	dishes/foods	 that	
required	 little	 cooking	 for	 the	 researchers	due	 to	 the	 lack	of	 time	of	 preparation	during	 the	
testing.	 The	 selected	 foods	 were	 chosen	 with	 the	 aim	 to	 satisfy	 all	 tastes	 and	 possible	
conditions	(e.g.	lactose	intolerance,	vegetarian	diets,	etc.)	thus	food	intake	was	not	restrained	
by	choice	or	quantity	(see	Table	2.4	for	list	of	foods	and	composition).	One	of	the	participants	
was	vegan	but	agreed	to	partake	in	the	study	because	free	range	organic	eggs	were	provided	
at	 breakfast.	 In	 her	 case	 the	 buffet	 was	 modified	 (five	 items	 were	 removed	 and	 five	 were	
exchanged)	to	ensure	that	there	was	enough	food	and	variety	(Table	2.4).	
Both	 free-living	 and	 laboratory	 settings	 present	 their	 own	 limitations	 when	 looking	 at	 the	
validity	of	measuring	techniques	for	food	intake.	Although	the	latter	can	be	very	precise	as	the	
researcher	is	measuring	the	amounts	of	food	intake	in	a	very	controlled	environment,	this	can	
also	have	an	 impact	on	 the	participant’s	eating	pattern	because	of	being	 in	 such	an	artificial	
environment	 (Stubbs	et	al	1998).	Nevertheless,	 this	potential	 change	produced	 in	 the	eating	
behaviour	was	expected	to	be	the	similar	in	each	session	as	the	settings	of	the	kitchen	where	
participants	had	their	lunch	were	kept	as	consistent	as	possible	and	food	intake	was	studied	by	
assessing	within	subject	effects,	thus	minimising	any	bias.	
CHAPTER	2	 Methods	
	
46	
	
	 	
Table	2.4.	Foods	available	in	buffet	lunch	with	nutritional	composition	per	portion	provided.	
Food	
Serving	 Energy	 Fat	
(g)	
Sat	fat	
(g)	
Carbs	
(g)	
Sugars	
(g)	
Fibre	
(g)	
Prot	
(g)	
Salt	
(g)	units	 g	 (kJ)	 (kcal)	
Hummus,	T	 	 50	 664	 161	 14	 1	 4	 0	 2	 4	 1	
Apples	Gala,	T		 1	 135	 304	 71	 0	 0	 16	 16	 2	 1	 0	
Banana,	T	 1	 158	 636	 150	 0	 0	 36	 19	 4	 2	 0	
Clementines	T	 2	 226	 398	 95	 0	 0	 20	 20	 3	 2	 0	
Carrots,	loose,	T	 	 70	 123	 30	 0	 0	 6	 5	 2	 0	 0	
Celery	sticks,	T	 	 80	 32	 8	 0	 0	 1	 1	 1	 0	 0	
Tomatoes,		T	 18	 142	 119	 28	 0	 0	 4	 4	 1	 1	 0	
Potato	Salad,	T	*	 	 270	 1858	 448	 35	 3	 28	 2	 3	 4	 1	
Pasta	Tuna	&	
Sweetcorn,	T	 	 295	 2295	 549	 25	 5	 59	 9	 3	 20	 1	
Moroccan	
Couscous,	T	 	 245	 2112	 502	 16	 1	 75	 41	 11	 9	 0	
Bright	Salad,	T	 	 83	 93	 22	 0	 0	 3	 3	 2	 1	 0	
Cheese,	Babybel	 4	 95	 1207	 291	 23	 15	 0	 0	 0	 21	 2	
Low-fat	Yoghurt,	T	*	 1	 120	 406	 96	 1	 1	 19	 15	 0	 3	 0	
Sausages,	
Lincolnshire,	T	 8	 66	 779	 187	 14	 5	 7	 1	 1	 9	 1	
Chicken	Nuggets,	T	*	 5	 77	 770	 185	 10	 1	 14	 1	 1	 10	 0	
Pizza,	Cheese	&	
Tomato,	T	 1	 160	 1934	 459	 12	 5	 68	 8	 2	 18	 1	
Bread	sticks,	T	 	 19	 331	 78	 1	 0	 14	 1	 1	 2	 0	
Crisps,	ready	
salted,	Walkers		 1	bag	 24	 527	 126	 8	 1	 12	 0	 1	 1	 0	
KitKat,	Milk	
Chocolate	 4	fingers	 45	 958	 229	 11	 6	 29	 23	 1	 3	 0	
Orange	Juice	
Smooth,	T	 	 500	 985	 230	 0	 0	 54	 41	 0	 5	 1	
Water	 	 500	 0	 0	 0	 0	 0	 0	 0	 0	 0	
Egg	Mayonnaise	
Sandwich	*	 	 139	 1202	 287	 13	 2	 26	 3	 5	 14	 1	
Chicken	&	
Sweetcorn	
Sandwich	*	 	
139	 1199	 287	 12	 1	 29	 3	 5	 14	 1	
TOTAL	(non-vegan	buffet)	 3594	 17974	 4291	 184	 42	 494	 192	 51	 142	 11	
Bean	&	Mint	
Salad,	T	ϒ	 	 215	 1288	 310	 13	 2	 26	 2	 14	 15	 2	
Soya	Fruit	
Yoghurt,	Alpro	ϒ	 1	 129	 396	 94	 3	 0	 12	 12	 2	 5	 0	
Vegetable	Spring	
Rolls,	T	ϒ	 6	 115	 1173	 281	 14	 6	 33	 4	 3	 6	 0	
Peanut	Butter	
Sandwich	ϒ	 	 113	 1477	 355	 20	 3	 23	 4	 7	 17	 0	
Beetroot	&	Mint	
hummus	
Sandwich	ϒ	 	
109	 755	 180	 5	 1	 23	 2	 6	 7	 1	
TOTAL	(vegan	buffet)		 2914	 11413	 2721	 95	 16	 361	 175	 62	 78	 6	
Nutritional	 composition	 of	 the	 foods	 was	 based	 on	 manufacturer’s	 information.	 Sat,	 saturated;	 Carbs,	
carbohydrates;	Prot,	protein,	T,	Tesco	*	Items	that	were	removed	in	the	vegan	buffet.	ϒ	Item	included	in	the	
vegan	buffet	only.	
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2.9. Appetite	sensations	assessment	(Study	3)	
Participants	rated	their	appetite	sensations	before	and	immediately	after	breakfast	and	every	
15	minutes	during	 the	 first	hour	post-breakfast	 and	 then	every	30	minutes	until	 lunch	 time.	
Feelings	of	satiety	were	assessed	by	four	questions	(1)	‘How	hungry	do	you	feel?,’	(2)	‘How	full	
do	you	feel?’,	(3)	‘How	strong	is	your	desire	to	eat?’	and	(4)	‘How	much	food	do	you	think	you	
can	 eat?’	 in	 which	 participants	 had	 to	 rate	 their	 appetite	 sensations	 with	 printed	 Visual	
Analogue	Scales	(VAS),	namely,	by	putting	a	mark	in	a	100	mm	line	per	each	question,	where	0	
=	(1)	‘not	hungry	at	all’,	(2)	‘extremely	full’;	(3)	‘not	strong	at	all’	and	(4)	‘nothing	at	all’	and	100	
=	(1)	‘extremely	hungry’,	(2)	‘not	at	all	full’;	(3)	‘extremely	strong’	and	(4)	‘a	large	amount’	(Fig.	
2.15)	 (Appendices).	 The	 distance	 between	 the	 origin	 (score	 =	 0)	 and	 the	mark	 was	 used	 to	
measure	the	participant’s	score.	
Each	question	was	then	analysed	separately	by	calculating	the	derived	AUC	from	the	scores	of	
all	the	time	points.	AUC	was	calculated	using	the	trapezoidal	method	at	min	60,	120,	180,	210	
and	240	from	baseline	(before	breakfast).	The	employment	of	VAS	has	been	validated	in	many	
studies	and	the	use	of	 total	AUCs	with	baseline	 levels	as	covariates,	has	been	recommended	
over	individual	time	scores	or	incremental	AUCs	within	participants	(Blundell	et	al	2010).	
	
2.10. Physical	activity	assessment	(Study	3)	
Physical	 activity	 patterns	 were	 assessed	 using	 a	 body	 monitoring	 system	 (SenseWear®,	
BodyMedia).	 	The	SenseWear	monitor	has	been	validated	as	a	reliable	tool	 to	measure	EE	 in	
Fig	2.15.	Example	Visual	Analogue	Scale	
scores	
Score: 22 
Score: 25 
Score: 7 
Score: 11 
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adults	in	free-living	conditions	(St-Onge	et	al	2007).	The	purpose	of	using	this	method	instead	
of	 others,	 e.g.	 PA	 diary,	 was	 to	 obtain	 valid	 data	 while	 adding	 minimal	 disruption	 to	 the	
participants’	 normal	 life	 and	 to	 maintain	 recruitment	 and	 compliance	 in	 the	 study.	 The	
SenseWear	 consisted	 of	 an	 armband	 that	 assessed	 PA	 and	 lifestyle	 (e.g.	 sleeping	 hours)	 by	
measuring	(1)	motion	and	(2)	the	steps	taken	with	a	3-axis	accelerometer,	and	(3)	the	galvanic	
skin	 response	 (i.e.	 the	 change	 in	 the	 electrical	 conductivity	 of	 the	 skin	 due	 to	 sweat	 or	
emotional	 stimuli),	 (4)	 the	 skin	 temperature	 and	 (5)	 the	 heat	 flux	 with	 different	 sensors.	
Participants	 were	 requested	 to	 wear	 the	 activity	 monitor	 on	 the	 upper	 right	 arm	 (triceps	
muscle)	throughout	the	day	(24	hours)	except	during	activities	 in	which	the	skin	 is	 in	contact	
with	water	(e.g.	showering)	as	the	equipment	instructions	advise	(Body	Media	2006).	Data	was	
downloaded	 and	 analysed	 as	 total	 daily	 energy	 expenditure	 (kcal/d)	 using	 the	 BodyMedia	
software	once	 individual	 characteristics	 (i.e.	 date	of	birth,	 height,	weight,	 sex)	were	entered	
into	the	system.	
	
2.11. MC	phases	definition	
Due	to	the	main	aim	of	this	thesis,	i.e.	to	determine	whether	changes	in	the	ovarian	hormones	
affects	different	metabolic	and	appetite-related	factors,	 it	was	deemed	appropriate	to	divide	
the	MC	according	to	the	levels	of	the	ovarian	hormones.	For	Studies	1	and	2,	measurements	of	
E2	and	P4	were	taken	three	times	a	week	during	a	whole	cycle,	thus	hormone	profiles	could	be	
mapped	very	easily	and	the	MC	in	the	NC	group	could	be	divided	in	three	phases	as	follows:	(1)	
MPh	from	day	1	until	the	last	day	of	bleeding;	(2)	FPh	from	the	subsequent	day	until	the	day	
after	the	E2	peak;	and	(3)	LPh	that	ended	on	the	day	prior	to	the	start	of	the	next	cycle.	This	
division	was	designed	to	find	low	concentrations	of	both	hormones	in	the	MPh,	high	E2	levels	
in	the	FPh	and	high	E2	and	P4	in	the	LPh.	Cycles	that	did	not	display	a	minimal	concentration	of	
15.9	nmol/l	were	considered	nonovulatory	or	not	normal	(Piers	et	al	1995).	 In	the	HC	group,	
the	MC	was	divided	into	two	stages:	(1)	on	HC	stage	(ON),	 i.e.	the	three	weeks	when	the	HC	
was	used;	and	(2)	off	HC	stage	(OFF),	i.e.	the	seven	days	when	the	HC	was	not	used.	
When	hormones	were	only	measured	three	times	during	the	MC	(Study	3),	MC	phases	were	
assigned	 before	 the	 participant	 attended	 the	 laboratory	 and	 only	 after	 hormonal	
measurements	could	confirm	the	correct	phase.	Scheduling	test	sessions	 to	 the	MPh	did	not	
present	any	difficulty	as	the	participant	notified	the	researcher	of	the	onset	of	the	menses	and	
a	visit	 to	 the	 laboratory	was	arranged	as	 soon	as	possible;	however,	 to	determine	when	 the	
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LPh	 began	 was	 more	 challenging	 as	 it	 is	 well	 documented	 that	 MC	 phase	 length	 can	 vary	
considerably	 amongst	women	 and	 even	within	 individuals	 (Fehring	 et	 al	 2006).	 Therefore,	 a	
fertility	monitor	 (Clear	Blue	Advanced	Fertility	Monitor)	was	used	 to	measure	urine	 levels	of	
estrone-3-glucuronide	(E3G)	(the	main	metabolite	of	E2)	and	LH.	The	advantage	of	these	type	
of	fertility	monitors	compared	to	others	is	that	the	LH	peak,	i.e.	ovulation,	can	be	anticipated	
by	tracking	E3G	concentrations	from	day	6	of	the	cycle	(Clearblue	2013).	Moreover,	it	has	been	
proved	to	be	a	valid	tool	when	arranging	laboratory	visits	upon	the	phases	of	the	MC	(Howards	
et	al	2009).		
Participants	were	asked	to	test	their	first	urine	of	the	morning	by	urinating	on	a	stick	for	three	
seconds	 and	 then	 placing	 into	 the	monitor	 to	 obtain	 a	 result.	 The	monitor	 displayed	 three	
possible	 readings:	 ‘low’	 (E3G	 levels	 low),	 ‘high’	 (E3G	 levels	 increased)	 and	 ‘peak’	 (LH	 levels	
high).	When	 participants	 obtained	 the	 ‘high’	 reading	 they	 notified	 the	 researcher	who	 then	
scheduled	the	next	 testing	session	based	on	the	day	of	 the	cycle	the	participant	was	on,	her	
MC	length	history	and	the	fact	that	it	usually	takes	approximately	five	days	to	reach	to	‘peak’	
after	a	‘high’	reading	(Howards	et	al	2009),	in	order	to	test	the	participant	at	very	high	levels	of	
E2.	Once	the	‘peak’	reading	appeared,	the	last	session	was	scheduled	to	test	when	P4	was	at	its	
highest	values	(in	the	mid-luteal	phase)	based	on	the	peak	day	and	the	usual	MC	length	of	the	
participant.	When	 participants	 did	 not	 reach	 ‘peak’	 they	 were	 asked	 to	 postpone	 their	 LPh	
testing	 until	 the	 next	 cycle	 to	 ensure	 that	 the	 P4	 levels	 were	 high	 enough	 to	 produce	 any	
potential	effects	on	the	parameters	studied	(i.e.	PYY	response,	GE	time,	appetite	feelings	and	
food	intake).	
	
2.12. Statistical	analyses	
Sample	 size	 was	 initially	 estimated	 by	 previous	 similar	 studies	 and	 after	 was	 calculated	
retrospectively	with	the	outcome	data	and	using	G*Power	3.1.9.2	(Universität	Kiel,	Germany)	
software.	Data	was	analysed	with	SPSS	Statistics	19.	The	normality	of	the	data	was	tested	using	
the	Shapiro-Wilks	 test.	When	data	were	not	normally	distributed,	non-parametric	 tests	were	
used.	 Differences	 between	 groups	 (NC	 vs	 HC	 users)	 were	 compared	 using	 the	 independent	
sample	 t-test	 or	 Mann-Whitney	 U	 test,	 where	 appropriate.	 One-way	 repeated	 measures	
ANOVA	or	Friedman	test	was	used	to	test	differences	across	the	phases	of	the	MC	in	the	NC	
group	and	paired	t-test	or	Wilcoxon	signed-rank	test	was	used	to	compare	between	the	two	
stages	of	the	MC	in	the	HC	group.	Statistical	significance	level	was	established	at	p	≤	0.05.		
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3. Ovarian	hormones	in	plasma	and	saliva	during	the	MC	(Study	1)	
3.1. Background	
During	the	design	of	a	human	study,	researchers	should	prioritise	the	use	of	testing	techniques	
that	have	been	shown	to	be	reliable,	affordable	and,	very	importantly,	that	are	less	invasive	for	
the	participants	taking	part.	Although	ultrasound	is	the	direct	method	to	monitor	the	ovaries	
action,	 this	 may	 be	 unfeasible	 in	 many	 studies	 due	 to	 its	 impracticability,	 thus	 the	
measurement	 of	 the	 ovarian	 hormones	 becomes	 the	 best	 available	 option	 (Hampson	 and	
Young	2007).	Natural	MC	is	usually	described	as	a	“28-days”	cycle	in	which	ovulation	occurs	on	
day	 14	 and	 the	 FPh	 and	 LPh	 are	 equally	 distributed	 around	 this	 event.	 However,	 it	 is	 well	
known	that	MC	length	varies	between	and	within	individuals	and	that	this	is	more	dependant	
on	the	length	of	the	FPh	rather	than	the	LPh	(Fehring	et	al	2006).	These	natural	variations	will	
have	an	impact	on	the	design	of	any	MC	related	study	as	these	are	indicating	differences	in	the	
time	exposure	of	each	of	the	ovarian	hormones	per	MC.	
Traditionally,	when	ultrasound	is	not	available,	monitoring	of	the	MC	this	would	be	done	from	
blood	samples,	but	for	the	last	decades	saliva	samples	have	progressively	become	a	common	
method	also	employed	by	 researchers	and	clinicians	 (Gröschl	2008).	The	difference	between	
the	 two	 specimens	 is	 that	 blood	 samples	 are	 mainly	 composed	 of	 the	 bound	 form	 of	 the	
steroid	 hormones,	 whereas	 saliva	 is	 primarily	 composed	 of	 the	 free	 (bioactive)	 form.	
Moreover,	 it	 is	 believed	 that	 hormone	 concentrations	 obtained	 from	 saliva	 reflect	 those	 of	
unbound	fraction	that	would	be	found	in	blood	(Tenovuo	1989),	thus	potentially	serving	as	a	
more	effective	biomarker	than	plasma	levels	in	certain	investigations	where	the	aim	is	to	study	
the	influence	of	those	on	the	matter	investigated.	Studies	in	the	past	have	shown	that	both	P4	
and	E2	 levels	 in	 saliva	 and	plasma	 correlate	well	 i.e.	 r	 =	 0.68	–	0.974	 (De	Boever	et	 al	 1986,	
Bolaji	 1994,	 Bourque	 et	 al	 1986,	 Walker	 et	 al	 1979,	 Worthman	 et	 al	 1990)	 in	 NC	 women.	
Nevertheless,	how	these	two	measurements	relate	 is	still	not	completely	elucidated	as	saliva	
concentrations	 are	 not	 only	 dependant	 on	 plasma	 concentrations,	 but	 also	 on	 the	 levels	 of	
their	plasma	carriers	(Elliott	et	al	2003).	
To	 our	 knowledge	no	 previous	 studies	 have	 looked	 at	 the	 correlations	 between	plasma	 and	
salivary	ovarian	hormones	throughout	a	MC	in	HC	users.	The	aim	of	this	study	was	to	explore	
the	patterns	that	the	ovarian	hormones	display	 in	plasma	and	saliva	throughout	the	MC	 in	a	
group	 of	 NC	 women	 and	 HC	 users.	 In	 particular,	 we	 aimed	 to	 study	 whether	 the	 levels	 of	
ovarian	hormones	changed	significantly	 in	 the	different	phases	of	 the	MC	 in	both	specimens	
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(saliva	 and	 plasma)	 and	 how	 this	 compared	 between	 groups	 as	 an	 average	 of	 the	 MC.	
Furthermore,	a	secondary	objective	of	this	investigation	was	to	study	the	correlations	between	
saliva	and	plasma	for	E2	and	P4	overall,	per	group	and	per	phase	of	the	MC.	
	
3.2. Methods	
3.2.1. Protocol	
Once	 the	participants	were	 accepted	 to	partake	 in	 the	 study,	 they	were	 asked	 to	notify	 the	
researcher	 upon	 the	 start	 of	 their	menstruation	 (defined	 as	 day	 1).	 Then	 they	 attended	 the	
laboratory	for	the	measurement	of	the	ovarian	hormones	in	plasma	and	saliva	on	the	following	
morning	and	three	times	a	week	during	a	whole	MC,	i.e.	until	the	start	of	the	menstruation	of	
the	next	cycle	(day	1	of	cycle	2)	(approximately	12	visits	in	total).	The	MC	in	the	NC	group	was	
divided	 in	 three	phases	as	 follow:	 (1)	MPh	 from	day	1	until	 the	 last	day	of	bleeding;	 (2)	FPh	
from	the	subsequent	day	until	 the	day	after	 the	E2	peak;	and	 (3)	 LPh	 that	ended	on	 the	day	
prior	to	the	start	of	cycle	2.	In	the	HC	group,	the	MC	was	divided	in	two	stages:	(1)	on	(ON),	i.e.	
the	21	days	when	the	HC	was	used;	and	(2)	off	 (OFF)	stage,	 i.e.	the	seven	days	when	the	HC	
was	not	used.		
On	the	testing	day	participants	attended	the	laboratory	in	the	morning	(between	07:00-10:00)	
after	a	10-12	hour	overnight	fast.	After	an	hour	in	the	laboratory,	they	rinsed	their	mouth	and	
after	 5	 min	 a	 ~2	 ml	 saliva	 sample	 was	 collected	 via	 passive	 drool	 and	 under	 standardised	
conditions	 (see	chapter	2.5.1).	 Saliva	 samples	were	kept	 in	 ice	until	 they	were	distributed	 in	
different	aliquots	to	be	stored	at	-40°C	within	four	hours	of	collection	until	they	were	analysed	
to	measure	 their	 contents	 of	 free	 E2	 and	 P4	 by	 ELISA.	 Variability	 between	 salivary	 E2	 and	 P4	
assay	duplicates	was	5.8	±	6.5	and	4.0	±	4.3	(%CV),	respectively.	Following	that,	a	venous	blood	
sample	 of	 6	ml	was	 collected	 for	 the	measurement	 of	 total	 E2	 and	 P4.	 Blood	 samples	were	
centrifuged	to	extract	their	plasma;	this	was	then	stored	at	-80°C	for	future	analyses	by	ECLIA.		
	
3.2.2. Calculations	and	statistical	analyses	
Sample	size	was	based	on	study	3	calculation	(see	chapter	4	for	more	details).	
Data	 were	 analysed	 using	 SPSS	 Statistics	 19.	 Values	 are	 expressed	 as	 means	 ±	 SD	 for	
descriptive	 parameters	 and	 means	 ±	 SE	 for	 measurements	 expressed	 as	 averages	 of	 the	
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Table	3.1.	Formulation	of	the	different	hormonal	contraceptives	used	by	participants.	
	
n	 Trade	name	(form)	 Hormone	Dose	
EthinylEstradiol	 Progesten	
1	 Leeloo	Ge	(oral)	 20	µg	 100	µg		 levonorgestrel	
1	 Loestrin	20	(oral)	 20	µg	 1000	µg		 norethisterone	
2	 Gedarel	(oral)	/	Marvelon	(oral)	 30	µg	 150	µg		 desogestrel	
1	 Microgynom	(oral)	 30	µg	 150	µg		 levonorgestrel	
1	 Evra	(patch)		 34	µg	 203	µg		 norelgestromin	
1	 Cilest	(oral)	 35	µg	 250	µg		 norethisterone	
2	 Dianette	(oral)	/	Midane	(oral)	 35	µg	 2000	µg		 cyproterone	acetate	
	
different	phases.	The	normality	of	the	data	was	tested	using	the	Shapiro-Wilks	test.	When	data	
were	 not	 normally	 distributed,	 non-parametric	 tests	 were	 used.	 Differences	 in	 ovarian	
hormones	 between	 groups	 were	 compared	 using	 the	 independent	 sample	 t-test	 or	 Mann-
Whitney	U	test,	where	appropriate.	One-way	repeated	measures	ANOVA	or	Friedman	test	was	
used	 to	 test	 differences	 in	 averaged	 hormones	 levels	 in	 plasma	 and	 saliva	 and	 the	 ratio	
between	the	two	specimens	across	the	phases	of	the	MC	in	the	NC	group	and	paired	t-test	or	
Wilcoxon	 signed-rank	 test	 was	 used	 when	 comparing	 the	 two	 stages	 of	 the	 MC	 in	 the	 HC	
group.	 Analyses	 were	 also	 performed	 without	 averaging	 concentrations	 of	 hormones	 per	
participant	 and	 phase,	 therefore	 all	 the	 data	 points	were	 used	 to	 compare	 between	 phases	
and	 groups.	 Correlations	 between	 specimens	 were	 analysed	 by	 Pearson’s	 or	 Spearman’s	
correlation	using	each	data	point	for	the	whole	sample	of	visits	as	well	as	per	each	group	and	
phases	of	the	MC.		
Statistical	significance	level	was	established	at	p	≤	0.05	except	in	the	Wilcoxon	tests	(used	for	
pairwise	comparisons	following	the	Friedman	tests)	when	a	Bonferroni	correction	was	applied	
so	that	all	effects	are	reported	at	a	0.0167	level	of	significance.		
	
3.3. Results		
3.3.1. Participants	characteristics	
Of	 the	 27	 women	 (16	 NC	 and	 11	 HC	 users)	 who	 started	 the	 study,	 two	 withdrew	 due	 to	
personal	reasons,	two	were	excluded	because	they	did	not	fulfil	the	inclusion	criteria,	e.g.	cycle	
length	<25	days	PCOS,	and	another	due	to	an	incomplete	data	set	(see	chapter	2.2).	Most	HC	
participants	were	using	a	combined	HC,	thus	one	participant	who	was	using	a	P4-only	HC	was	
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Table	3.3.	Ovarian	hormone	levels	in	plasma	and	saliva	as	an	average	of	the	MC	in	the	NC	and	
the	HC	group.	
	
	 NC	(n	11)	 HC	(n	9)	 p	
Plasma	E2	(pg/ml)	 147.3	±	8.1	 21.1	±	3.6	*	 <0.001	
Plasma	P4	(ng/ml)	 5.20		±	0.52	 0.57	±	0.09	*	 <0.001	
Salivary	E2	(pg/ml)	 2.58		±		0.14	 2.03		±		0.24	*	 0.049	
Salivary	P4	(pg/ml)	 122.8		±	20.3	 125.6	±	28.2	 0.937	
Means	±	SE.	*	Significantly	different	to	NC.	
also	excluded	from	the	study	as	her	ovarian	hormones	pattern	was	very	different	to	what	was	
seen	in	the	NC	or	HC	women	.	The	HC	formulations	can	be	found	in	Table	3.1.	
Therefore,	the	results	presented	are	based	on	a	sample	of	20	healthy	women	(11	NC	and	9	HC	
users).	The	majority	of	the	women	were	Caucasian	(6	NC	and	9	HC	users)	and	the	rest	had	an	
Arab	(4	NC)	or	Asian	(1	NC)	ethnic	background.	Table	3.2	presents	the	physical	characteristics	
of	the	participants.	There	were	no	significant	differences	in	any	of	these	variables	between	the	
two	groups	except	for	waist	circumference	(p	=	0.041).		
Regarding	the	MC	characteristics,	the	average	length	for	the	whole	MC,	the	MPh,	FPh	and	LPh	
was	29	±	3,	5	±	1,	13	±	5	and	11	±	3	days,	respectively	in	the	NC	group.	In	the	HC	group,	28	±	1,	
21	±	1	and	7	±	1	days	was	the	averaged	count	for	the	MC,	ON	and	OFF	stages,	respectively.	
	
	
3.3.2. Changes	in	ovarian	hormones	across	the	phases	of	the	MC	
As	an	average	of	the	MC,	E2	and	P4	levels	in	plasma	were	significantly	higher	in	the	NC	than	the	
HC	group	(Table	3.3).	 In	saliva,	only	E2	 levels	were	significantly	higher	 in	the	NC	compared	to	
the	HC	women,	whereas	P4	levels	were	kept	at	similar	levels	(Table	3.3).	
Table	3.2.	Baseline	characteristics	of	the	NC	and	HC	groups.	
	
	 NC	(n	11)	 HC	(n	9)	 p	
Age	(y)	 27	±	6	 23	±	4	 0.089	
BW	(kg)	 65.5	±	11.6	 57.5	±	9.2	 0.131	
Height	(m)	 1.67		±		0.08	 1.66	±	0.06	 0.710	
BMI	(kg/m2)	 23		±	3	 21	±	2	 0.063	
FM	(kg)	 20.2	±	7.2	 15.7	±	7.3	 0.213	
FM	(%)	 29.8	±	6.1	 26.2	±	8.0	 0.305	
FFM	(kg)	 45.4	±	5.1	 41.8	±	3.6	 0.107	
Waist	(cm)	 73.3	±	6.5	 67.5	±	4.3	*	 0.041	
Hip	(cm)	 101.1	±	7.6	 95.8	±	8.0	 0.167	
Waist-to-hip	ratio	 0.73	±	0.03	 0.71	±	0.05	 0.307	
Means	±	SD.	BW,	body	weight;	FM,	fat	mass;	FFM,	fat	free	mass.		
*	Significantly	different	to	NC.	
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In	 the	 NC	 group,	 significant	 changes	 were	 observed	 throughout	 the	 phases	 of	 the	 MC	 in	
plasma	E2	χ2(2,	N=	11)	=	16.55,	and	P4	χ2(2,	N=	11)	=	15.27	(p	<	0.001	in	both).	In	particular,	E2	
was	 significantly	 higher	 in	 the	 FPh	 and	 LPh	 (median	 =	 87.7	 and	 167.5	 pg/ml,	 respectively)	
compared	 to	 the	MPh	 (median	=	41.3	pg/ml),	 z	 =	 -2.93,	p	=	0.003	 for	both,	whereas	P4	was	
significantly	increased	in	the	LPh	(median	=	10.69	ng/ml)	compared	to	the	MPh	(median	=	0.97	
ng/ml),	z	=	-2.85,	p	=	0.004	and	the	FPh	(median	=	0.80	ng/ml),	z	-2.93,	p=	0.003	(Fig.	3.1).	
	
Although	the	ovarian	hormones	 in	saliva	showed	a	similar	pattern	as	 in	plasma	(see	Fig	3.2),	
changes	 in	 salivary	 E2	 did	 not	 reach	 statistical	 significance	 across	 the	 phases	 of	 the	MC	 (p=	
0.059)	(Fig	3.1).	Nevertheless,	salivary	P4	changed	significantly	throughout	the	MC	χ2	(2,	N=	9)	=	
10.89,	 p=	 0.004,	 showing	 significantly	 higher	 levels	 in	 the	 LPh	 (median	 =	 162.6	 pg/ml)	
compared	to	the	FPh	(median	=	61.2	pg/ml),	z	=	-2.67,	p	=	0.008,	but	not	the	MPh	(median	=	
72.2	pg/ml),	z	=	-1.60,	p	=	0.110	(Fig	3.1).		
When	looking	at	the	ovarian	hormones	in	the	HC	users,	a	different	fluctuation	pattern	to	the	
NC	women	was	 observed	 throughout	 the	MC.	 As	 depicted	 in	 Fig.	 3.2,	 while	 plasma	 P4	 was	
constantly	 kept	 at	 very	 low	 levels	 (similar	 to	 that	 seen	 in	 plasma	 concentrations	 during	 the	
MPh	 and	 FPh	 of	 the	MC),	 plasma	 E2	 experienced	 a	 peak	 during	 the	weeks	OFF	 the	 pill	 just	
before	participants	started	using	the	HC	again.	Thus,	plasma	E2	was	significantly	higher	in	the	
weeks	OFF	the	pill	by	almost	two	fold	(Z	=	-2.073.	p=	0.038)	(Fig	3.3).	
Fig.	3.1.	E2	(A)	and	P4	(B)	levels	in	plasma	and	saliva	in	the	different	phases	of	the	MC	in	the	NC	
group	(means	±	SE)	
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In	saliva,	P4	levels	were	constantly	kept	at	similar	levels	in	the	diferent	weeks	of	the	MC	in	the	
HC	 group	 (p	 =	 0.483)	 (Fig	 3.3),	 although	 individual	 concentrations	 ranged	 widely	 with	some	
showing	 similar	 levels	 to	 those	 observed	 in	 the	 NC	 group	 (19.28	-	259.99	 pg/ml).	 Similarly,	
salivary	E2	levels	were	marginaly	changed	(p=	0.144).	
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3.3.3. Ratios	and	correlations	between	specimens	
Saliva:plasma	ratios	in	the	specimens	changed	for	E2	(p<	0.001)	and	P4	χ2(2,	N=	9)	=	10.89,	p=	
0.004	 across	 the	 phases	 of	 the	 MC	 in	 the	 NC	 (Fig	 3.4).	 Ratio	 of	 specimens	 for	 E2	 was	
significantly	higher	in	the	MPh	compared	to	the	other	phases	(Fig	3.4)	and	ratio	of	specimens	
for	P4	was	significantly	lower	in	the	LPh	compared	to	the	other	phases.	In	the	HC	group,	ratio	
between	specimens	changed	significantly	for	E2	(p	=	0.026),	being	~	60%	greater	in	the	weeks	
ON	than	in	the	OFF,	but	not	for	P4	(Fig	3.4).		
Regarding,	the	correlations	between	the	two	specimens	measuring	the	ovarian	hormones,	the	
results	showed	a	weak,	but	significant,	correlation	between	salivary	and	plasma	E2	(r	=	0.290,	p	
<	0.001)	but	not	for	P4	 (r	=	0.111,	p	=	0.145)	when	 looking	at	all	 the	measurements	with	the	
two	groups	combined	(n	=	160	and	175	for	E2	and	P4,	respectively).	However,	when	selecting	
the	measurements	of	only	the	NC	women	(n=	111	and	99),	significant	weak	correlations	were	
found	 for	 both	 hormones,	 (r=	 0.227;	 p=	 0.017	 and	 r=	 0.352;	 p	 <0.001	 for	 E2	 and	 P4,	
respectively).	Nevertheless,	further	analyses	per	each	phase	of	the	MC	(Table	3.4)	showed	that	
solely	 in	the	LPh	significant	correlations	existed	between	the	two	specimens	and	that	only	P4	
was	strongly	correlated	(r	=	0.607,	p	<0.001)	(Fig	3.5).		
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In	 the	HC	 group,	 there	were	 no	 correlations	 between	 saliva	 and	plasma	 for	E2	 and	 P4	when	
looking	at	the	whole	cycle	or	in	each	phase	(Table	3.5).		
	
	 	
Table	3.4.	Correlations	between	saliva	and	plasma	for	E2	and	P4	levels	 in	the	different	phases	
of	the	MC	in	the	NC	group.	
	
	 MPh	 FPh	 LPh	
E2	
r	 -0.264	 0.225	 0.343	
p	 0.236	 0.113	 0.020	
n	 22	 51	 46	
P4	
r	 0.135	 0.249	 0.607	
p	 0.559	 0.111	 <0.001	
n	 21	 42	 43	
Bold	indicates	significant	correlation	
Table	3.5.	Correlations	between	saliva	and	plasma	for	E2	and	P4	levels	in	the	HCs	group	and	
in	their	different	stages	of	the	MC	in	the	HC	group.	
	
	 MC	 ON	 OFF	
E2	
r	 -0.028	 0.156	 -0.108	
p	 0.847	 0.371	 0.714	
n	 49	 35	 14	
P4	
r	 0.159	 0.205	 0.084	
p	 0.170	 0.130	 0.724	
n	 76	 56	 20	
Bold	indicates	significant	correlation	
Fig	3.5.	Correlations	between	plasma	and	salivary	E2	(A)	and	P4	(B)	concentrations	in	the	LPh		
A	 B	
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Table	3.7.	 Saliva:plasma	ratio	 for	E2	and	P4	 in	 the	different	phases	of	 the	MC	 in	NC	 from	all	
data	points.	
	
	 MPh	 FPh	 LPh	 p	
E2	ratio		 0.06	±	0.04	
a	 0.03	±	0.02	b	 0.002	±	0.01	c	 <0.001	
P4	ratio	 0.10	±	0.08	 0.15	±	0.11	 0.02	±	0.01	
a
	 <0.001	
Means	±	SD.	Different	superscripts	denote	significant	differences	between	phases.	
3.3.4. Ovarian	hormones	analysed	as	averages	of	all	the	data	points	
This	 section	 aimed	 to	 study	 the	 ovarian	 hormones	 between	 groups	 and	 within	 the	 MC	 by	
analysing	the	data	of	all	the	visits	of	the	participants.	
Both	plasma	E2	and	P4	were	again	significantly	higher	in	the	NC	women	as	well	as	salivary	E2,	
but	there	were	no	differences	in	salivary	P4	(Table	).		
	
Within	the	MC	of	the	NC	women,	plasma	E2	and	P4	changed	significantly	(p<0.001	for	both).	E2	
was	significantly	lower	in	the	MPh	compared	to	the	FPh	and	LPh	(49.8	±	29.5	vs.	163.1	±	149.0	
and	172.9	±	77.8	pg/ml,	respectively)	(p	<0.001	for	both),	and	also	was	significantly	higher	 in	
the	LPh	compared	to	the	FPh	(p=	0.014).	P4	was	significantly	higher	 in	the	LPh	than	the	MPh	
and	FPh	(11.49	±	7.72	vs.	2.04	±	5.32	and	0.84	±	0.35	ng/ml,	respectively)	(p<0.001	for	both).	
The	 salivary	 hormones	 displayed	 the	 same	 pattern,	 but	 once	 again	 only	 P4	 levels	 fluctuated	
significantly	within	a	MC,	being	significantly	higher	 in	the	LPh	compared	to	the	MPh	and	FPh	
(174.6	 ±	 124.7	 vs.	 99.4	 ±	 82.1	 and	 100.2	 ±	 63.6	 pg/ml,	 respectively)	 (p=0.014	 and	 0.010,	
respectively).	Salivary	E2	levels	were	2.42	±	0.76,	2.82	±	0.64	and	2.63	±	0.71	for	the	MPh,	FPh	
and	LPh,	respectively	(p=0.166).	The	ratio	between	specimens	was	affected	by	the	phase	of	the	
MC	for	both,	E2	and	P4	(p<0.001)	(table).	
In	the	HC	group,	only	plasma	E2	was	significantly	increased	in	the	OFF	stage	compared	to	the	
ON	 (34.9	 ±	 27.2	 and	 19.7	 ±	 24.4	 pg/ml,	 respectively).	 The	 ratio	 between	 specimens	 only	
Table	3.6.	Ovarian	hormone	levels	in	plasma	and	saliva	as	an	average	of	all	data	points	NC	
and	the	HC	group	of	the	MC.	
	
	 NC	 HC	 p	
Plasma	E2	(pg/ml)	 146.0	±	118.7	 24.4	±	26.0	*	 <0.001	
Plasma	P4	(ng/ml)	 5.13		±	7.28	 0.55	±	0.23	*	 <0.001	
Salivary	E2	(pg/ml)	 2.20		±		0.67	 2.67		±		0.70	*	 <0.001	
Salivary	P4	(pg/ml)	 132.85		±	104.11	 137.44	±	83.63	 0.383	
Means	±	SD	*	Significantly	different	to	NC.	
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changed	significantly	in	E2,	being	significantly	lower	in	the	OFF	stage	compared	to	the	ON	stage	
(0.10	±	0.07	vs.	0.20	±	0.12,	respectively).	
	
3.4. Discussion		
This	 study	 set	out	with	 the	aim	of	exploring	 the	patterns	 that	 the	ovarian	hormones	exhibit	
throughout	a	MC	in	plasma	and	saliva	in	a	group	of	NC	women	and	HC	users.	Our	findings	are	
in	agreement	with	 the	 literature	which	 states	 that	plasma	E2	 levels	 are	 increased	 in	 the	FPh	
and	LPh	of	the	MC	while	P4	is	raised	in	the	LPh	of	the	MC	in	NC	women	(Hampson	and	Young	
2007).	Nevertheless,	E2	levels	in	plasma	were	also	significantly	higher	in	the	LPh	than	the	FPh	
when	analysing	the	data	per	individual	points,	rather	than	when	comparing	averages	of	phases	
within	participants.	This	is	somehow	surprising	but	it	might	have	been	affected	by	the	fact	that	
the	FPh	can	 include	days	 in	which	E2	 levels	are	still	very	 low,	 the	days	 immediately	after	 the	
cease	of	the	MPh	and	therefore,	lowering	the	average	E2	concentrations	of	the	FPh.				
Although	P4	in	saliva	fluctuated	similarly	to	that	in	plasma,	only	when	analysing	all	data	points,	
salivary	P4	levels	were	significantly	higher	in	the	LPh	than	the	MPh.	A	possible	reason	for	not	
reaching	 the	 statistical	 difference	 between	 these	 two	 phases	 when	 analysing	 the	 average	
concentrations	might	be	due	to	the	between	individual	differences.	
In	 contrast,	 significant	 changes	within	a	MC	were	not	 found	 in	 salivary	E2	despite	 showing	a	
strong	trend	(p	=	0.057)	towards	the	pattern	seen	in	plasma.	This	was	consistent	when	all	data	
points	were	used	 for	 the	analyses.	A	 reason	behind	 these	dissimilarities	between	 specimens	
could	rely	on	not	having	a	big	enough	sample	or	rather,	because	salivary	E2	does	not	change	as	
robustly	as	 in	plasma	 (18	vs.	 73%	difference	 in	 concentrations	between	 the	MPh	and	FPh	 in	
saliva	and	plasma,	respectively).	In	fact,	this	was	seen	by	Elliott	et	al	(2003)	who	measured	E2	
one	 day	 in	 the	MPh	 and	 another	 in	 the	 mid-LPh	 (after	 confirmed	 ovulation)	 and	 found	 no	
differences	 in	 salivary	 levels	 but	 found	 significant	 differences	 in	 plasma.	Our	 results	 suggest	
that	 although	 (total)	 E2	 in	 plasma	 is	 significantly	 lower	 in	 the	 MPh	 compared	 to	 the	 other	
phases,	its	expected	unbound	levels	are	kept	constant	throughout	the	phases	of	the	MC,	thus	
having	an	 impact	on	 the	 significantly	higher	 saliva:plasma	 ratio	 in	 the	MPh	compared	 to	 the	
other	phases.	
With	 the	 purpose	 of	 understanding	 the	mechanisms	 underlying	 these	 changes	 in	 free	 E2	 in	
plasma,	 special	 attention	 needs	 to	 be	 given	 to	 the	 SHBG	 as	 this	 is	 the	main	 plasma	 carrier	
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(shared	 with	 testosterone),	 therefore	 its	 concentration	 becomes	 crucial	 (Tenovuo	 1989).	
Different	 studies	 have	 shown	 how	 SHBG	 concentrations	 vary	 across	 the	 phases	 of	 the	MC,	
being	significantly	higher	in	the	FPh	and	LPh	compared	to	the	MPh	(Day	et	al	2005,	Rothman	et	
al	 2011).	 Assuming	 this	 also	 occurred	 in	 our	 participants,	 it	 could	 be	 argued	 that	 SHBG	
augmented	more	 robustly	 than	 total	 E2,	 thus	 reducing	 the	 fraction	of	 free	 E2.	 This	 has	been	
seen	 in	 studies	 looking	 at	 total	 and	 free	 testosterone	 levels	 across	 the	MC	 (Rothman	 et	 al	
2011).		
Likewise,	P4	saliva:plasma	ratio	changed	significantly,	being	lower	in	the	LPh	compared	to	the	
other	phases	as	a	result	of	an	inflated	increase	from	the	FPh	to	the	LPh	in	plasma	P4	compared	
to	 the	 rise	 observed	 in	 saliva	 (~13	 vs.	 ~2	 fold	 increase,	 respectively).	 Similar	 changes	 in	 the	
ratio	between	 specimens	have	been	described	by	others	 i.e.	 from	0.053-0.096	 in	 the	FPh	 to	
0.011-0.016	in	the	LPh	(Bourque	et	al	1986,	Cedard	et	al	1984).		
Interestingly,	 changes	 in	 the	 ratio	 between	 specimens	 throughout	 the	 MC	 were	 consistent	
despite	the	analyses	performed,	i.e.	from	the	average	of	each	phase	within	participants	or	by	
pooling	all	data	together	per	MC	phase.	Alterations	in	the	ratio	between	specimens	across	the	
MC	 inevitably	had	an	 impact	on	 the	correlations.	The	 findings	of	 the	present	 study	 revealed	
that	E2	and	P4	levels	measured	in	saliva	and	plasma	were	significantly	correlated	but	with	weak	
association	in	the	NC	women.	The	weak	correlation	in	P4	was	somehow	unexpected	as	others	
have	 found	 stronger	 associations	 i.e.	 r	 =	 0.68	 –	 0.974)	 (De	 Boever	 et	 al	 1986,	 Bolaji	 1994,	
Bourque	et	al	1986,	Walker	et	al	1979).	Nevertheless,	a	recent	study	that	employed	not	only	
the	same	technique	(ELISA)	but	also	the	same	reagent	kit	(Salimetrics)	for	the	measurement	of	
salivary	 P4,	 found	 that	 correlation	 levels	 between	 saliva	 and	 dried	 blood	 spot	 samples	 (a	
previously	 tested	method)	were	 similar	 to	 those	 seen	 in	 our	 study	 (r	 =	 0.345)	 (Konishi	 et	 al	
2012).	Thus,	 it	might	be	that	 the	technique	employed	 in	 the	present	study	was	not	sensitive	
enough	 to	 accurately	 determine	 salivary	 P4.	 However,	 our	 results	 showed	 an	 improved	
correlation	when	only	selecting	 the	days	within	 the	LPh	 (r	=	0.607),	which	was	supported	by	
the	changes	in	the	ratio	between	saliva	and	plasma	throughout	the	MC.	This	agrees	with	the	
findings	of	Bourque	et	al	(1986)	in	which	saliva	and	plasma	P4	correlation	was	improved	from	r	
=	0.68	 to	 r	=	0.78	by	 calculating	 the	associations	only	 in	 LPh.	 Furthermore,	 their	 results	also	
showed	 a	 non-existent	 correlation	 during	 the	 FPh.	 Finally,	 they	 demonstrated	 that	 levels	 of	
salivary	P4	were	unaffected	by	changes	in	the	saliva	flow	rate.		
The	weaker	correlation	seen	in	the	ratio	between	specimens	for	E2	in	the	LPh	(r	=	0.343)	could	
be	related	to	inter-individual	differences	between	women.	This	has	been	previously	suggested	
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by	Lu	et	al	(1999)	where	not	only	women	presented	a	wide	range	of	individual	correlations	for	
E2	 collected	 in	 serum	 and	 saliva	 (r	 =	 0.40	 –	 0.85),	 but	 also	 one	 of	 the	 participants	 had	 a	
negative	 correlation	 which	 may	 have	 affected	 the	 opportunity	 of	 finding	 a	 significant	
correlation	 between	 specimens	 as	 a	 group.	 Nevertheless,	 it	 is	 worth	 noting	 that	 although	
blood	 samples	were	 collected	 in	 the	morning,	 saliva	 samples	were	 collected	 in	 the	 evening,	
which	may	have	had	an	important	effect	on	the	levels	of	E2	as	shown	by	the	fluctuations	that	
occur	within	a	day	(Bao	et	al	2003).		
As	 expected,	 E2	 and	P4	 levels	 in	plasma	were	 significantly	decreased	 in	 the	HC	group	by	 the	
action	 of	 the	 drug	 impairing	 the	 synthesis	 of	 the	 endogenous	 hormones	 as	 the	 two	
gonadotropins,	 FSH	 and	 LH,	 are	 inhibited	 (Monga	 and	 Dobbs	 2011).	 Nevertheless,	 salivary	
concentrations	were	only	significantly	different	between	groups	 for	E2.	The	analyses	method	
had	no	 impact	on	 the	 results	when	 comparing	 the	 two	groups.	 This	was	 surprising	although	
Liening	 et	 al	 (2010)	 encountered	 similar	 results	 in	 a	 less	 controlled	 study.	 Furthermore,	 this	
becomes	more	unforeseen	when	levels	of	CBG,	i.e.	the	main	P4	transporter,	would	have	been	
expected	to	increase	due	to	the	use	of	HC	(Endrikat	et	al	2002),	thus,	in	theory,	impairing	the	
availability	of	free	P4.	A	possible	reason	for	this	might	be	related	to	the	measurement	assays	
employed;	 there	might	have	been	a	 cross-reaction	with	 the	HC	progestins	 that	 resulted	 in	a	
false	positive	in	the	assessment	of	endogenous	P4	levels.		
Regarding	 the	 changes	 within	 the	 cycle	 of	 the	 HC	 users,	 neither	 salivary	 E2	 nor	 P4	 varied	
significantly	between	the	two	stages.	Nonetheless,	saliva:plasma	ratio	 in	E2	was	decreased	 in	
the	OFF	phase	due	to	the	significant	increase	in	E2	in	plasma	(but	not	in	saliva)	at	that	phase.	
SHBG	has	been	shown	to	increase	~1.6-fold	during	OFF	compared	to	ON	stage	(Endrikat	et	al	
2002),	 which	 might	 explain	 the	 insufficient	 increase	 in	 free	 (salivary)	 E2	 during	 OFF,	 thus	
affecting	the	ratio	 in	specimens	between	stages.	The	analyses	method	had	no	 impact	on	the	
results	when	comparing	the	two	phases	of	the	HC	users	MC.	
To	our	 knowledge,	no	 studies	have	 looked	at	 the	associations	between	 saliva	and	plasma	 in	
the	 ovarian	 hormones	 in	 HC	 users.	 The	 present	 study	 showed	 no	 correlations	 between	
specimens	in	this	group.	Reasons	behind	this	discrepancy	between	groups	might	relate	to	the	
known	changes	in	the	regulation	and	the	concentrations	of	SHBG	and	testosterone	induced	by	
the	HC	(Zimmerman	et	al	2014).	If	concentrations	of	salivary	P4	corresponded	to	the	progestins	
of	 the	 HC	 rather	 than	 the	 endogenous	 hormone,	 our	 results	 for	 this	 parameter	 would	 be	
invalid	in	this	group.	Further	research	is	required	to	assess	the	salivary	concentrations	of	P4	in	
HC	users	with	an	ELISA	assay	as	results	from	a	study	using	a	radio-immunoassay	have	indeed	
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shown	 how	 HC	 users	 present	 significantly	 lower	 levels	 in	 salivary	 P4	 than	 in	 NC	 women	
(Schultheiss	et	al	2003).		
Although	the	purpose	of	our	study	was	exploratory	rather	than	mechanistic,	the	interpretation	
of	our	findings	was	limited	by	the	lack	of	some	measurements	such	as	SHBG,	testosterone	and	
CBG	concentrations	as	these	are	determinants	of	total	and	free	E2	and	P4	concentrations.		
To	 conclude,	 our	 findings	 showed	 that	 salivary	 ovarian	 hormones,	 which	 represent	 the	
unbound	fraction	of	the	concentrations	in	plasma,	are	not	in	a	linear	relationship	with	those	in	
plasma	across	the	MC	because	of	the	changing	ratio	between	the	two	specimens	throughout	
the	 phases	 of	 the	MC.	 	 In	 addition,	 fluctuations	 in	 saliva	 are	 in	 a	 much	 smaller	 proportion	
compared	to	those	observed	in	plasma	which	may	be	affected	by	changes	in	the	SHBG.	Finally,	
HC	users	showed	suppressed	plasma	ovarian	hormones	as	a	result	of	the	use	of	the	HC.	This	
was	 also	 seen	 in	 salivary	 E2,	 but	 could	 not	 be	 seen	 in	 P4	 due	 to	 cross-reactivity	 with	 the	
progestins	of	the	HC.		
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4. RMR	and	substrate	metabolism	during	the	MC	(Study	2)	
4.1. Background	
Daily	 total	 energy	 expenditure	 encompasses	 BMR,	 PA	 and	 dietary-induced	 thermogenesis.	
From	these	three	constituents,	the	most	important	is	BMR	or	RMR	as	it	can	account	for	up	to	
70%	of	the	total	energy	expenditure	(Payne	and	Waterlow	1971).	Hence,	the	determination	of	
BMR/RMR	is	crucial	for	estimating	energy	requirements,	particularly	in	overweight	and	obese	
populations	 which	 are	 more	 likely	 to	 obtain	 inaccurate	 estimations	 from	 the	 predictive	
equations	(i.e.	>10%	difference	to	the	actual	RMR)	(Frankenfield	et	al	2003).	
Age,	 body	 composition,	 sex,	 race	 and	physical	 fitness	 are	 features	 that	 have	been	 shown	 to	
influence	RMR	(Arciero	et	al	1993,	Forman	et	al	1998,	Van	Pelt	et	al	1997,	Ravussin	et	al	1982).	
Furthermore,	ovarian	hormones	might	affect	 the	daily	 variability	of	RMR	as	previous	 studies	
reported	a	higher	 (intra-)	 coefficient	of	variation	 (CV%)	 in	women	than	men,	 i.e.	1.7-10.4	vs.	
2.5-4.0	%	(Diffey	et	al	1997,	Henry	et	al	1989,	2003,	Soares	and	Shetty	1987).	In	fact	previous	
research	 has	 shown	 that	 women	 might	 experience	 a	 cyclical	 pattern	 in	 energy	 demands	
characterised	by	an	increase	in	RMR	after	ovulation	until	the	start	of	menstruation	(Solomon	
et	al	1982,	Webb	1986).	Whether	 the	 increase	 in	RMR	comes	 from	a	higher	expend	of	both	
energy	suppliers	 (i.e.	carbohydrates	and	 fat)	or	whether	 it	comes	 from	an	 increase	 in	mainly	
one	of	 them	 is	 still	uncertain	although	 the	 literature	suggests	 towards	a	higher	 fat	oxidation	
post-ovulation	(Matsuo	et	al	1998,	1999).			
In	contrast,	it	appears	that	women	who	are	using	hormonal	contraceptives	(HC)	experience	a	
more	 constant	 RMR	 throughout	 their	 cycles	 (Curtis,	Henry	 and	Ghusain-Choueiri	 1996).	 This	
seems	to	support	the	hypothesis	that	ovarian	hormones,	or	fluctuations	in	ovarian	hormones,	
can	 induce	 changes	 in	 RMR	 as	 women	who	 take	 HC	 present	more	 stable	 ovarian	 hormone	
levels.	 Nevertheless,	 current	 hormonal	 contraceptive	 preparations	 are	 present	 in	 very	
different	forms	and	concentrations,	therefore	how	these	might	modulate	RMR	is	uncertain.			
Despite	the	necessity	of	measuring	RMR	in	order	to	accurately	determine	 individuals’	energy	
requirements,	 under	 certain	 circumstances,	 due	 to	 the	 cost	 or	 the	 availability	 of	 the	
instruments,	 researchers	 and	 nutritionists	 rely	 on	 predictive	 equations	 of	 RMR.	 From	 the	
original	 Harris	 and	 Benedict	 equations	 in	 1919	 until	 the	 Henry	 equations	 in	 2005,	 	 many	
equations	 have	 been	 formulated	 based	 on	 different	 populations	 (EFSA	 2013).	 Although	 it	 is	
well	 recognised	 that	 the	best	 predictive	 equations	 are	 those	 calculated	 from	 the	population	
studied,	it	was	recently	accepted	that	the	Harris-Benedict	(1917),	Schofield	et	al	(1985),	Mifflin	
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et	 al	 (1990),	Müller	 et	 al	 (2004)	 and	 Henry	 (2005)	 equations	 are	 all	 equally	 valid	 for	 adults	
(EFSA	 2013).	 Nevertheless,	 studies	 have	 found	 a	 lack	 of	 agreement	 between	 measured	
(RMRm)	and	predicted	RMR	(RMRp)	(Weijs	and	Vansant	2010).	Moreover,	the	effect	of	the	MC	
on	the	accuracy	of	these	predictions	has	never	been	studied	before.		
To	our	knowledge,	no	previous	studies	investigating	RMR	during	the	MC	have	averaged	more	
than	 two	days	 in	each	MC	phase	using	blood	hormone	measurements	 to	define	MC	phases,	
therefore	the	aim	of	our	study	was:	
• To	 investigate	whether	RMR	 in	the	LPh	 is	significantly	higher	than	 in	the	FPh	and/or	
the	MPh	and	whether	 this	was	 associated	with	 changes	 in	 the	 levels	 of	 the	ovarian	
hormones.	
• To	 study	whether	 substrate	 oxidation	 rates	 and	 contribution	 to	 energy	 expenditure	
experienced	any	significant	changes	during	the	MC.		
• To	 compare	 the	 variability	 of	 RMR	and	 substrate	metabolism	between	women	who	
are	taking	or	not	HC.	
• To	explore	how	 the	accuracy	of	RMR	predicted	by	validated	equations	was	affected	
throughout	a	MC.	
	
4.2. Methods	
4.2.1. Protocol	
Once	 the	participants	were	 accepted	 to	partake	 in	 the	 study,	 they	were	 asked	 to	notify	 the	
researcher	 upon	 the	 start	 of	 their	menstruation	 (defined	 as	 day	 1).	 Then	 they	 attended	 the	
laboratory	 for	 the	 measurement	 of	 RMR,	 substrate	 oxidation,	 ovarian	 hormones	 and	 body	
composition	 on	 the	 following	 day	 and	 three	 times	 a	week	 during	 a	whole	MC,	 i.e.	 until	 the	
start	of	 the	menstruation	 in	 the	 following	cycle	 (day	1	of	 cycle	2)	 (approximately	12	visits	 in	
total).	The	MC	in	the	NC	group	was	divided	in	three	phases	as	follow:	(1)	MPh	from	day	1	until	
the	last	day	of	bleeding;	(2)	FPh	from	the	subsequent	day	until	the	day	after	the	E2	peak;	and	
(3)	LPh	that	ended	on	the	day	prior	to	the	start	of	the	next	cycle.	In	the	HC	group,	the	MC	was	
divided	in	two	stages:	(1)	on	HC	stage	(ON),	 i.e.	the	three	weeks	when	the	HC	was	used;	and	
(2)	off	HC	stage	(OFF),	i.e.	the	seven	days	when	the	HC	was	not	used.		
On	the	testing	day	participants	attended	the	laboratory	in	the	morning	(between	07:00-10:00)	
after	a	10-12	hour	overnight	fast	and	rested	while	lying	down	for	30	minutes	to	achieve	a	state	
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of	 stabilization	 after	 their	 commute	 to	 the	 laboratory.	 RMR	 and	 substrate	 oxidation	 were	
measured	with	a	hooded	open	circuit	indirect	calorimeter	GEM	(GEMNutrition	Ltd,	Daresbury,	
UK)	for	30	minutes	under	standardized	conditions	(Compher	et	al	2006)	(see	section	2.6).	The	
first	 five	minutes	of	measurement	were	automatically	discarded	so	 that	 the	participants	had	
enough	 time	 to	 adapt	 to	 the	 hood.	 Thus,	 the	 average	 of	 the	 remaining	 25	 minutes	
measurement	was	used	to	calculate	the	RMR	and	substrate	oxidation.	The	room	temperature	
where	the	indirect	calorimeter	was	kept	was	21.2	±	1.2°C	and	a	blanket	was	offered	in	case	the	
participant	 felt	 cold.	 	 Following	 that,	 a	 ~2	 ml	 saliva	 sample	 was	 collected	 via	 unstimulated	
passive	 drool	 technique	 and	 under	 standardised	 conditions	 (see	 section	 2.5)	 to	 measure	
concentrations	of	E2	and	P4	in	saliva.	Saliva	samples	were	kept	in	ice	and	then	stored	at	-40°C	
within	four	hours	of	collection	until	they	were	analysed	with	an	ELISA.	Finally,	a	venous	blood	
sample	of	6	ml	was	collected	for	the	measurement	of	E2	and	P4.	Samples	were	centrifuged	to	
extract	their	plasma;	this	was	then	stored	at	-80°C	for	future	analyses	by	ECLIA.		
	
4.2.2. Calculations	and	statistical	analyses	
RMR	was	calculated	as	absolute	RMR	(i.e.	per	day)	and	relative	RMR	(i.e.	per	kg	of	BW	per	day)	
as	 RMR	 can	 be	 influenced	 by	 body	 size.	 Bias	 was	 determined	 as	 the	 mean	 percentage	
difference	between	RMRm	and	RMRp	and	accuracy	as	the	percentage	of	participants	with	an	
RMRp	within	±10%	of	RMRm.	
Based	on	previous	studies	investigating	differences	in	RMR	between	phases	of	the	MC,	it	was	
determined	that	a	sample	size	of	14	would	be	adequate	to	detect	changes	in	RMR	during	the	
MC	in	NC	women	(Day	et	al	2005).	Retrospective	analyses,	using	the	G*Power	software	with	a	
partial	eta	square	(ɳ2)	of	0.207	and	α	=	0.05,	determined	that	there	would	have	been	an	80.0	%	
chance	 of	 correctly	 rejecting	 the	 null	 hypothesis	 of	 no	 differences	 in	 the	 RMR	 across	 the	
phases	of	the	MC	with	a	total	of	21	participants.	
Data	was	analysed	with	SPSS	Statistics	19.	Values	are	expressed	as	means	±	SD	for	descriptive	
parameters	and	means	±	SE	for	averaged	measurements	within	the	MC	phases.	The	normality	
of	the	data	was	tested	using	the	Shapiro-Wilks	test.	When	data	were	not	normally	distributed,	
non-parametric	 tests	were	 used.	 Levels	 of	 inter-	 and	 intra-individual	 variation	 of	 RMR	were	
calculated	by	determining	the	coefficient	of	variation	(CV	%).	Differences	in	RMR	and	ovarian	
hormones	 between	 groups	 were	 compared	 using	 the	 independent	 sample	 t-test	 or	 Mann-
Whitney	U	test,	where	appropriate.	One-way	repeated	measures	ANOVA	or	Friedman	test	was	
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used	 to	 test	 differences	 across	 the	 phases	 of	 the	MC	 in	 the	 NC	 group	 and	 paired	 t-test	 or	
Wilcoxon	signed-rank	test	was	used	to	compare	between	the	two	stages	of	the	MC	in	the	HC	
group.	 Associations	 between	 RMR	 and	 hormone	 levels	 were	 analysed	 by	 Pearson’s	 or	
Spearman’s	correlation.	A	multiple	 regression	model	with	body	composition	and	 the	ovarian	
hormone	 levels	 (from	 plasma	 and	 saliva)	 as	 predictive	 variables	 was	 performed	 to	 predict	
RMR.	The	ratio	between	the	two	specimens	(i.e.	plasma	and	saliva)	of	E2	and	P4	as	well	as	the	
ratio	 between	 the	 two	 ovarian	 hormones	 for	 each	 specimen	were	 calculated	 for	 each	 data	
point	to	be	included	in	the	multiple	regression	models.	Statistical	significance	level	was	set	at	p	
≤	0.05.	
	
4.3. Results	
4.3.1. Participants	characteristics	
Of	 the	 26	 women	 (15	 NC	 and	 11	 HC	 users)	 who	 started	 the	 study,	 two	 withdrew	 due	 to	
personal	reasons,	two	were	excluded	because	they	did	not	fulfil	the	inclusion	criteria,	i.e.	cycle	
length	<25	days,	and	one	was	excluded	due	to	incomplete	data	set	(see	chapter	2.2).	Most	HC	
participants	were	using	a	combined	HC,	thus	one	participant	who	was	using	a	P4-only	HC	was	
also	excluded	from	the	study	as	the	effect	of	this	type	of	HC	on	the	production	of	endogenous	
hormones	was	different	to	that	observed	in	the	combined	HC	users.	The	HC	formulations	can	
be	found	in	table	4.1.	
	
Therefore,	the	results	presented	are	based	on	a	sample	of	20	healthy	women	(10	NC	and	10	
HC	users).	The	majority	of	the	women	were	Caucasian	(6	NC	and	8	HC	user)	and	the	rest	had	
an	 Arab	 (3	 NC	 and	 1	 HC	 user)	 or	 Asian	 (1	 NC)	 ethnic	 background.	 Table	 4.2	 presents	 the	
Table	4.1.	Formulation	of	the	different	hormonal	contraceptives	used	by	participants.	
	
n	 Trade	name	(form)	 Hormone	Dose	
Ethinylstradiol	 Progesten	
1	 Leeloo	Ge	(oral)	 20	µg	 100	µg		 levonorgestrel	
1	 Mercilon	(oral)	 20	µg	 150	µg		 desogestinel	
1	 Loestrin	20	(oral)	 20	µg	 1000	µg		 norethisterone	
2	 Gedarel	(oral)	/	Marvelon	(oral)	 30	µg	 150	µg		 desogestrel	
1	 Microgynom	(oral)	 30	µg	 150	µg		 levonorgestrel	
1	 Evra	(patch)		 34	µg	 203	µg		 norelgestromin	
1	 Cilest	(oral)	 35	µg	 250	µg		 norethisterone	
2	 Dianette	(oral)	/	Midane	(oral)	 35	µg	 2000	µg		 cyproterone	acetate	
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physical	 characteristics	 and	 the	 PAI	 of	 the	 participants	 in	 the	 two	 groups.	 There	 were	 no	
significant	differences	in	any	of	these	variables	between	the	two	groups.		
	
According	 to	 the	Premenstrual	Syndrome	Screening	Tool	 (PSST)	 (Steiner	et	al	2003),	none	of	
the	 participants	 suffered	 from	 Premenstrual	 Dysphoric	 Disorder.	 However,	 seven	 women	
displayed	PMS	according	to	the	PSST	(2	NC	and	5	HC	users).	
	
4.3.2. RMR	
As	an	average	of	the	MC,	RMR	was	1656	±	88	and	1579	±	49	kcal/d	(6929	±	368	and	6606	±	203	
kJ/d)	 for	 NC	 and	 HC	 groups,	 respectively,	 with	 no	 significant	 differences	 between	 groups.	
Relative	to	BW,	this	corresponded	to	26.3	±	0.7	and	27.8	±	0.9	kcal/kg/d	for	NC	and	HC	groups,	
respectively.	
The	 inter-individual	 variation	 (CV%)	 in	 RMR	 in	 NC	 and	 HC	 group	 was	 15.9%	 and	 9.7%,	
respectively.	 When	 accounting	 for	 differences	 in	 BW,	 the	 inter-individual	 variation	 in	
RMR/kg/d	was	7.8%	CV	and	10.0%	CV	in	NC	and	HC	group,	respectively.		
In	 the	 NC	 group,	 although	 RMR	 was	 higher	 in	 the	 LPh	 than	 the	 MPh	 and	 the	 FPh	 (mean	
difference:	45	±	142	and	91	±	94	kcal/d,	respectively),	the	differences	across	the	three	phases	
of	MC	were	not	significant	(p	=	0.122)	(Table	4.3).	Similarly,	no	significant	differences	in	RMR	
were	found	between	the	ON	and	OFF	stages	in	the	HC	group	(p	=	0.971)	(Table	4.4).	 	
Table	4.2.	Baseline	characteristics	of	the	NC	and	HC	groups.	
	
	 NC	(n	10)	 HC	(n	10)	 p	
Age	(y)	 26.9	±	6.2	 23.5	±	4.3	 0.171	
BW	(kg)	 63.6	±	11.0	 57.8	±	9.	3	 0.216	
Height	(m)	 1.68	±	0.09	 1.66	±	0.06	 0.547	
BMI	(kg/m2)	 22.5		±	2.2	 21.0	±	2.4	 0.159	
FM	(kg)	 18.7	±	6.0	 16.0	±	7.3	 0.382	
FM	(%)	 28.6	±	5.5	 26.9	±	8.3	 0.579	
FFM	(kg)	 41.5	±	3.7	 41.5	±	3.7	 0.108	
Waist	(cm)	 72.2	±	6.1	 67.9	±	4.5	 0.090	
Hip	(cm)	 99.8	±	7.1	 96.1	±	8.0	 0.279	
Waist-to-hip	ratio	 0.72	±	0.04	 0.71	±	0.04	 0.429	
PAI	 8.4	±	1.4	 7.9	±	1.1	 0.420	
Means	±	SD.	BW,	body	weight;	FM,	fat	mass;	FFM,	fat	free	mass;	PAI,	physical	activity	
index	
CHAPTER	4	 RMR	and	substrate	metabolism	during	the	MC	(Study	2)	
	
68	
	
Similar	intra-individual	variation	in	RMR	was	observed	in	the	NC	and	HC	groups,	i.e.	6.5	±	0.9%	
CV	 vs.	 5.3	 ±	 0.3	 %	 CV,	 respectively	 (p	 =	 0.453).	 However,	 the	 CV	 in	 the	 NC	 group	 ranged	
between	3.0-11.7%,	whereas	a	narrower	CV	range	was	observed	in	the	HC	group	(3.3-6.7%).	In	
fact,	when	subdividing	 the	NC	group	 into	high	 (≥5%)	and	 low	 (<	5	%)	CV	 (in	agreement	with	
Henry	et	al	(2003)),	a	distinctive	pattern	in	RMR	was	displayed,	i.e.	with	a	clear	rise	in	the	LPh	
of	the	high	CV	participants	(n	=	5)	and	a	steady	plateau	in	the	low	CV	group	(n	=	5)	(Fig	4.1).	
The	difference	between	the	LPh	and	the	FPh	in	the	high	CV	group	increased	to	176	kcal/d	(734	
kJ/d),	however,	it	was	not	significant	(p	=	0.156).	Women	in	the	low	CV	NC	group	only	showed	
an	 averaged	 difference	 of	 7	 kcal/d	 (29	 kJ/d)	 between	 these	 two	 phases	 (see	 Fig	 4.2.	 for	
individual	differences	between	phases	in	the	high	and	low	CV	NC	women).		
Table	4.3.	RMR	at	the	different	phases	of	the	MC	in	the	NC	group.	
	
	 MPh	 FPh	 LPh	 p	
RMR	(kcal/d)	 1649	±	100	 1603	±	80	 1695	±	80	 0.122	
RMR	(kcal/kg/d)	 26.1	±	0.8	 25.6	±	0.8	 26.9	±	0.6	 0.089	
RMR	high	CV	(kcal/d)	 1727	±	194	 1625	±	151	 1800	±	159	 0.108	
RMR	low	CV	(kcal/d)	 1571	±	64	 1582	±	76	 1589	±	60	 0.564	
Means	±	SE.	High	CV	≥5%;	low	CV	<5%	
Table	4.4.	RMR	at	the	different	stages	of	the	MC	in	the	HC	group.	
	
	 ON	 OFF	 p	
RMR	(kcal/d)	 1583	±	51	 1574	±	47	 0.711	
RMR	(kcal/kg/d)	 27.8	±	0.9	 27.9	±	1.1	 0.953	
Means	±	SE.ON,	stage	taking	the	HC;	OFF,	stage	not	taking	the	HC	
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Fig	4.2.	RMR	diference	(∆)	between	phases	of	the	MC	(kcal/d)	calculated	as	(A)	FPh	–	MPh,	(B)	LPh	–	
FPh	and	(C)	LPh	–	MPh.	( )	are	medians	of	the	diferences	in	RMR	between	phases.	
A	 C	B	
	
	 	
Fig	4.1.	Averaged	 RMR	 (kcal/d)	 per	 individual	 and	 phase	 in	 the	 high	 CV	 and	 low	 CV	groups	of	NC	
women	
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4.3.3. Ovarian	hormones	
In	 the	 NC	 group,	 all	 participants	 successfully	 ovulated	 during	 their	 MC	 as	 reached	 P4	
concentrations	 were	 >	 5	 ng/ml	 during	 the	 LPh	 (Piers	 et	 al	 1995).	 Plasma	 E2	 levels	 were	
significantly	 higher	 in	 the	 FPh	 and	 LPh	 compared	 to	 the	 MPh,	 whereas	 P4	 levels	 were	
significantly	 greater	 in	 the	 LPh	 than	 the	MPh	 and	 FPh	 (p	 <	 0.001	 all)	 (Table	 4.5).	 Although	
overall	salivary	hormones	followed	the	same	pattern,	pairwise	comparisons	between	salivary	
E2	levels	did	not	reach	statistical	significance	(Table	4.5).	
	
In	 the	 HC	 group,	 plasma	 E2	 levels	 in	 three	 participants	 were	 below	 the	 detection	 limit	 (<5	
pg/ml),	thus	their	data	was	removed	from	this	part	of	the	analyses.	There	were	no	differences	
in	plasma		E2	(n	=	7)	and	P4	(n	=	10)	between	the	two	stages	of	the	MC	in	the	HC	group,	despite	
a	 strong	 tendency	 for	 greater	 E2	 levels	 in	 the	OFF	 stage	 compared	 to	 the	ON	 stage	 (39.60	±	
6.63	vs.	18.03	±	5.12	pg/ml)	(z	=	-1.859,	p	=	0.063).	No	differences	were	found	between	stages	
in	salivary	concentrations	for	either	hormone.	
Plasma	E2	and	P4	 levels	as	an	average	of	the	cycle	were	higher	 in	the	NC	group	compared	to	
the	HC	 group	 (153.24	 ±	 8.92	 vs.	 24.42	 ±	 3.70	 pg/ml	 and	 5.46	 ±	 0.55	vs.	 0.53	 ±	 0.08	 ngl/ml,	
respectively)	 (p	 <0.001).	No	 significant	 differences	were	 found	 in	 salivary	 concentrations	 for	
either	hormone	between	groups.	
	
4.3.4. RMR	and	ovarian	hormones	in	the	LPh	
There	were	 no	 correlations	 between	 plasma	 P4	 or	 E2	 and	 absolute	 RMR	 (kcal/d)	 or	 relative	
(kcal/kg/d)	RMR	 in	the	LPh	(Table	4.6).	However,	 there	was	a	significant	negative	correlation	
between	absolute	RMR	and	P4	levels	in	saliva	(r	=	-0.467	p	=	0.002)	as	well	as	in	the	ratio	of	P4	
levels	 between	 specimens	 (i.e.	 saliva:plasma)	 (r	 =	 -0.404	 p	 =	 0.009).	Moreover,	 there	was	 a	
Table	4.5.	Ovarian	hormone	levels	in	plasma	and	saliva	at	the	different	phases	of	the	MC	in	the	
NC	group	
	
	 MPh	 FPh	 LPh	 p	
Plasma	E2	(pg/ml)	 45.47	±	6.53	
a	b	 176.39	±	2.29	 174.28	±	2.22	 <0.001	
Plasma	P4	(ng/ml)	 0.86	±	0.05
	a	 0.84	±	0.09	a	 11.65	±	1.09	 <0.001	
Salivary	E2	(pg/ml)	 2.21	±	0.23	 2.79	±	0.15	 2.75	±	0.17	 0.046	
Salivary	P4	(pg/ml)	 87.58	±	17.57	
a	 84.22	±	20.64	a	 201.23	±	35.46		 <0.001	
Means	±	SE.	a	Significantly	different	to	the	LPh.	b	Significantly	different	to	the	FPh.	
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positive	correlation	between	absolute	RMR	and	the	ratio	of	the	two	hormones	(E2:P4)	in	saliva	
and	 plasma	 showed	 (Table	 4.6).	 When	 RMR	 was	 controlled	 by	 BW,	 no	 correlations	 were	
observed	with	the	ovarian	hormones	in	saliva	or	plasma	(Table	4.6).		
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Table	4.7.	Correlations	between	P4	levels	and	body	composition	in	the	LPh.	
	
P4	 BW	 FFM	 FM	 %FM	
Saliva	 r	
-.572	 -.267	 -.482	 -.545	
p	 <0.0001	 0.084	 0.001	 <0.0001	
Plasma	
r	 -0.319	 -0.288	 -0.076	 -0.180	
p	 0.022	 0.041	 0.594	 0.207	
Bold	indicates	significant	correlation	(p<0.05)	
Table	4.8.	Substrate	oxidation	rates	(g/min)	and	contribution	(%)	in	the	MC	of	the	NC	and	HC	
groups	
	
	 NC	(n	10)	 HC	(n	10)	 p	
Fat	oxidation	rates	(g/min)	 0.062	±	0.007	 0.050	±	0.006	 0.458	
CHO	oxidation	rates	(g/min)	 0.152	±	0.011	 0.168	±	0.017	 0.437	
Fat	contribution	(%)	 47	±	4	 41	±	5	 0.205	
CHO	contribution	(%)	 53	±	4	 59	±	5	 0.205	
Means	±	SE.	CHO,	carbohydrate	
In	 order	 to	 better	 understand	 the	 potential	 role	 of	 P4	 levels	 in	 RMR	 and	 its	 variability,	
correlations	between	this	hormone	and	other	parameters	were	made	(Table	4.7).	
Regarding	the	different	models	that	explain	RMR,	we	found	that	there	was	no	model	that	used	
the	ovarian	hormones	 to	explain	 the	variance	 in	RMR	which	could	be	accepted	 (i.e.	was	not	
violating	 any	 of	 the	 statistical	 assumptions)	 when	 pooling	 all	 the	 data	 points	 of	 all	 the	
participants	(NC	and	HC	users).	Thus	we	subsequently	ran	the	models	in	the	NC	group	and	only	
when	the	LPh	was	selected.	 	A	multiple	 linear	 regression	model	 that	 included	BW,	FM,	FFM,	
and	 E2	 and	 P4	 ratios	 between	 specimens	 revealed	 that	 BW,	%FM	 and	 salivary	 to	 plasma	 P4	
levels	 could	 significantly	 explain	 76%	 of	 the	 variance	 in	 RMR	 in	 that	 phase	 of	 the	MC	 (p	 =	
<0.001).	BW	and	%FM	together	explained	73%	of	 the	variance,	 thus	 the	 ratio	 in	P4	between	
specimens	added	3	points	 to	 the	variance,	with	all	 the	assumptions	of	 a	multiple	 regression	
(e.g.	homoscedasticity,	multicollinearity)	taken	into	account.	
	
4.3.5. Substrate	metabolism	
The	respiratory	exchange	ratio	(RER)	of	the	MC	was	similar	between	groups	(0.851	±	0.012	vs.	
0.871	 ±	 0.017	 for	 NC	 and	 HC	 groups,	 respectively).	 Likewise,	 substrate	 oxidation	 rates	 and	
contribution	to	energy	spent	did	not	differ	significantly	between	groups	(Table	4.8).		
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Table	4.9.	Substrate	oxidation	rates	in	the	different	phases	of	MC	in	the	NC	and	HC	groups	
	
	
NC	(n	10)	 p	 HC	(n	10)	 p	
MPh	 FPh	 LPh	 	 ON	 OFF	 	
RER	 0.842	±	0.014	 0.858	±	0.012	 0.851	±	0.014	 0.451	 0.890	±	0.009	 0.893	±	0.019	 0.849	
Fat	
(g/min)	 0.064	±	0.024	 0.058	±	0.021	 0.063	±	0.026	 0.495	 0.050	±	0.006	 0.053	±	0.009	 0.959	
CHO	
(g/min)	 0.145	±	0.014	 0.151	±	0.010	 0.157	±	0.012	 0.670	 0.169	±	0.016	 0.165	±	0.022	 0.796	
Means	±	SE	CHO,	carbohydrate	
Moreover	no	differences	were	observed	in	RER	or	substrate	oxidation	rates	between	phases	of	
the	MC,	nor	between	ON	and	OFF	stages	(Table	4.9).		
	
Similarly,	no	significant	differences	were	found	in	substrate	contribution	to	energy	expenditure	
between	phases	of	the	MC	nor	between	ON	and	OFF	weeks	(Fig	4.3).		
	
	
	
	
	
	
	 	
	
4.3.6. RMRp	vs.	RMRm	
RMRp	underestimated	RMRm	by	14%	(260	±	22	kcal/d	i.e.	1088	±	21	kJ/d)	as	an	average	of	all	
predictive	 equations	 with	 <50%	 of	 the	 whole	 sample	 of	 women	 having	 an	 accurate	 RMRp	
(Table	4.10).	When	comparing	 the	reliability	of	 the	equations	between	groups,	 the	 results	 in	
terms	of	bias	 (i.e.	RMRm	–	RMRp)	 showed	 that	both	groups	produced	an	error	of	 the	 same	
magnitude	(14%)	with	a	similar	prevalence	of	accurate	predictions	(37%	and	32%	for	NC	and	
HC	groups,	respectively).	
A	 B	
Fig	4.3.	Substrate	contribution	(%)	to	energy	expenditure	during	the	phases	of	the	MC	in	the	
NC	group	(A)	and	in	the	ON	and	OFF	stages	of	the	HC	group	(B).	
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Regarding	the	efect	that	the	MC	had	on	RMRp,	a	magnified	error	was	observed	in	the	LPh	as	
the	bias	(Table	4.11)	and	the	prevalence	of	inaccurate	predictions	(Fig	4.4)	increased	in	the	NC	
group.		
	
	
Table	4.11.	Bias	(%)	of	the	predictive	equations	from	RMRm	as	an	average	of	the	phases	of	the	
MC	in	the	NC	group	(means	±	SD).	
	
Predictive	equation	 MPh	(%)	 FPh	(%)	 LPh	(%)	
Harris	Benedict	 11	±	11	 8	±	11	 13	±	9	
Schodfield_1	 14	±	11	 11	±	11	 16	±	9	
Schodfield_2	 13	±	11	 11	±	10	 16	±	9	
Miflin	 14	±	9	 12	±	9	 17	±	7	
Muler_1	 14	±	10	 12	±	10	 17	±	8	
Muler_2	 13	±	10	 11	±	10	 19	±	11	
Muler_3	 15	±	10	 13	±	10	 18	±	8	
Muler_4	 13	±	11	 11	±	12	 16	±	9	
Henry_1	 16	±	11	 14	±	10	 18	±	8	
Henry_2	 15	±	10	 13	±	10	 18	±	7	
	
	
Fig	 4.4.	Accuracy	 of	 RMRp	 in	 the	 diferent	 phases	 of	 the	 MC	 for	 the	 ten	 predictive	
equations	in	the	NC	group.	HB,	Haris	Benedict;	Schod,	Schodfield.	
Table	 4.10.	 Mean	 bias	 (±	 SD)	and	 accurate	 predictions	 (%)	 of	 the	 predictive	 equations	 from	
RMRm	in	the	MC.	
Predictive	equation	 Bias	(%)	 Accuracy	(%)	
Harris	Benedict	 11	±	10	 40	
Schodfield_1	 14	±10	 40	
Schodfield_2	 14	±	10	 40	
Miflin	 15	±	8	 30	
Muler_1	 15	±	9	 40	
Muler_2	 13	±	9	 40	
Muler_3	 16	±	9	 40	
Muler_4	 14	±	10	 40	
Henry_1	 16	±	9	 30	
Henry_2	 16	±	9	 30	
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An	example	of	the	absolute	bias	in	RMRp	across	the	phases	of	the	MC	in	the	NC	group	using	
the	Henry_1	equation	is	shown	in	Fig	4.5.		
In	 the	 HC	 group,	 there	 were	 no	 diferences	 between	 weeks	 ON	 and	 OFF	 in	 the	 bias	 or	 the	
accuracy	 in	 any	 of	 the	 equations	 except	 for	 the	 Harris	 Benedict	 where	 accurate	 predictions	
improved	in	the	ON	week	(60	vs.	40	%).	
	 	
	
Fig	4.5.	Diference	between	RMRm	and	RMRp	predicted	by	the	Henry_1	equation	against	RMRm	in	
the	MPh	(A),	FPh	(B)	and	LPh	(C).	
A	
B	
C	
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4.4. Discussion	
The	 aim	 of	 this	 study	 was	 to	 investigate	 whether	 RMR	 is	 significantly	 increased	 in	 the	 LPh	
compared	to	the	MPh	and	the	FPh	in	women	who	have	natural	and	regular	MCs	as	a	result	of	a	
higher	 day-to-day	 variability	 in	 their	 RMR	 compared	 to	 men	 and	 women	 taking	 HC.	 This	
research	is	of	importance	to	have	a	better	understanding	of	women’s	energy	metabolism	as	it	
is	 well	 known	 that	 RMR	 is	 the	 predominant	 constituent	 of	 total	 daily	 energy	 expenditure.	
Having	 an	 accurate	measurement	 of	 the	 RMR	 is	 crucial	 to	 estimate	 energy	 requirements	 in	
light	of	the	current	increasing	trend	of	overweight	and	obese	females	(WHO	2015)	as	well	as	
all	the	comorbidities	associated	with	energy	balance.		
	
4.4.1. RMR	throughout	the	MC	
The	present	investigation	showed	that	there	were	no	significant	differences	in	RMR	across	the	
phases	of	the	MC	in	a	group	of	ten	healthy	NC	women	and	in	the	different	stages	of	a	MC	and	
in	 ten	women	using	 combined	HC.	 This	 suggests	 that,	 in	 general,	women	are	as	 effective	 as	
men	in	maintaining	their	RMR	constant	and	therefore	changes	in	energy	balance	and	BW	and	
composition	may	come	from	other	variables	of	the	energy	balance	equation,	e.g.	EI,	PA.	This	is	
in	 agreement	with	 some	 (Horton	 et	 al	 2002,	 Howe	 et	 al	 1993,	 Piers	 et	 al	 1995)	 but	 not	 all		
previous	research	as	some	studies	have	shown	that	RMR	increases	in	the	LPh	compared	to	the	
FPh	(Curtis,	Henry,	Birch,	et	al	1996,	Matsuo	et	al	1999,	Solomon	et	al	1982).		
The	reasons	behind	these	discrepancies	might	be	related	to	the	different	methods	employed	
in	the	studies.	In	fact,	to	our	knowledge	this	is	the	first	study	that	averages	RMR	along	with	the	
ovarian	hormone	levels	for	more	than	two	days	in	each	phase	of	the	MC	(except	for	the	MPh	
due	 to	 its	 short	 length).	 This	 is	 of	 relevance	not	 only	 because	previous	 significant	 variations	
found	 could	 be	 stimulated	 by	 other	 uncontrolled	 factors,	 e.g.	 variability	 of	 the	 indirect	
calorimeter,	 participant	not	 stable	during	a	measurement,	meal	 standardization	of	 the	night	
before,	but	also	because	significant	differences	 in	RMR	would	need	to	be	sustained	for	more	
than	one	day	to	induce	any	physiological	effect	on	the	energy	balance	equation	provided	that	
all	 other	 factors,	 such	 as	 PA	 and	 energy	 intake,	 are	 constant.	 Therefore,	 having	 a	 more	
accurate	picture	of	RMR	in	the	different	phases	of	the	MC,	by	repeating	measures	more	than	
twice	 in	 each	 phase,	 could	 confirm	 whether	 such	 potential	 variations	 are	 metabolically	
meaningful	 in	 terms	of	 frequency	 (i.e.	 number	 of	 different	 RMR	 values)	 and	magnitude	 (i.e.	
difference	between	RMR	measurements).	
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Another	 common	 drawback	 of	 some	 previous	 research	was	 to	 divide	 the	MC	 by	 changes	 in	
body	 temperature	 or	 by	 counting	 retrospectively	 since	 the	 start	 of	 the	 MPh.	 These	 two	
methods	present	clear	disadvantages	as	they	have	been	found	to	be	not	accurate	in	all	women	
due	 to	 the	 large	variability	 in	 the	 length	of	 the	cycle	and	 its	phases	and	 the	unavailability	of	
finding	a	clear	temperature	change	on	the	ovulation	day	(Fehring	et	al	2006,	Guida	et	al	1999).	
Furthermore,	depending	on	the	study	design,	the	phases	of	the	MC	were	differently	defined	in	
terms	 of	 number	 and	 the	 criteria	 of	 classifying	 each	 phase.	 For	 instance,	 depending	 on	 the	
study	there	were	two,	three	or	even	four	phases	divided	by	pre-	and	post-ovulation	or	by	early	
and	 late	FPh	and	LPh.	Therefore,	 this	becomes	 challenging	not	only	when	comparing	 results	
between	 studies,	 but	 also	 when	 determining	 the	 accuracy	 of	 the	 findings	 presented.	
Therefore,	 our	 study	 design	 should	 had	 been	 able	 to	 precisely	 obtain	 any	 representative	
changes	in	RMR	amongst	phases	of	the	MC,	provided	that	a	big	enough	sample	size	was	used.		
Nevertheless,	 our	 findings	 suggested	 that,	 despite	 reaching	 a	 91	 kcal	 averaged	 difference	
between	the	LPh	and	the	FPh,	this	was	not	statistical	significant.	It	would	be	inappropriate	to	
ignore	 the	possibility	 that	 the	 lack	of	 statistical	difference	was	due	 to	an	 insufficient	 sample	
size,	thus,	our	results	need	to	be	carefully	interpreted.	
	
4.4.2. RMR	variability	
The	present	study	showed	an	intra-individual	variation	in	RMR	of	3.0-11.7%	in	NC	women.	This	
is	broadly	consistent	with	earlier	findings	suggesting	a	wider	variability	in	the	CV	of	RMR	within	
NC	 women	 than	 men	 (Curtis,	 Henry,	 Birch,	 et	 al	 1996,	 Henry	 et	 al	 2003,	 Piers	 et	 al	 1995,	
Solomon	 et	 al	 1982).	 This	 suggests	 that	 a	 single	 measurement	 of	 RMR	 might	 depict	 an	
erroneous	 starting	 point	 for	 the	 calculation	 of	 daily	 energy	 requirements	 in	 several	 women	
whose	RMR	is	so	variable.	 Indeed,	there	was	an	average	of	111-226	kcal/d	(464-991	kJ/d)	(7-
14%)	increase	in	the	LPh	compared	to	the	FPh	in	the	group	of	women	with	a	high	CV	within	the	
NC	 group.	 It	 has	 been	 estimated	 that	 a	 daily	 100	 kcal	 (418	 kJ)	 deficit	 (achieved	 by	 greater	
energy	 expenditure	 and	 /	 or	 lower	 energy	 intake)	 can	 lead	 to	 a	 decrease	 in	 BW	 overtime	
(James	 O	 Hill	 et	 al	 2003).	 Thus,	 the	 increase	 in	 RMR	 from	 the	 FPh	 to	 the	 LPh	 in	 some	 NC	
women,	namely	in	those	with	high	CV	in	RMR,	might	be	of	clinical	and	physiological	relevance	
despite	the	insufficient	statistical	significance.	On	the	other	hand,	participants	with	a	low	CV	in	
RMR	experienced	no	more	 than	~50	kcal/d	 (~223kJ/d)	difference	between	 these	 two	phases	
with	no	clear	direction	 (i.e.	energy	deficit	or	 surplus).	 Less	apparent	was	 the	effect	between	
the	 LPh	 and	 the	MPh	 assuming	 that	 the	 pattern	 observed	 in	 the	 high	 CV	 group	 is	 repeated	
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cyclically;	 all	 expect	 one	 participant	 displayed	 a	 carry-over	 effect	 as	 RMR	 appeared	 to	 be	
reduced	 from	 the	 LPh	 but	 not	 the	 low	 levels	 of	 the	 FPh.	 Therefore,	 when	 measuring	 or	
estimating	 energy	 requirements	 for	 a	 woman,	 one	 should	 take	 into	 account	 that	 some	
individuals	may	experience	large	differences	in	caloric	needs	depending	on	the	MC	phase.	
	
4.4.3. Determinants	of	RMR	
The	present	study	showed	significant	increases	in	P4	in	the	LPh	compared	to	the	MPh	and	the	
FPh	with	values	reaching	the	5	ng/ml	limit	which	is	considered	the	minimum	concentration	to	
confirm	the	existence	of	ovulation	in	NC	women	(Piers	et	al	1995).	
Previous	research	linked	the	increase	in	P4	in	the	LPh	to	an	increase	in	RMR,	sleeping	metabolic	
rate	 (SMR)	 and	 24h-energy	 expenditure	 (Matsuo	 et	 al	 1998,	 Meijer	 and	 Westerterp	 1992,	
Solomon	et	al	1982,	Webb	1986)	due	to	its	increasing	effect	on	body	temperature	(Barton	and	
Wiesner	1945);	however,	 in	many	studies	P4	 levels	 in	blood	were	not	measured	thus	a	direct	
association	between	the	two	could	not	be	obtained	and	assumptions	of	ovulatory	cycles	were	
made	without	evidence.	This	may	have	therefore,	biased	the	outcome	of	studies	 in	which	P4	
levels	 might	 have	 not	 increased	 to	 the	 abovementioned	 threshold	 (Meijer	 and	 Westerterp	
1992,	Solomon	et	al	1982,	Webb	1986).		
Nonetheless,	even	when	P4	has	been	successfully	detected	in	urine,	energy	expenditure	(Webb	
et	 al.	 1986)	 and	 increments	 in	 SMR	 (Bisdee	 et	 al.	 1989)	 have	 not	 always	 been	 significantly	
correlated	with	pregnandiol-3alpha-gucorinide	 (the	urinary	metabolite	of	P4).	 Similarly	Howe	
et	al.	(1993)	found	that	plasma	P4	and	E2	levels	of	14	women	were	not	correlated	to	their	RMR	
in	the	LPh.	This	agrees	with	our	findings	as	no	correlations	between	the	ovarian	hormones	and	
RMR	(absolute	or	relative)	were	found.		
However,	 to	 our	 knowledge,	 this	 is	 the	 first	 study	 to	 measure	 and	 show	 a	 significant	
correlation	between	RMR	and	salivary	P4.	The	fact	that	salivary	hormones	are	significantly	and	
more	strongly	correlated	to	RMR	than	their	counterparts	in	plasma	is	somehow	expected	since	
the	 first	 represent	 the	 unbound	 or	 biologically	 active	 form	 of	 these	 hormones.	 However,	
having	a	negative	correlation	between	salivary	P4	and	RMR	(r	=	-0.467)	was	unexpected	due	to	
the	 above	mentioned	 thermogenic	 effect	 of	 P4(Barton	 and	Wiesner	 1945).	 This	 association,	
nonetheless,	was	 supported	 by	 the	 significantly	 negative	 correlation	 of	 RMR	with	 plasma	 to	
saliva	ratio	of	P4	levels	(r	=	-0.307),	namely	the	greater	the	portion	of	unbound	to	bound	P4,	the	
smaller	the	RMR	in	the	LPh.	Moreover,	a	positive	correlation	between	salivary	E2	-	P4	ratio	and	
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RMR	was	 found,	 i.e.	 the	greater	 the	proportion	of	salivary	E2	 to	P4,	 the	higher	the	measured	
RMR.	This	rather	contradictory	result	may	be	due	to	the	possible	interference	of	other	factors,	
e.g.	BW,	which	cannot	be	ruled	out.	 In	 fact,	 salivary	P4	was	negatively	correlated	 to	BW,	FM	
and	 %FM.	 Even	 plasma	 P4	 was	 negatively	 correlated	 to	 BW.	 That	 was	 corroborated	 by	 the	
disappearance	 in	 the	 association	 between	 P4	 levels	 and	 adjusted	 RMR	 (by	 BW).	 Another	
potential	confounding	factor	that	has	been	suggested	in	the	literature	to	have	a	thermogenic	
effect	is	norepinephrine,	as	a	β-adrenergic	supporter	of	the	sympathetic	nervous	system	(Day	
et	al	2005).	Nevertheless,	the	effect	of	this	catecholamine	seems	to	vary	amongst	 individuals	
(Day	et	al	2005)	which	could	partly	explain	the	differentiation	between	women	with	a	high	and	
a	low	RMR	CV.	
Despite	not	 showing	a	 significant	 and	direct	 relationship	between	plasma	ovarian	hormones	
and	RMR,	 it	 cannot	be	rejected	 that	 these	might	still	have	an	effect	on	RMR.	An	example	of	
this,	 was	 the	 investigation	 by	 Day	 et	 al	 (2005)	 in	 which	 sex	 hormone	 concentrations	 were	
induced	 to	 postmenopausal	 levels	 by	 the	 intake	 of	 an	 anti-gonadotropin-releasing	 hormone	
(GnRH)	during	six	days	starting	at	the	FPh	of	the	MC.		This	resulted	in	a	significant	reduction	in	
RMR	 compared	 to	 the	 LPh	 and	 the	MPh.	 Similarly,	 the	 physiological	 decrease	 in	 E2	 in	 post-
menopausal	women	has	been	linked	to	a	significantly	lower	RMR	(r	=	0.38,	p	<	0.05)	(Lynch	et	
al	2002).	However,	this	may	not	necessarily	indicate	a	direct	effect	of	the	hormones,	rather	a	
consequence	of	the	decrease	in	FFM,	which	in	turn	can	be	associated	to	the	depletion	in	sex	
hormones.		
Regarding	the	impact	that	the	measured	hormones	might	have	in	determining	the	variance	of	
RMR	in	the	LPh,	we	found	that	only	the	ratio	of	unbound	to	bound	P4	could	add	three	points	
into	 a	model	 that	 could	 explain	 76%	 of	 the	 variance	 of	 RMR.	 The	 71%	 of	 the	 variance	was	
explained,	as	expected,	by	BW	and	%FM.	How	BW	and	body	composition	have	a	major	impact	
on	RMR	has	been	demonstrated	repeatedly	throughout	the	literature	(Javed	et	al	2010,	Nelson	
et	al	1992).	To	our	knowledge	this	is	the	first	study	showing	a	small	but	significant	contribution	
of	 the	 ovarian	 hormones	 into	 RMR.	 Only	 Howe	 et	 al	 (1993)	 found	 that	 P4	 had	 a	 significant	
effect	 on	 the	 increase	 of	 SMR	 in	 the	 LPh	 in	 a	 group	 of	women	 in	which	 dietary	 intake	was	
controlled.	 Furthermore,	Meijer	 and	Westerterp	 (1992),	 showed	 that	 their	 regression	model	
predicting	 SMR	 improved	 when	 adding	 the	 MC	 phase	 (either	 pre-	 or	 post-	 ovulation).	 This	
model,	however,	was	based	from	a	population	of	men	and	women	and	men	were	then	treated	
as	pre-ovulation	phase.		
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4.4.4. Substrate	metabolism	
The	outcome	of	this	study	indicated	that	the	participants	were	oxidising	a	higher	proportion	of	
calories	derived	from	carbohydrates	(CHO)	than	fat	in	both	groups	(53%	and	59%	vs.	47%	and	
41%	 in	 the	NC	and	HC	groups,	 respectively).	This	was	somewhat	surprising	because	RER	was	
measured	at	rest	and	under	a	10-12h	fasted	state,	when	a	fat	contribution	of	>50%	is	expected	
(Melzer	2011).	A	plausible	explanation	behind	this	inconsistency	could	be	a	high	carbohydrate	
diet	or	a	 low	 training	volume	 (Goedecke	et	al	2000).	Since	our	 sample	of	participants	would	
not	be	classified	as	highly	active	subjects,	it	could	be	hypothesised	that	their	fat	metabolism	at	
rest	 is	 less	 predominant	 than	 in	more	 trained	 individuals.	 Furthermore,	McNeill	 et	 al	 (1988)	
showed	how	fasting	RER	could	be	rapidly	changed	by	diet	in	an	experiment	where	11	women	
were	submitted	into	two	different	diets	containing	(1)	45%	CHO	and	41%	fat	and	(2)	54%	CHO	
and	31%	 fat	 for	4	days	 in	each	diet.	Their	 results	 revealed	a	 significant	 increase	 in	RER	 from	
diet	(1)	to	(2)	(0.824	and	0.851	for	diets	(1)	and	(2),	respectively).	There	was	a	decrease	in	fat	
contribution	 from	 59	 to	 46%	 (when	 protein	 oxidation	 is	 considered	 negligible).	 This	 paper	
provides	 evidence	 of	 not	 only	 how	 small	 changes	 in	 your	 diet	 can	 have	 an	 impact	 on	 your	
substrate	metabolism	 at	 rest,	 but	 also	 it	 presented	 a	wide	 intra-individual	 variability	 in	 RER	
amongst	women	(0.790	-	0.890).		
The	fact	that	no	significant	changes	were	observed	in	the	rate	of	substrate	metabolism	across	
the	 phases	 of	 the	 MC	 coincides	 with	 past	 research	 (Horton	 et	 al	 2002,	 Piers	 et	 al	 1995).	
Although	 the	 results	 of	 the	 present	 study	 showed	 no	 significant	 differences	 in	 substrate	
metabolism	when	comparing	the	LPh	and	the	FPh,	fat	oxidation	rates	were	still	increased	8%	in	
the	LPh	which	explains	the	rise	in	RMR	at	the	end	of	the	MC.	In	contrast,	CHO	oxidation	rates	
were	only	marginally	 increased	(3%)	in	this	phase.	These	results	are	in	line	with	Matsuo	et	al	
(1998,	 1999)’s	 studies	 in	 which	 RER	 was	 reduced	 in	 the	 LPh,	 indicating	 a	 higher	 fat	
contribution,	but	without	reaching	the	statistical	significance.	
	
4.4.5. NC	vs.	HC	users	
The	present	study	did	not	find	any	significant	differences	in	RMR	(absolute	or	relative	to	BW)	
between	 NC	 women	 and	 a	 group	 of	 women	 taking	 different	 formulas	 of	 a	 combined	
monophasic	 HC.	 Similarly,	 Diffey	 et	 al	 (1997)	 showed	 no	 differences	 in	 RMR	 between	 NC	
women	and	combined	HC	users.	However,	when	using	BW	or	FFM	and	FM	as	covariates,	they	
found	 that	 HC	 users	 had	 approximately	 5%	 higher	 RMR	 than	 the	 NC	 women.	 Kimm	 and	
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colleagues	 (2001)	also	 found	50	kcal/d	 (207	kJ/d)	greater	 in	RMR	adjusted	by	 race,	FFM	and	
FM	 in	 a	 group	 of	 young	 women	 taking	 HC	 than	 in	 the	 controls	 (p	 =	 0.04).	 Moreover,	 a	
longitudinal	study	showed	a	rise	in	RMR	by	30kcal/d	(151	kJ/d)	after	the	injection	of	a	P4-only	
HC	compared	to	RMR	during	the	FPh	(Pelkman	et	al	2001).	In	contrast,	Suh	et	al.	(2003)	did	not	
find	any	differences	in	energy	expenditure	at	rest	before	and	after	the	intake	of	a	triphasic	HC	
during	 4	 months,	 although	 that	 was	 in	 a	 post-absorptive	 state	 3h	 after	 consuming	 a	
standardised	breakfast	 in	a	group	of	moderately	active	women.	Differences	between	studies	
may	be	due	to	methods	used	and,	more	 importantly,	 the	 type	of	HC	used	and	the	time	that	
these	have	been	used.	With	regards	to	the	CV%	of	RMR,	the	result	shown	in	the	present	study	
for	the	HC	group	was	slightly	higher	than	that	observed	by	Curtis	et	al	(1996)	(i.e.	4.5%),	and	
our	 findings	 support	 a	wider	 variability	 in	 RMR	 between	 individuals	who	 are	NC	 than	 those	
who	are	under	HC.	
Regarding	 the	 substrate	 metabolism,	 the	 present	 study	 showed	 no	 significant	 differences	
between	 groups	 although	CHO	oxidation	 rates	 and	 contribution	 to	 total	 energy	 expenditure	
was	higher	as	an	average	of	the	cycle	and	in	individual	phases	in	the	HC	group	compared	to	the	
NC	women.	This	is	in	agreement	with	the	longitudinal	study	by	Suh	et	al	(2003)	in	which	CHO	
contribution	to	energy	expenditure	at	rest	increased	from	56%	to	66%,	albeit	not	significantly.	
They	 also	 showed	 a	 significant	 increase	 in	 insulin	 levels	 after	 using	 the	 HC	 for	 4	 months,	
suggesting	 that	 glucose	 flux	 might	 be	 impaired	 by	 a	 defect	 on	 the	 insulin	 sensitivity	 as	 a	
consequence	of	using	HC.	In	fact,	a	cross-sectional	study	with	two	groups	of	sedentary	women,	
one	 taking	 HC	 and	 the	 other	 being	 in	 the	 LPh	 of	 their	 MC	 (NC)	 showed	 how	 the	 former	
displayed	 a	 significantly	 higher	 postprandial	 glucose	 response	 with	 24%	 higher	 (not	
significantly)	fasting	insulin	levels	compared	to	the	latter	(Jankowski	et	al	2004).	In	conjunction	
these	 studies	 indicate	 the	possibility	 that	 substrate	metabolism	might	be	 indeed	affected	by	
HC	but	significant	results	might	have	not	been	attained	because	of	the	different	composition	
of	 the	HC,	 the	 characteristics	of	 the	participants	 (active	vs.	 sedentary)	 and	 the	 small	 sample	
size	of	the	studies.			
As	expected,	HC	users	presented	lower	ovarian	hormone	levels	than	their	counterparts	due	to	
the	suppressing	effect	that	the	estrogens	and	progestins	exert	on	the	FSH,	thus	impairing	the	
ovary	activity	and	 the	production	of	endogenous	sex	steroid	hormones	(Frye	2006).	The	 fact	
that	 E2	 levels	 were	 not	 detectable	 in	 blood	 in	 three	 of	 the	 HC	 users	 is	 not	 completely	
unforeseen	 as	 although	 the	 concentrations	 of	 ethinylestradiol	 were	 similar	 between	 the	
different	 drugs,	 i.e.	 20-35	 µg,	 ethinylestradiol	 has	 been	 shown	 to	 have	 diverse	
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pharmacokinetics	 that	 affects	 the	 absorption,	 metabolism,	 bioavailability	 and	 elimination	
differently	between	races,	cycles	and	individuals		(Goldzieher	and	Stanczyk	2008).	
	
4.4.6. RMRp	vs.	RMRm	
Our	 results	 showed	 that	 ten	 validated	 equations	 that	 predict	 RMR	 in	 adults	 were	 not	
appropriate	 in	 estimating	 RMR	 in	 a	 group	 of	 20	 (mainly)	 Caucasian	 not	 obese	 women	 of	 a	
fertile-age.	Not	only	because	less	than	half	of	the	sample	had	inaccurate	predictions	with	any	
of	the	ten	equations,	but	also	because	the	average	bias	was	of	-260	kcal/d	(~1088	kJ/d).	That	is	
concerning	 because	 the	majority	 of	 nutrition	 practices	 do	 not	 possess	 the	means	 by	 which	
RMR	can	be	measured,	thus	they	rely	on	estimations	from	equations	such	as	those	used	in	the	
present	study.		
Nevertheless	 these	 results	 need	 to	 be	 interpreted	 cautiously	 since	 the	 usual	 sample	 size	 of	
studies	looking	at	predictive	equations	of	RMR	is	larger	(50-100	subjects).	The	reader	needs	to	
be	 reminded	 though,	 that	 the	 primary	 purpose	 of	 this	 investigation	 was	 to	 look	 at	 the	
variability	 in	 RMRm	 in	 women	 throughout	 a	 MC	 which	 requires	 more	 than	 one	 visit	
(approximately	12)	to	the	laboratory	per	participant	thus	resulting	unpractical	for	a	study	that	
aims	to	determine	the	reliability	of	predictive	equations.	However,	the	authors	valued	its	input	
to	 the	 literature	 since	 to	our	 knowledge	no	others	have	 investigated	 this	matter.	Moreover,	
the	fact	that	RMRm	was	an	average	of	different	days	rather	than	a	snapshot	of	one	visit	might	
improve	the	accuracy	of	the	measurement	per	se.	
Combining	bias	and	accuracy	of	each	equation,	it	could	be	suggested	that	the	Harris	Benedict	
equation	was	the	most	reliable	of	the	ten	and	that	the	Henry	equations,	especially	the	number	
1,	were	the	weakest	 in	predicting	RMR	for	our	sample.	However,	 it	would	not	be	sensible	to	
prioritise	any	particular	equation	of	the	ten	since	their	accuracy	rate	may	be	considered	poor.	
This	disagrees	with	a	recent	study	by	Weijs	and	Vansant	(2010)	in	which	536	Dutch	women	of	a	
wide	range	of	BMI,	showed	to	have	a	bias	of	-1.8%	(with	Mifflin	RMRp)	to	3.0%	(with	Muller_1)	
and	 an	 accuracy	 of	 59%	 (with	 Schodfield_1)	 to	 70%	 (with	 Muller_3).	 This	 reliability	 was	
maintained	 or	 improved	 when	 looking	 at	 the	 non-obese	 subset	 of	 their	 sample,	 therefore	
other	reasons	might	explain	these	differences.	Firstly,	their	population	could	be	any	women	of	
>18y	which	included	post-menopausal	women	and	secondly	they	were	using	another	indirect	
calorimeter.	Regarding	the	second	concern,	a	recent	study	(Kennedy	et	al	2014)	demonstrated	
that	RMR	measured	under	our	indirect	calorimeter	(i.e.	the	GEM)	was	significantly	higher	than	
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the	Deltatrac	which	was	commonly	used	in	the	past	and	is	no	longer	available	(Allen	et	al	2000,	
Diffey	et	al	1997,	Van	Pelt	et	al	1997).	This	may	explain,	in	part,	the	consistent	underestimation	
of	RMRp;	nonetheless,	the	authors	suggested	that	the	GEM	was	a	reliable	instrument	for	the	
measurement	of	 repeated	 readings,	 thus	making	 it	 appropriate	 for	 the	main	purpose	of	our	
study.	 Furthermore,	 Kennedy	 et	 al	 (2014)	 questioned	 the	 validity	 of	 the	 Deltatract	 as	 an	
accurate	comparison	due	to	the	poor	available	maintenance	of	such	an	old	instrument.	
The	fact	the	RMRp	was	more	biased	in	the	LPh	was	not	surprising	once	recognised	that	(a)	the	
error	 was	 an	 underestimation	 and	 (b)	 RMRm	 tended	 to	 increase	 in	 that	 phase	 of	 the	 MC.	
Finally,	the	higher	relative	number	of	accurate	predictions	in	the	HC	group	seemed	to	respond	
to	a	small	sample	size	artefact	rather	than	a	meaningful	outcome.	
	
4.4.7. Limitations	
The	main	limiting	factor	of	our	findings	is	that	the	sample	size	obtained	might	have	not	been	
sufficiently	 large	to	show	significant	differences	 in	RMR	across	the	phases	of	the	MC.	 Indeed	
the	retrospective	analyses	to	calculate	sample	size	showed	that	a	total	of	21	NC	women	would	
have	been	required	to	study	RMR	throughout	the	phases	of	the	MC.	Nevertheless,	the	 initial	
estimation	based	on	previous	studies	was	of	a	smaller	size	and	this	limitation	might	be	blunted	
by	the	observed	inter-variability	between	participants,	e.g.	high	and	low	CV	in	RMR.	This	was	
restricted	by	practical	 limitations	 related	 to	 the	difficulty	of	 the	 testing	protocol	 involved	 for	
each	 participant,	 i.e.	many	 visits	 to	 the	 laboratory	 in	 specific	 times	 and	 the	 use	 of	 invasive	
techniques	such	as	the	venepuncture.	Another	limitation	of	the	study	was	that	participants	in	
the	 HC	 group	were	 using	 different	 HC	 prescribed	 by	 their	 GP.	 Nevertheless,	 the	 researcher	
ensured	that	all	HC	users	were	under	the	same	type	of	HC,	i.e.	combined	and	monophasic,	to	
minimize	 differences	 between	 individuals.	 Moreover,	 a	 within-subject	 design	 was	 used	 to	
compare	the	RMR	at	the	different	stages	of	the	MC	
Having	 all	 the	 participants	 starting	 in	 the	 same	 phase	 of	 the	 MC	 might	 have	 had	 a	
learning/adapting	 effect	 under	 the	 ventilated	 hood	 indirect	 calorimeter.	 Nevertheless,	 the	
trend	towards	an	increase	rather	than	a	reduction	in	RMR	at	the	end	of	the	cycle,	suggests	that	
an	adaptation	to	the	hood	throughout	the	days	did	not	occur	and	that	the	initial	10	min	under	
the	hood	before	the	measurements	were	enough	for	the	participants	to	be	rested	during	the	
data	collection.	Furthermore,	having	participants	starting	at	the	other	phases	would	have	just	
increased	the	difficulty	for	the	researcher	from	a	practical	point	of	view	as	MC	phases	would	
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require	to	be	defined	before	the	ovarian	hormones	were	measured	or	phases	of	different	MC	
would	have	been	needed.	
Finally,	other	parameters	such	as	testosterone,	epinephrine	and	noradrenaline	that	could	have	
confounded	or	explained	better	the	influence	of	the	ovarian	hormones	on	RMR	could	not	be	
measured.	 These	 have	 been	 associated	 with	 changes	 in	 energy	 and	 substrate	 regulation	
(Mauras	et	al	1998,	Shi	et	al	2009)	and	they	might	also	fluctuate	within	the	MC	(Matsuo	et	al	
1998,	Rothman	et	al	2011).		
	
4.5. Conclusion	
To	conclude,	the	present	investigation	examined	RMR	across	the	phases	of	the	MC	in	a	group	
of	NC	women	and	HC	users.	This	 is	 the	 first	 time	that	 the	average	of	more	than	two	days	 in	
each	phase	along	with	the	ovarian	levels	have	been	used	to	explore	the	variability	of	RMR	in	
NC	 women	 and	 HC	 users.	 Moreover,	 participants	 were	 tested	 within	 the	 same	MC	 using	 a	
within-subject	 design,	 therefore	 minimising	 inter-individual	 and	 inter-cycle	 differences	
compared	to	previous	studies.	This	study	has	found	that	in	the	population	studied,	there	were	
no	 significant	 variations	 in	RMR	 in	NC	women	and	HC	users	 throughout	 their	MC.	However,	
some	 individuals	 presented	 clinically	meaningful	 changes	 in	 their	 RMR	which	 confirmed	 the	
high	 inter-individual	variability	amongst	women	and	highlights	the	need	of	personalisation	 in	
the	design	and	prescription	of	diets	in	this	population.	Moreover,	this	is	the	first	study	to	show	
a	negative	correlation	between	RMR	and	salivary	P4	as	well	as	the	ratio	between	plasma	and	
saliva	P4	during	the	LPh.	Nevertheless,	these	associations	disappear	when	RMR	is	adjusted	with	
BW.	Finally,	 the	 ratio	between	 saliva	and	plasma	 for	P4	 levels	 contributed	 in	 the	variance	of	
RMR	in	the	LPh	in	a	model	where	BW	and	%FM	explained	the	majority	of	RMR	variance.	
Further	 research	 needs	 to	 be	 done	 to	 understand	 the	 possible	 underlying	mechanisms	why	
some	NC	women	may	be	more	likely	to	experience	substantial	changes	in	their	RMR	and	what	
are	the	consequences	in	the	long	term.	Namely,	why	are	there	women	with	a	high	and	a	low	
intra-variation	in	their	RMR	and	is	there	any	long-term	metabolic	benefit	in	having	a	high	or	a	
low	 variability.	 Since	 both	 groups	 of	 NC	 women	 showed	 to	 maintain	 their	 BW,	 it	 could	 be	
hypothesised	 that	 women	 in	 the	 high	 CV	 group	 need	 to	 unconsciously	 compensate	 their	
energy	requirements	by	changing	their	EI	to	maintain	their	BW,	thus	potentially	making	them	
more	efficient	in	adapting	to	acute	changes	in	energy	balance	in	the	long	term.	
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5. Appetite	responses	during	the	MC	(Study	3)	
5.1. Background	
It	 is	 well	 known	 that	 the	 process	 of	 digesting	 food	 involves	 numerous	 actions	 by	 different	
organs	in	order	to	prepare	food	for	its	absorption	in	the	intestine.	Once	the	bolus	reaches	the	
stomach,	this	will	be	held	to	be	mixed	with	the	gastric	juices	to	form	the	chyme	and	be	broken	
down	 into	particles	small	enough	to	go	 through	 the	pyloric	 sphincter	 (Smolin	and	Grosvenor	
1994).	 The	 rate	 at	which	 the	 chyme	passes	 into	 the	 small	 intestine	 and	 the	 amount	of	 time	
required	 to	 fully	 empty	 the	 stomach	 is	 dependent	 on	 the	 characteristics	 of	 the	 meal,	 i.e.	
volume,	energy	density,	weight,	acidity	(Malagelada	and	Azpiroz	2010).	
Nonetheless,	 this	 is	 ultimately	 regulated	 by	 different	 gastric	 and	 intestinal	 hormones	 (e.g.	
gastrin,	CCK,	GLP-1)	that	will	ensure	the	availability	of	the	 intestine	to	continue	the	digestive	
and	absorptive	process	(Smolin	and	Grosvenor	1994).	PYY	is	one	of	the	multiple	regulators	of	
the	digestion	process	and	its	main	role	is	to	mediate	the	ileal	brake,	i.e.	the	delay	in	the	transit	
of	the	chyme	through	the	gastrointestinal	tract	(Onaga	et	al	2002),	that	results	in	an	increase	
in	satiety.	PYY’s	secretion	in	the	distal	intestine	is	stimulated	post-prandially	and	this	is	related	
to	the	caloric	and	macronutrient	content	of	the	meal	(Adrian	et	al	1985,	Batterham	et	al	2003).		
Multiple	studies	have	shown	how	changes	in	GE	and	PYY	response	to	a	meal-test	can	have	an	
impact	 on	 the	 appetite	 sensations	 and	 the	 subsequent	 food	 intake	 (Clegg	 and	 Shafat	 2010,	
Stoeckel	 et	 al	 2008).	 Nevertheless,	 many	 of	 the	 studies	 conducted	 in	 this	 area	 avoid	 the	
participation	of	women	or	control	 their	protocol	by	testing	women	 in	a	specific	phase	of	the	
MC,	 as	 it	 is	 generally	 accepted	 that	 women	 can	 experience	 changes	 in	 their	 habitual	 food	
intake	upon	the	phase	of	 their	MC	(McNeil	and	Doucet	2012).	These	changes	seem	to	result	
from	a	bigger	meal	size	(rather	than	from	an	increased	number	of	meals)	in	the	LPh	than	the	
FPh	(Asarian	and	Geary	2013).	Therefore,	 it	could	be	suggested	that	women	may	experience	
changes	 in	 their	 food	 intake	due	 to	 fluctuations	 experienced	primarily	 in	 their	 satiation	 (the	
process	of	finishing	meal),	rather	than	their	satiety	(the	process	inhibiting	the	start	of	a	meal),	
throughout	 the	MC.	 Furthermore,	 in	 light	 of	 the	 global	 higher	 obesity	 prevalence	 in	women	
than	men	(WHO	2015),	having	a	better	understanding	on	women’s	appetite	physiology	seems	
imperative.	
The	objective	of	this	study	was	to	 investigate	the	appetite	response	across	the	phases	of	the	
MC.	Precisely	we	aimed	to	study	whether	eating	the	same	breakfast	in	each	phase	of	the	MC	
would	change	the	GE	rate,	the	PYY	response	and	the	satiety	feelings	of	the	meal	to	ultimately	
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have	an	impact	on	the	food	intake	of	a	buffet	lunch	served	four	hours	later.	Furthermore,	the	
aim	was	to	associate	any	potential	differences	to	the	naturally	occurring	fluctuations	in	E2	and	
P4	of	 the	MC.	We	secondly	aimed	to	 investigate	whether	 food	 intake	measured	during	three	
days	for	each	MC	phase	changes	significantly	and	whether	food	intake	on	the	days	under	the	
free-living	conditions	was	affected	by	the	MC	phase.	
	
5.2. Methods	
5.2.1. Protocol	
Once	 the	participant	was	accepted	 to	partake	 in	 the	 study,	 she	was	given	a	 fertility	monitor	
(Clearblue)	 to	 assist	 in	 the	 scheduling	 of	 her	 visits	 to	 the	 laboratory	 based	 on	 the	 three	
different	MC	phases	 i.e.	MPh,	 FPh	 and	 LPh.	 The	 three	 chosen	days	were	 aimed	 to	display	 a	
very	 distinguishable	 profile	 in	 the	 ovarian	 hormones:	MPh,	 E2	 and	 P4	 at	 low	 concentrations;	
FPh,	E2	at	high	concentrations	while	P4	remains	low;	and	LPh,	E2	and	P4	at	high	concentrations.	
The	MPh	visit	was	scheduled	as	soon	as	the	participant	notified	the	start	of	a	new	MC	and	this	
was	performed	within	4	days	of	 starting	 the	MC.	 From	day	6	of	 the	MC,	participants	 tested	
their	morning	urine	using	the	fertility	monitor	to	measure	their	E3G	and	LH	levels.	The	testing	
days	for	the	FPh	and	LPh	were	scheduled	based	on	each	individual’s	MC	profile	and	the	fertility	
monitor	readings	(see	more	details	in	chapter	2.11).		
Once	 the	 visit	 to	 the	 laboratory	was	 scheduled,	participants	were	also	asked	 to	 record	 their	
food	intake	for	three	days	in	each	MC	phase:	(1)	the	day	before	coming	to	the	laboratory,	(2)	
the	 testing	day	and	 (3)	 the	day	after	 the	visit	 to	 the	 laboratory.	 (See	Fig	5.1	 for	 an	example	
testing	timeline	within	a	MC).	Moreover,	they	were	asked	to	wear	a	body	monitoring	system	
to	estimate	their	PA	 levels	to	be	able	to	validate	their	EI	 from	the	food	diary	and	detect	any	
potential	misreporting.		
In	 the	 evening	 before	 each	 test	 day,	 participants	 were	 asked	 to	 avoid	 the	 consumption	 of	
caffeine	and	alcohol	and	the	practice	of	any	unusual	strenuous	exercise	 that	 they	would	not	
usually	do	as	part	of	their	normal	‘daily	lifestyle’.	 	
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Notifications	between	participant	
and	the	researcher	
Fertility	test:	“Low”	 Testing	day	at	the	
laboratory	
Food	diary Fertility	test:	“High”  
Physical	Activity	monitor Fertility	test:	“Peak”  
Fig	5.1.	Example	experiment	time	line	during	a	MC.	
During	the	visits	to	the	laboratory	participants	were	requested	to	arrive	between	7:00-9:30h	to	
get	their	body	composition	assessed	and	then	a	cannula	was	inserted	into	their	arm	to	obtain	
the	 baseline	 blood	 sample	 (t	 =	 0).	 Immediately	 after,	 they	 filed	 in	 the	 VAS	 for	 appetite	
sensations	 and	 the	 first	 breath	 sample	 for	 measurement	 of	 GE	 was	 colected.	 Then	 the	
participant	was	taken	to	the	kitchen	to	consume	the	standardised	breakfast	labeled	with	13C	
octanoic	 acid	 which	 included	 scrambled	 eggs	 on	 toast,	 pineapple	 and	 a	 drink	 of	 their	 choice	
(water,	cofee	or	tea	with/out	milk	and	sugar).	Participants	were	asked	to	finish	their	breakfast	
within	15min.	As	soon	as	they	finished	their	breakfast,	they	were	taken	straight	away	to	the	
lab	 to	 colect	 the	 first	 post-ingestion	 breath	 sample,	 blood	 sample	 and	 satiety	 scores.	
Subsequent	breath	samples	were	taken	every	15	min	until	min	240.	Subsequent	blood	samples	
and	satiety	scores	were	taken	every	15	min	until	t	=	60	thereafter	every	30	min	until	t	=	240.	
Each	blood	measurement	required	only	4ml	to	quantify	the	total	PYY	concentrations	(except	at	
baseline	 when	 two	 tubes	 were	 used	 to	 measure	 the	 ovarian	 hormones	 as	 wel,	 i.e.	 8ml),	
therefore	a	total	of	48ml	of	blood	in	11	time	points	were	colected	over	4	hours.	See	flow	chart	
for	clarification	of	the	protocol	(Fig	5.2).	
	
+ 
* 
	
+	 +	+	 +	 *	+	
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+	 *
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0	 	 30	 	 60	 	 90	 	 120	 	 150	 	180	 	210	 240	
Time	(min)	
	Breakfast	
Breath	sample,	blood	sample	and	VAS	
Breath	sample	only	
Fig	5.2.	Timeline	of	events	during	each	of	the	testing	days	in	the	laboratory.	
Immediately	 after	 the	 last	 blood	 sample,	 the	 cannula	 was	 removed	 and	 the	 participant	 was	
taken	 to	 the	 kitchen	 for	 an	ad-libitum	lunch	 bufet	 (see	 details	 of	 foods	 included	 and	 the	
nutritional	composition	in	chapter	2.8.2).	Participants	were	invited	to	eat	until	comfortably	ful	
and	 folowing	 that	 they	 were	 free	 to	 leave.	 Lunch	 intake	 was	 calculated	 by	 subtracting	 the	
weight	of	the	food	 left	 from	 that	 of	 the	 food	 prepared	 for	 the	 bufet	 and	 intakes	 of	 energy,	
carbohydrates,	 sugars,	 protein,	 fats,	 saturated	 fat,	 fibre	 and	 sodium	 were	 determined	
according	to	the	food’s	label.	
Blood	 samples	 were	 centrifuged	 to	 extract	 their	 plasma;	 this	 was	 then	 stored	 at	-80°C	 for	
future	 analyses	 by	 ECLIA	 for	 E2	and	 P4	and	 ELISA	 for	 total	 PYY	 (see	 chapter	 2.4.2).	 Averaged	
intra-duplicates	 CV	 for	 PYY	 ELISA	 assays	 was	 6.26	 ±	 1.40	 %.	 Breath	 samples	 were	 analysed	
using	an	isotope	ratio	mass	spectrometer	to	quantify	the	excess	amount	of	labeled	oxidised	
octanoic	 acid	 (i.e.	13CO2)	 above	 baseline	 for	 each	 time	 point.	 This	 was	 expressed	 as	 the	
percentage	of	dose	recovered	per	hour	and	this	was	fitted	into	a	non-linear	regression	model	
(Ghoos	et	al	1993)	(see	chapter	2.7.3	for	more	details).	Food	intake	recorded	by	food	diaries	
was	measured	by	the	use	of	a	nutrition	analyses	software	(Nutritics	V3.74	Professional	Edition)	
and	 intakes	 of	 energy,	 carbohydrates,	 sugars,	 protein,	 fats,	 saturated	 fat,	 fibre	 and	 sodium	
were	determined	per	day	and	per	phase	of	the	MC	for	each	participant.	Physical	activity	levels	
from	 the	 activity	 monitor	 were	 averaged	 across	 the	nine	days	 and	 then	 compared	 to	 the	 EI	
reported	from	the	food	diaries.	
	
5.2.2. Calculations	and	statistical	analyses	
PYY	 peak	 was	 defined	 as	 the	 highest	 PYY	 concentrations	 achieved	 post-baseline.	
Concentrations	 of	 PYY	 and	 VAS	 scores	 were	 used	 to	 calculate	 their	 total	 AUC	 using	 the	
trapezoidal	method.	
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From	the	curve	created	by	the	percentage	of	dose	recovered	per	hour	of	the	breath	samples	
model,	different	GE	parameters	could	be	calculated	using	Ghoos	et	al	(1993)	and	Schommartz	
et	al	(1997)’s	equations	(see	chapter	2.7.3	for	more	details).	
One-way	repeated	measures	ANOVA	or	Friedman	test	was	used	to	test	differences	across	the	
phases	of	the	MC	for	PYY	AUCs	at	every	hour,	ovarian	hormone	levels,	GE	parameters	and	food	
intake	 across	 the	 phases	 of	 the	MC.	When	 significant	 differences	were	 found,	 a	 Bonferroni	
post-hoc	pairwise	comparison	or	a	Wilcoxon	signed-rank	test	was	performed,	according	to	the	
normality	of	the	data.	
A	2-way	repeated	measures	ANOVA	with	 time	and	MC	phase	as	 factors	was	used	to	analyse	
PYY	levels	and	PYY	change	from	baseline	within	subjects	as	an	assessment	of	the	postprandial	
changes	across	the	MC.	
AUC	 for	VAS	was	analysed	with	another	2-way	 repeated	measures	ANOVA	that	 included	 the	
baseline	scores	as	covariates	in	the	analyses.		
Associations	 between	 EI	 and	 PYY,	 GE	 and	 appetite	 feelings	 as	 well	 as	 between	 ovarian	
hormones	and	the	appetite	markers	(i.e.	EI	and	PYY,	GE	and	appetite	feelings)	were	analysed	
by	Pearson’s	or	Spearman’s	correlation,	according	to	the	normality	of	the	data.		
A	 sample	 of	 nine	 women	 was	 based	 on	 the	 only	 other	 study	 that	 has	 looked	 at	 appetite	
hormones	 responses	 In	 the	 MC	 (Brennan	 et	 al	 2009).	 Retrospective	 analyses,	 using	 the	
G*Power	software	with	a	partial	eta	square	(ɳ2)	of	0.410	and	α	=	0.05,	determined	that	there	
would	have	been	an	83.4	%	chance	of	correctly	rejecting	the	null	hypothesis	of	no	differences	
in	the	Thalf	across	the	phases	of	the	MC	with	a	total	of	10	participants.	Another	retrospective	
analyses	with	a	partial	eta	square	(ɳ2)	of	0.363	and	α	=	0.05,	determined	that	there	would	have	
been	an	80.0	%	chance	of	correctly	rejecting	the	null	hypothesis	of	no	differences	 in	the	PYY	
AUC	at	240	across	the	phases	of	the	MC	with	a	total	of	11	participants.	
	
5.3. Results	
5.3.1. Participants	characteristics	
	Fifteen	 women	 signed	 the	 consent	 form	 of	 which	 three	 had	 to	 be	 excluded	 because	 of	
violating	the	inclusion	criteria	(i.e.	irregular	MC	and	suspicion	of	suffering	Gilbert’s	syndrome)	
(see	chapter	2.2).	Of	the	twelve	remaining	women	who	started	the	study,	two	withdrew	due	to	
personal	 reasons	 and	 another	 who	 completed	 the	 study	 had	 to	 be	 excluded	 because	 of	
unconfirmed	ovulation	and	unavailability	to	reschedule	the	LPh	testing	day.	Thus	the	following	
results	are	based	on	a	population	of	nine	NC	women	(Table	5.1).	
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5.3.2. MC	characteristics	and	ovarian	hormones	
Average	 MC	 length	 was	 29	 ±	 3	 days.	 Of	 the	 nine	 participants	 included,	 four	 had	 a	 “peak”	
reading	i.e.	ovulation	was	confirmed	by	the	fertility	monitor,	within	their	first	MC,	while	three	
participants	only	ovulated	on	the	second	MC.	Averaged	“peak”	reading	happened	on	day	14	±	
3	of	the	MC.	The	two	remaining	participants	attended	to	their	LPh	visit	at	what	it	was	expected	
to	be	their	mid-LPh.	Plasma	P4	levels	indicated	that	these	participants	had	ovulated	despite	not	
having	 a	 “peak”	 reading	 in	 the	 fertility	monitor.	 P4	 levels	were	 >5ng/ml	which	 is	 considered	
high	enough	to	have	ovulated	(Piers	et	al	1995).	Moreover,	one	of	these	two	participants	had	a	
positive	LH	peak	 in	her	personal	fertility	monitor,	thus	participants	were	kept	 in	the	study	as	
they	seemed	to	have	ovulated	despite	not	having	been	detected	by	the	fertility	monitor.	
There	 were	 significant	 differences	
in	E2	and	P4	concentrations	amongst	
the	 three	 phases	 of	 the	 MC	 (p	 <	
0.001	 and	 <0.0001,	 respectively)	
(Fig	5.3).	E2	levels	were	significantly	
increased	 in	 the	 FPh	 and	 LPh	
compared	to	the	MPh	whereas	and	
P4	levels	were	significantly	higher	in	
the	LPh	compared	to	the	other	two	
phases.	 Fig	 5.3.	 E2	 and	 P4	 concentrations	 in	 the	 different	
phases	of	the	MC	(means	±	SD).	
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Table	5.1.	Participants’	characteristics	at	baseline	
	 Mean	±	SD	
Age	(years)	 31	±	6	
Height	(m)	 1.67	±	0.09	
BW	(kg)	 63.4	±	12.8	
BMI	(kg/m2)	 22.6	±	2.7	
FM	(%)	 29.0	±	7.4	
FM(kg)	 19.1	±	7.8	
FFM	(kg)	 44.4	±	6.3	
Waist-to-hip	ratio	 0.77	±	0.07	
PAI	 8.26	±	0.98	
BW,	body	weight;	FM,	fat	mass;	FFM,	fat	free	mass;	PAI,	physical	activity	index	
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5.3.3. GE		
The	13CO2	curve	was	 formed	throughout	 the	 4	h	 after	 breakfast,	 ensuring	 that	 there	 was	
enrichment	by	the	breakfast	with	13C.	An	example	of	this	can	be	seen	in	Fig	5.4	
There	 was	 a	 significant	 overal	 efect	 of	 the	 phase	 of	 the	 MC	 on	 Thalf	and	 Tasc	(Table	 5.2)	 but	
none	of	the	specific	comparisons	between	phases	indicated	a	significant	diference.	However	
the	efects	observed	seem	to	mainly	reflect	that	Thalf	was	quicker	in	the	LPh	compared	to	the	
FPh	and	the	MPh	(mean	diference:	28	±	31	and	13	±	15	min,	p	=	0.081	and	0.092,	respectively)	
and	Tasc	was	faster	in	the	LPh	compared	to	the	FPh	(mean	diference:	27	±	29	min,	p	=	0.077).	
There	 was	 a	trend	 towards	 a	 diference	 in	 Tlag	across	 the	 phases	 of	 the	 MC	 (p	 =	 0.072).	 No	
diferences	were	found	in	Tlat	across	the	phases	of	the	MC.	
Table	5.2.	GE	parameters	shown	in	minutes	for	MPh,	FPh	and	LPh.	
GE	parameter	(min)	 MPh	 FPh	 LPh	 p	
Thalf	 101	±	23	 116	±	46	 88	±	22	 0.015	
Tlag	 48	±	8	 51	±	14	 43	±	12	 0.072	
Tlat	 52	±	7	 53	±	12	 48	±	13	 0.264	
Tasc	 128	±	23	 143	±	41	 116	±	13	 0.011	
Mean	±	SD	
	
5.3.4. Total	PYY	
Due	 to	 sampling	 issues,	 a	 total	 of	 seven	 samples	 (2%)	 could	 not	 be	 colected.	 Of	 these,	 four	
were	the	150-240	min	samples	of	one	participant’s	FPh,	therefore,	comparisons	from	min	150	
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Fig	5.4.	Example	of	a	participant’s	breath	13CO2	curves,	expressed	in	excess	atom	fraction	over	the	
time	folowing	each	of	the	three	phases	of	the	MC.	
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onwards	 are	 only	 from	 8	 participants.	 The	 three	 remaining	 samples	 (1%)	 belonged	 to	 three	
diferent	 phases,	 thus	 concentrations	 for	 these	 time	 points	 were	 estimated	 as	 explained	 in	
chapter	2.4.3.		
PYY	 levels	 were	 significantly	 diferent	 at	 baseline	 across	 the	 phases	 of	 the	 MC	 (p	 =	 0.004),	
being	significantly	lower	in	the	LPh	compared	to	the	MPh	(59.9	±	40.5	vs.	91.2	±	47.5	pg/ml)	(p	
=	 0.008),	 but	 not	 to	 the	 FPh	 (64.9	 ±	 9.4	 pg/ml,	 p	 =	 0.079).	PYY	peak	 was	 lower	 in	 the	 LPh	
compared	to	the	MPh	and	FPh	(117	±	50	vs.	133	±	47	and	132	±	48	pg/ml,	respectively)	but	it	
was	not	significantly	diferent	(p	=	0.264).	
The	2-way	ANOVA	analyses	showed	that	there	was	not	a	significant	phase	x	time	interaction	in	
PYY	levels	(p	=	0.169)	(Fig	5.5).	Nevertheless,	an	overal	phase	efect	was	shown	(p	=	0.041),	yet	
there	 were	 no	 significant	 diferences	 between	 specific	 phases	 in	 total	 PYY	 concentrations.	
However	 the	 efects	 observed	 seemed	 to	 reflect	 that	 PYY	 levels	 were	 lower	 in	 the	 LPh	
compared	to	the	MPh	(p	=	0.080).	Furthermore,	there	was	a	significant	time	efect	(p	<	0.001),	
as	PYY	levels	increased	significantly	from	baseline	to	t	=	45,	60,	90	and	120	(p	≤	0.05	for	al),	as	
wel	 as	 from	 post	 breakfast	 (t	 =	 15	 min)	 to	 90	 (p	 =	 0.030).	 Finaly,	 there	 was	 a	 significant	
reduction	in	PYY	concentrations	from	t	=	180	to	210	(p	=	0.017).		
When	looking	at	the	change	in	PYY	levels	at	every	time	point,	we	found	that	only	time	had	a	
significant	efect	(p	<0.001),	whereas	made	no	statistical	diference	(p	=	0.846)	and	there	was	
not	a	phase	x	time	interaction	efect	(p	=	0.213)	(Fig	5.6).	
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Fig	5.5.	PYY	levels	at	each	time	point	in	the	diferent	phases	of	the	MC	(Means	±	SD).	
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There	was	a	significant	overal	efect	on	PYY	AUC	at	t	=	60,	120,	180	and	240,	but	only	at	t	=	60,	
there	was	a	significant	diference	between	specific	phases,	i.e.	LPh	vs.	MPh	(4627	±	2712	vs.	
5883	 ±	 2601	 pg/ml/min)	 (p	 =	 0.021)	 (Fig	 5.7).	 However	 the	 efects	 observed	 seem	 to	 mainly	
reflect	 that	 the	 PYY	 AUCs	 at	 t	 =	 120,	 180	 and	 240	 were	 smaler	 in	 the	 LPh	 compared	 to	 the	
MPh	(p	=	0.066,	0.129	and	0.113,	respectively).	
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Fig	 5.7.	 Total	 PYY	 AUCs	 at	 t	 =	 60,	 120,	 180	 and	 240	 in	 the	 diferent	 phases	 of	 the	 MC	
(Means	±	SD).	a	Significantly	diferent	to	the	LPh	within	the	same	time	AUC.	
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Fig	5.6.	Change	in	PYY	levels	from	baseline	to	each	time	point	in	the	diferent	phases	of	the	MC	
(Means	±	SD).	
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5.3.5. Satiety	ratings	
There	 were	 no	 significant	 differences	 in	 AUC	 for	 any	 of	 the	 four	 satiety	 questions	 when	
analysing	 them	 in	 a	 two-way-ANOVA	 (time	 x	 phase)	 with	 the	 baseline	 measurements	 as	
covariates.	AUC	for	the	questions	“how	hungry	do	you	feel”	and	“how	strong	is	your	desire	to	
eat”	 showed	 to	 be	 the	 highest	 in	 hunger	 and	 strongest	 in	 desire	 to	 eat	 for	 every	 hour	 as	
follows:	LPh	>	FPh	>	MPh.	In	contrast,	for	questions	of	“How	full	do	you	feel?”	and	“How	much	
food	do	you	think	you	can	eat?”	there	was	not	a	consistent	pattern	between	phases	in	each	of	
the	time	AUCs	(Fig	5.8).		
	
5.3.6. Ad-libitum,	post-lunch	and	averaged	food	intake		
For	this	section	of	the	results,	a	participant’s	data	was	excluded	as	her	eating	behaviour	and	
food	diary	analyses	showed	a	strong	 indication	that	she	was	restricting	her	EI	during	the	ad-
libitum	 buffet-lunch	as	well	 as	underreporting	her	 food	 intake	 in	 the	 food	diary.	 Specifically,	
when	comparing	her	EE	measured	from	the	PA	monitor	against	 the	EI	 from	her	 food	diary	 it	
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Fig	5.8.	Total	AUCs	(mm/min)	at	t	=	60,	120,	180	and	240	in	the	different	phases	of	the	MC	for	the	
four	appetite	sensations	questions:	(1)	‘How	hungry	do	you	feel?’	(A),	(2)	‘How	full	do	you	feel?’	(B),	
(3)	 ‘How	strong	is	your	desire	to	eat?’	(C)	and	(4)	 ‘How	much	food	do	you	think	you	can	eat?’	(D).	
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was	found	that	her	EI,	as	an	average	of	the	days	measured,	was	1807	kcal/d,	whereas	her	EE	
was	of	3045	kcal/d.	That	equals	to	41	%	difference.	Considering	that	her	predictive	RMR	would	
be	of	1616	kcal/d	(using	Harris	&	Benedict	formula),	this	amount	of	EI	might	not	be	sufficient	
to	accomplish	her	energy	requirements	of	the	day.	Moreover,	the	activity	monitor	and	the	life	
style	questionnaire	showed	that	she	was	a	moderately	active	person,	thus	the	data	that	was	
collected	regarding	her	eating	patterns	did	not	seem	genuine	enough	to	be	included.	
During	the	buffet	 lunch	there	were	no	significant	differences	in	EI,	CHO,	protein	or	fat	 intake	
between	phases	of	the	MC	(Table	5.3).	Similarly	no	differences	were	observed	in	food	intake	
once	participants	left	the	laboratory.	In	addition,	as	an	average	of	the	three	days	in	each	MC	
phase,	non-significant	differences	were	found	in	food	intake.	Finally,	food	intake	as	an	average	
of	the	day	before	and	after	the	laboratory	visit,	i.e.	food	intake	under	free-living	conditions	did	
not	change	significantly	for	energy,	CHO,	fat	or	protein	intake	across	the	MC	(Table	5.3).	
Table	5.3.	 Food	 intake	during	and	after	 the	ad	 libitum	 lunch	and	as	an	average	of	 the	 three	
measured	days	in	each	MC	phase.	
		 MPh	 FPh	 LPh	
Ad	libitum	lunch	
Energy	(kcal)	 931	±	193	 984	±	178	 956	±	194	
CHO	(g)	 113	±	20	 119	±	20	 116	±	27	
Fat	(g)	 38	±	11	 41	±	10	 39	±	8	
Protein	(g)	 29	±	6	 30	±	6	 30	±	7	
	 	 	 	
After	Ad	libitum	lunch	
Energy	(kcal)	 1131	±	339	 1308	±	660	 1192	±	485	
CHO	(g)	 134	±	47	 156	±	93	 141	±	54	
Fat	(g)	 42	±	14	 52	±	25	 56	±	31	
Protein	(g)	 43	±	21	 39	±	16	 34	±	18	
	 	 	 	
Average	of	3	days	
Energy	(kcal)	 2352	±	358	 2368	±	604	 2443	±	412	
CHO	(g)	 271	±	41	 274	±	70	 279	±	54	
Fat	(g)	 101	±	21	 97	±	25	 106	±	22	
Protein	(g)	 84	±	17	 77	±	10	 85	±	15	
	 	 	 	
Free-living	conditions	 	 	 	
Energy	(kcal)	 2292	±	146	 2203	±	598	 2386	±	520	
CHO	(g)	 264	±	52	 255	±	64	 270	±	67	
Fat	(g)	 103	±	26	 91	±	26	 103	±	27	
Protein	(g)	 79	±	19	 70	±	13	 84	±	20	
Means	±	SD	
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5.3.7. Relationships	between	PYY,	GE,	appetite	feelings	and	EI	
There	was	a	significant	moderate	correlation	between	peak	PYY	and	Thalf	and	Tasc	(r	=	0.396	and	
0.410,	p	=	0.041	and	0.034).	Moreover,	 there	was	a	 trend	 for	a	moderate	correlation	of	PYY	
AUC	at	time	180	and	240	with	Thalf	and	Tasc	 (r	=	0.4	for	all,	p	=	0.08	and	0.07	for	Thalf	and	Tasc	
correlations,	respectively).		
AUCs	 from	 the	 VAS	 question	 1	 (“how	 hungry	 do	 you	 feel”)	 at	 t	 =	 240	 showed	 a	 significant	
moderate	 correlation	with	 Tasc	 (r	 =	 0.416,	 p	 =	 0.031).	 No	 other	 correlations	were	 found	 for	
appetite	ratings	with	other	GE	parameters,	PYY	response	or	food	intake.	
No	significant	correlations	were	found	between	EI	and	PYY,	GE	or	appetite	feelings.	
	
5.3.8. Relationships	between	appetite	markers	and	the	ovarian	hormones		
There	was	a	moderate	negative	correlation	between	Thalf	and	Tasc	and	P4	levels	(r	=	-0.490	and	-
0.426,	p=	0.010	and	0.027,	respectively).	Moreover,	Thalf	and	Tasc	were	positively	correlated	to	
E2:P4	ratio	(r	=	0.437	and	0.407,	p=	0.023	and	0.035).	
There	were	no	correlations	between	PYY	AUCs	or	peak	PYY	and	the	ovarian	hormones.	
Similarly,	 no	 correlations	 between	 appetite	 sensations	 or	 food	 intake	 and	 the	 ovarian	
hormones	were	found.	
	
5.4. Discussion	
The	aim	of	this	study	was	to	investigate	whether	appetite	responses	vary	after	consuming	the	
same	breakfast	 in	 the	different	phases	of	 the	MC.	This	 research	 is	of	 importance	 in	order	 to	
extend	the	current	knowledge	in	appetite	regulation	 in	a	subset	of	the	adult	population	who	
seems	to	be	at	a	higher	risk	of	developing	obesity	than	men	(WHO	2015).	
	
5.4.1. GE	throughout	the	MC	
Our	 results	 showed	 that	 the	 time	 to	 empty	 half	 of	 the	 breakfast	 from	 the	 stomach	 to	 the	
duodenum	(Thalf)	was	significantly	different	across	the	phases	of	MC,	being	on	average	28	and	
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13	minutes	 quicker	 in	 the	 LPh	 compared	 to	 the	 FPh	 and	MPh,	 respectively.	 Looking	 at	 the	
different	GE	parameters,	it	could	be	suggested	that	the	reduction	in	the	GE	time	(represented	
by	 Thalf)	 was	 because	 of	 a	 significantly	 shorter	 Tasc	 and,	 potentially,	 a	 faster	 Tlag	 in	 the	 LPh	
compared	to	the	other	phases.	This	is,	GE	rate	only	became	altered	between	phases	after	the	
initial	delay	in	the	rate	of	food	emptying	from	the	stomach,	namely	Tlat.	Therefore,	the	effect	
seen	in	the	GE	time	by	the	MC	phase	seems	to	respond	to	a	change	in	the	later	stages	of	the	
GE	process,	when	the	highest	GE	rates	are	present	(Tasc)	and	potentially,	the	time	taken	to	the	
stomach	to	reach	this	stage	(Tlag).	Namely,	in	the	LPh,	high	GE	rates	might	have	been	reached	
quicker	 and	 once	 attained,	 these	 were	 sustained	 for	 a	 shorter	 period	 which	 resulted	 in	 a	
reduction	of	 the	 time	 required	 to	 empty	 the	 same	amount	of	 food	 from	 the	 stomach	when	
compared	to	the	other	two	phases	of	the	MC.	Because	Tasc	was	maintained	for	less	time	in	the	
LPh,	GE	rates	achieved	during	that	period	had	to	be	of	a	higher	velocity	to	achieve	a	shorter	GE	
time.	
Faster	GE	during	the	LPh	in	comparison	to	the	FPh	has	previously	been	described	(Brennan	et	
al	 2009),	 however,	 others	 have	 found	 opposite	 results	 (Gill	 et	 al	 1987)	 or	 no	 differences	
(Horowitz	et	al	1985,	Monés	et	al	1993)	between	these	two	phases,	thus	a	definite	position	in	
this	matter	cannot	be	made	with	the	available	evidence.	Discrepancies	amongst	studies	might	
rely	on	different	test	meals	in	terms	of	calories	and	nutrient	composition	(Horowitz	et	al	1985)	
and	the	fact	that	some	women	might	not	have	ovulated	as	that	was	not	tested	(Monés	et	al	
1993).	
Furthermore,	attention	is	warranted	as	our	outcome	does	not	only	support	those	who	found	
differences	between	the	LPh	and	the	FPh	(Brennan	et	al	2009),	but	also	suggests	that	the	GE	
effect	seen	in	the	LPh	is	large	enough	to	be	compared	to	the	MPh,	as	well.	As	far	as	we	know,	
this	is	the	first	study	to	add	the	MPh	as	another	time	point	to	investigate	GE	within	the	MC	and	
our	findings	suggest	that	this	should	be	included	in	future	investigations.	
	
5.4.2. PYY	throughout	the	MC	
To	 our	 knowledge,	 this	 is	 the	 first	 investigation	 to	 indicate	 that	 pre-	 and	 post-prandial	 PYY	
levels	significantly	change	amongst	the	phases	of	the	MC.	The	results	of	the	study	suggest	that	
during	the	LPh	there	are	lower	PYY	levels	when	participants	are	fasted,	but	also	these	have	a	
smaller	response	when	comparing	 it	 to	the	MPh.	Moreover,	 this	was	kept	consistently	 lower	
every	post-prandial	hour	until	the	end	of	the	test	(4	hours	later	the	start	of	the	breakfast).	The	
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MC	effect	on	the	PYY	response	seem	to	partly	result	from	the	significant	differences	found	at	
baseline	(when	fasted)	as	the	statistical	significance	was	lost	when	looking	at	the	change	in	PYY	
levels	from	baseline	(p	=0.213).	
PYY	secretion	is	dependent	on	the	presence	of	food	in	the	lower	intestine	(ileum,	colon)	where	
the	 L-cells	 are	 located,	 thus	 by	 direct	 contact	 (Fu-Cheng	 et	 al	 1995),	 but	 also	 by	 digestive	
events	that	occur	at	upper	sections	of	the	gastrointestinal	tract,	 i.e.	duodenum	and	stomach.	
Specifically,	 there	 is	 evidence	 that	 gastrin,	 which	 is	 known	 to	 stimulate	 the	 production	 of	
gastric	acid,	can	inhibit	the	release	of	PYY	as	seen	in	rats	(Gomez	et	al	1996).	Meanwhile,	the	
increase	in	gastric	acid	concentrations	will	trigger	the	synthesis	of	PYY	as	part	of	the	ileal	brake	
of	 the	 digestion	 process,	 thus	 creating	 a	 feedback	 loop	 between	 the	 upper	 and	 lower	
gastrointestinal	 tract.	 In	some	(Adamopoulos	et	al	1982)	but	not	all	 (Frick	et	al	1990,	Uvnäs-
Msoberg	et	al	1989)	studies,	gastrin	levels	were	elevated	in	the	LPh	when	compared	to	the	FPh	
which,	provided	this	is	the	case	of	our	participants,	could	partly	explain	the	impairment	in	the	
PYY	 release	 and	 the	 consequent	 unavailability	 to	 reduce	 the	 GE	 time	 in	 the	 LPh.	 This	 was	
supported	by	the	positive	correlation	found	between	Thalf	and	PYY	peak,	and	the	tendency	for	a	
positive	correlation	with	the	PYY	AUC	at	t	=	180	and	240.		
Another	 potential	 mechanism	 that	 could	 have	 contributed	 to	 the	 different	 PYY	 responses	
would	be	changes	in	the	CCK	secretion.	CCK	release	after	the	infusion	of	long-chain	fatty	acids	
in	the	duodenum	has	been	shown	to	up-regulate	PYY	secretion	by	is	CCK-receptor	1	(Degen	et	
al	 2007),	 thus,	 if	 CCK	 secretion	 is	 inhibited	 in	 the	 LPh	 that	 could	 in	 turn	 impair	 PYY	 release.	
Although,	Brennan	et	al	(2009)	found	that	CCK	secretion	was	maintained	across	the	MC,	that	
could	 have	been	determined	by	 the	 fact	 that	 participants	 only	 ingested	 a	 glucose	 drink	 and	
CHOs	are	known	to	be	less	effective	 in	stimulating	the	CCK	than	fats	(Hildebrand	et	al	1990),	
thus	there	could	still	be	a	potential	for	CCK	modulating	the	changes	in	PYY	secretion	across	the	
phases	of	the	MC.	
	
5.4.3. Ovarian	hormones	associations	
One	 interesting	 finding	of	our	 study	was	 the	 significant	negative	correlation	between	P4	and	
Thalf.	Despite	being	only	a	moderate	correlation,	our	results	agree	with	Brennan	et	al’s	findings	
and	 corroborate	 the	 idea	 that	 the	 ovarian	 hormones	 might	 have	 and	 influence	 in	 GE.	
Furthermore,	the	fact	that	the	ratio	between	E2	and	P4	is	also	significantly	correlated,	suggests	
that	both	hormones	are	somehow	related	to	the	changes	in	the	GE	process.	
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Although	our	results	did	not	indicate	a	direct	association	between	PYY	levels	and	the	ovarian	
hormones,	 these	may	have	exerted	 their	 influence	by	other	 factors	 involved	 in	 the	digestive	
process	e.g.	GE,	other	appetite-hormonal	secretions.	
Considering	the	natural	occurring	changes	in	E2	between	the	MPh	and	FPh	it	seemed	necessary	
to	investigate	three	rather	than	two	phases	and	this	was	corroborated	by	the	outcome	of	the	
study.	
	
5.4.4. Food	intake	and	appetite	sensations	throughout	the	MC	
Although	increases	in	food	intake	in	the	ad-libitum	lunch	were	expected	in	the	LPh	as	seen	in	
previous	literature	(McNeil	and	Doucet	2012),	our	results	did	not	find	significant	fluctuations	in	
EI	or	macronutrient	 intake	across	 the	phases	of	 the	MC.	 In	 fact,	even	 looking	at	 food	 intake	
after	the	lunch	buffet	as	well	as	the	overall	day,	differences	were	negligible.	This	could	be	due	
to	the	fact	that	the	majority	of	the	food	intake	of	the	day	(while	in	the	laboratory)	was	already	
purposely	 kept	 constant,	 thus	 leaving	 little	 room	 for	 any	 changes.	Nevertheless,	 food	 intake	
under	the	free-living	conditions,	which	was	183	and	94	kcal/d	higher	 in	the	LPh	compared	to	
the	 FPh	 and	 MPh,	 respectively,	 was	 not	 significantly	 different	 throughout	 the	 MC	 phases,	
either.	Despite	not	reaching	the	statistical	significance,	fluctuations	were	within	the	spectrum	
of	+50-100	kcal/d	which	are	recognised	to	be	of	enough	magnitude	to	induce	the	progressive	
development	of	obesity	(Mozaffarian	et	al	2011).			
The	unchanged	food	intake	during	the	lunch	buffet,	is	somehow,	expected	since	there	were	no	
significant	 differences	 in	 the	 appetite	 sensations	 post-breakfast,	 suggesting	 that	 food	 intake	
was	 responding	 to	 actual	 appetite	 perceptions	 and	 not	 to	 other	 extrinsic	 factors.	 However,	
direct	 correlations	 were	 not	 found	 between	 food	 intake	 and	 appetite	 sensations	 which	
manifests	 the	 difficulty	 in	 assessing	 subjective	 measurements.	 In	 fact,	 the	 only	 correlation	
found	with	appetite	sensations,	i.e.	Tasc	and	hunger	ratings,	cannot	be	explained	by	the	known	
literature.	Since	this	correlation	was	only	moderate	(r	=	0.416)	and	it	appears	to	be	opposite	to	
what	it	would	be	expected,	it	could	be	suggested	to	respond	to	a	random	effect	
Although,	 the	 assessment	 of	 food	 intake	 in	 a	 controlled	 setting	 presents	 important	
advantages,	such	as	the	availability	to	accurately	quantify	what	it	is	consumed,	it	also	presents	
several	 limitations	that	cannot	be	 ignored.	For	 instance,	eating	behaviour	can	be	altered	due	
to	 eating	 in	 a	 non-familiar	 and	 unnatural	 environment,	 or	 because	 of	 the	 expectations	 the	
participants	believe	that	the	researcher	might	have	(Stubbs	et	al	1998).	Nevertheless,	we	tried	
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to	minimise	 this	effect	by	providing	a	 sensible	 variety	of	 foods	 that	 the	participant	 could	be	
familiar	 with.	 On	 the	 other	 hand,	 although	 food	 diaries	 can	 avoid	 the	 limitations	 of	 the	
laboratory	setting,	they	can	also	present	different	drawbacks	such	as	the	misreporting	shown	
in	 one	 of	 our	 participants	 as	well	 as	 in	 other	 studies	 (de	 Vries	 et	 al	 1994).	 Therefore,	 both	
methods	 agreed	 on	 the	 idea	 that	 there	 were	 no	 significant	 alterations	 in	 food	 intake	
throughout	the	phases	of	the	MC.	Inconsistencies	with	other	studies	might	rely	on	the	limited	
sample	 size,	 although	 others	 have	 proved	 significant	 differences	 with	 the	 same	 number	 of	
participants	 (Dalvit-McPhillips	 1983).	 Thus,	 differences	 between	 the	 latter	 study	 and	 ours	
could	 partly	 be	 due	 to	 the	 dietary	 assessment	 techniques	 employed	 i.e.	 dietary	 interview	
during	60	days	vs.	nine	days	of	food	diaries.	
Finally,	although	PYY	response	significantly	changed	throughout	the	MC,	the	magnitude	of	the	
change	(mean	change	in	total	PYY	AUC	at	min	240	in	LPh:	29	and	22%	compared	to	the	MPh	
and	 FPh,	 respectively)	 might	 not	 have	 been	 substantial	 enough	 to	 elicit	 modifications	 in	
appetite	sensations	and	subsequent	food	intake.	
	
5.4.5. Limitations	
Despite	GE	time	and	PYY	response	showing	to	be	significantly	different	across	the	MC,	pairwise	
comparisons	could	not	achieve	the	statistical	significance	and	that	could	be	due	to	the	small	
sample	 size.	 In	 fact,	 if	 applied	 a	 t-test	 to	 compare	 Thalf	 between	 the	 LPh	 and	 FPh	 or	 MPh,	
significant	differences	would	have	been	found,	however	with	the	ANOVA	and	the	Bonferroni	
correction,	 the	 statistical	 significance	was	 diminished.	Nevertheless,	we	 employed	 the	 same	
size	used	by	previous	studies	(Brennan	et	al	2009).	
Our	study	did	not	distinguish	the	two	different	forms	of	PYY,	 i.e.	PYY1-36	and	PYY3-36.	 It	 is	well	
known	that	with	food	intake	PYY1-36	is	cleaved	by	the	dipeptidyl	peptidase	IV	to	PYY3-36	and	that	
only	the	latter	form	has	almost	exclusive	and	high	affinity	to	Y-2	receptors	of	the	ARC.	This	is	of	
relevance	as	Y-2	 receptors	are	 the	only	 subtype	of	Y-receptors	 that	 can	 induce	appetite	and	
BW	 suppression	 by	 stimulating	 the	 activity	 of	 the	 α-MSH	 through	 the	 inhibition	 of	 the	 NPY	
release	(Ballantyne	2006).	Thus,	although	unlikely,	changes	in	the	concentrations	of	total	PYY	
could	respond	to	alterations	in	the	proportion	between	the	two	forms	of	PYY.	Thus	it	cannot	
be	dismissed	 that	 lower	PYY	 response	 in	 the	 LPh	was	mainly	 relying	on	 a	diminished	PYY1-36	
secretion	and	conversion,	 therefore,	 inducing	minimal	changes	 in	 food	 intake.	Future	studies	
could	improve	our	findings	by	measuring	the	two	forms	of	PYY.	
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5.5. Conclusion	
To	 our	 knowledge	 this	 is	 the	 first	 study	 to	 investigate	 GE	 time	 and	 PYY	 response	 after	
consuming	 the	 same	breakfast	 three	 times	 in	 the	MC	 in	which	ovarian	hormones,	 E2	 and	P4	
presented	very	distinguishable	levels.	Our	results	found	significant	differences	in	GE	time	and	
PYY	response	that	suggest	the	LPh	as	the	quickest	in	GE	time	with	the	smallest	PYY	response	of	
the	 all	MC	 phases.	 Appetite	 sensations	 or	 food	 intake	were	 not	 affected	 by	 the	MC.	 Finally	
changes	in	the	GE	time	could	be	influenced	by	the	fluctuations	in	the	ovarian	hormones.	
Further	research	needs	to	be	done	to	confirm	the	findings	of	our	study	and	to	have	a	better	
understanding	of	the	underlying	mechanisms	for	these	changes	 in	GE	time	and	PYY	response	
across	the	MC	as	they	could	potentially	direct	us	to	novel	dieting	strategies	in	women.	Finally,	
our	 findings	 suggest	 that	 any	 functional	 food	 studies	 aimed	 to	 change	 satiation	 should	 take	
into	account	the	 likely	modifications	 in	the	processing	of	 food	that	women	might	experience	
throughout	 the	MC	by	 re-testing	 their	 products	 in	 the	 different	MC	phases	 to	 ultimately	 be	
able	to	demonstrate	the	effects	of	a	dietary	intervention	in	this	population.	
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6. General	discussion	and	future	research	
Sex	 differences	 in	 physiological	 factors	 involved	 in	 the	 regulation	 of	 energy	 homeostasis	
such	as	RMR,	body	composition	and	food	intake	have	been	studied	for	a	very	long	time	in	
animal	 models	 and	 humans	 (Arciero	 et	 al	 1993,	 Asarian	 and	 Geary	 2013,	 Lemieux	 et	 al	
1993).	 All	 these	 factors	 are	 without	 doubt	 highly	 inter-related	 and	 dependent	 on	 each	
other,	e.g.	women	tend	to	have	a	higher	BF%	than	men	which	results	in	a	smaller	relative	
RMR	 that	 will	 ultimately	 reduce	 women’s	 energy	 requirements	 in	 comparison	 to	 men.	
More	 importantly,	 these	 differences	 seem	 to	 be	 ultimately	 regulated	 by	 the	 sex	 steroid	
hormones	 i.e.	 oestrogens,	 progesterone	 and	 androgens.	 Since	 levels	 of	 E2	 and	 P4	 suffer	
cyclical	fluctuations	within	a	MC,	it	seems	reasonable	to	question	whether	factors	like	the	
abovementioned	are	influenced	by	these	hormones.	Furthermore,	the	fact	that	the	current	
global	 prevalence	 of	 overweight	 and	 obesity	 in	 adults	 of	 >18	 years	 is	 greater	 in	 women	
than	men	might	 indicate	 that	women	are	 less	 efficient	 in	 achieving	body	energy	balance	
(WHO	2015).		
Therefore,	 this	 thesis	was	set	up	with	 the	aim	of	extending	the	current	knowledge	 in	 the	
regulation	 of	 energy	metabolism	 in	women	within	 the	MC.	 The	 areas	 of	 particular	 focus	
were	 the	 RMR	 and	 the	 appetite	 responses	 to	 a	meal,	 therefore	 encompassing	 elements	
involved	 in	 both	 sides	 of	 the	 energy	 balance	 equation,	 i.e.	 EE	 and	 EI.	 Furthermore,	 we	
aimed	to	explore	the	role	that	E2	and	P4	might	have	in	the	regulation	of	these	and	how	both	
hormones	 are	 related	 with	 their	 respective	 salivary	 counterparts.	 Our	 key	 findings	 are	
summarised	below:		
• Saliva:plasma	ratio	for	E2	and	P4	changed	significantly	across	the	phases	of	the	MC	
in	NC	women	due	to	the	more	robust	alterations	 in	the	concentrations	of	plasma	
vs.	saliva.	
• In	NC	women,	 only	 the	 LPh	 showed	a	 significant	 and	 strong	 correlation	between	
saliva	and	plasma	P4.	Correlations	for	E2	were	significant,	but	very	weak.		
• In	HC	users,	both	plasma	ovarian	hormones	were	suppressed	whereas	only	salivary	
E2	was	reduced	when	compared	to	the	NC	group.	Salivary	P4	suppression	due	to	the	
intake	of	HC	could	not	be	confirmed	due	to	the	assay	technique	employed.		
• Intra-subject	variability	in	RMR	was	greater	in	NC	compared	to	HC	users.		
• Increases	 in	 RMR	 in	 the	 LPh	 of	 NC	 women	 did	 not	 reach	 statistical	 significance	
despite	 showing	 clinically	 meaningful	 fluctuations,	 particularly	 in	 half	 of	 the	
participants	studied.		
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• RMR	 in	 the	 LPh	 was	 significantly	 and	 negatively	 correlated	 to	 salivary,	 but	 not	
plasma,	 P4.	 This	 may	 explain	 some	 of	 the	 variance	 in	 an	 RMR	 predictive	model,	
although	BW	might	have	confounded	this	association.	
• There	exist	 significant	differences	 in	GE	 time	and	PYY	 response	 to	a	 standardized	
breakfast	across	the	MC	phases.	These	results	show	the	LPh	to	be	the	quickest	 in	
GE	time	and	with	the	smallest	PYY	response	of	the	three	MC	phases.	Furthermore,	
PYY	response	seemed	to	be	influenced	by	the	significant	differences	in	fasting	PYY	
levels.	
• The	significant	correlations	of	Thalf	with	P4	and	E2-P4	ratio	suggest	that	both	ovarian	
hormones	are	somehow	related	to	the	changes	 in	the	GE	process	throughout	the	
MC.	
• The	introduction	of	the	MPh	as	a	different	or	an	extra	phase	of	the	MC	seems	to	be	
relevant	when	studying	physiological	changes	across	the	MC,	particularly	in	the	GE	
and	appetite	hormones	response.	
The	findings	of	our	work	cannot	entirely	prove	that	NC	women	exhibit	cyclical	changes	 in	
the	regulation	of	the	energy	balance	system	within	a	MC,	but	they	indicate	that	RMR	can	
increase	in	the	LPh	of	some	NC	women	to	levels	that	would	ultimately	affect	their	BW.	Our	
participants	 did	 not	 exhibit	 any	 significant	 changes	 in	 their	 BW,	 therefore,	 either	 the	
increase	in	energy	demands	was	compensated	in	the	other	phases	of	the	MC	by	a	relative	
lower	RMR	or	changes	in	the	other	side	of	the	energy	equation	were	made	to	compensate	
the	 calorie	 deficit	 within	 the	 same	 phase.	 Indeed,	 our	 outcome	 also	 suggests	 that	 the	
consequent	increase	in	TEE	could	be	self-compensated	by	modifying	the	digestion	process	
of	 certain	 foods.	 Specifically,	 by	 the	 joint	 action	 of	 a	 quicker	 GE	 with	 a	 smaller	 PYY	
response,	women	would	experience	a	reduced	satiation	in	the	LPh	that	would	result	in	an	
increase	 in	food	 intake	and	thus	the	maintenance	of	BW.	Although	the	changes	 in	satiety	
feelings	and	 food	 intake	could	not	be	shown	by	our	 results,	a	great	number	of	 studies	 in	
the	past	have	demonstrated	how	EI	 increases	 in	 the	LPh	compared	 to	 the	FPh.	Thus,	our	
findings	 support	 the	 idea	 that	 the	 regulatory	 mechanisms	 by	 which	 energy	 balance	 is	
achieved,	might	experience	various	alterations	according	to	the	phases	of	the	MC.	It	would	
not	be	sensible	to	assume	that	the	compensatory	mechanisms	studied	in	this	thesis	(i.e.	GE	
time	 and	 PYY	 response)	 are	 the	 only	 two	 factors	 changing	 across	 the	 phases	 of	 the	MC	
since	 as	 described	 in	 the	 literature	 review	 there	 are	many	 factors	 regulating	 what,	 how	
much	and	when	do	we	eat.	For	instance,	there	is	evidence	certain	areas	of	the	corticolimbic	
brain	 of	 women	 only	 respond	 to	 high	 calorie	 (but	 not	 low	 calorie)	 food	 cues	 in	 the	 LPh	
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which	has	been	related	to	the	changes	in	food	preferences	within	the	MC	(Van	Vugt	2010).	
Whether	any	of	these	regulatory	changes	are	beneficial	or	not	in	the	maintenance	of	BW	in	
the	 long	 term	 remains	 unknown,	 although	 a	 priori	 it	 seems	 that	 women	 should	 be	 as	
efficient	as	men,	yet	men’s	energy	regulatory	systems	appear	to	be	more	stable.		
Reasons	behind	the	global	tendency	of	higher	obesity	prevalence	in	women	than	men	may	
more	 likely	 rely	 on	 a	 combination	 of	 external	 and	 internal	 factors	 (e.g.	 socioeconomic	
status,	PA	levels)	rather	than	a	unique	sex-related	cause.	Nevertheless,	taking	into	account	
the	outcome	of	our	investigations,	it	could	be	questioned	whether	pre-menopausal	women	
might	be	more	or	less	prone	to	imbalances	in	energy	balance	with	an	impact	on	their	BW	
and	composition	due	to	alterations	in	their	homeostatic	system	within	a	MC.		
If	 the	 findings	 of	 our	 research	 could	 be	 confirmed	 by	 further	 investigations	 and	 indeed	
energy	 regulation	 varied	 according	 to	 the	 phase	of	 the	MC,	 nutritional	 strategies	 for	 the	
prevention	of	obesity	in	the	female	population	could	follow	a	new	approach.	For	example,	
GP’s/nutritionists	could	provide	information	to	women	with	the	aim	to	make	them	aware	
that	if	they	feel	hungrier	or	have	a	higher	food	consumption	pre-menstrually,	they	should	
bear	in	mind	that	this	is	to	be	expected	and	that	they	could	increase	their	intake	but	they	
should	also	use	sources	of	food	known	to	be	healthy	and	not	surrender	to	the	high	caloric	
cravings.	
Despite	being	unable	to	assess	the	direct	underlying	mechanisms	of	the	alterations	in	RMR	
and	GE	and	PYY	 response	within	a	MC,	 it	 could	be	 suggested	 that	 the	 fluctuations	 in	 the	
ovarian	hormones	have	an	 influence	by	affecting	 the	homeostatic	contributors	studied	 in	
the	present	investigation	and	others,	e.g.	leptin,	insulin	(Asarian	and	Geary	2013,	Shi	et	al	
2009).	 In	 addition,	 the	 fact	 that	 only	 salivary	 (but	 not	 plasma)	 P4	 had	 a	 significant	
correlation	with	RMR	might	support	the	idea	that	salivary	ovarian	hormones	act	differently	
or	 rather,	 have	 a	 different	 association	 with	 some	 of	 the	 metabolic	 parameters	 to	 the	
plasma	counterparts.		
In	summary,	the	novelty	of	our	work	relies	on	the	different	assessment	method	employed	
for	the	RMR	(Study	2)	which	provides	a	more	accurate	output	of	the	changes	in	RMR	within	
a	 MC.	 Furthermore,	 by	 adding	 the	 measurement	 of	 the	 salivary	 ovarian	 hormones	 we	
discovered	the	influence	of	salivary	P4	on	RMR	as	it	contributed	in	the	variance	of	RMR	and	
it	was	significantly	and	negatively	correlated	to	it.	Finally,	as	far	as	we	know,	this	is	the	first	
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investigation	(Study	3)	to	explore	and	find	that	PYY	response	to	a	meal	changes	significantly	
throughout	the	MC	and	that	this	was	related	to	differences	shown	in	GE.	
	
6.1. Limitations,	implications,	and	future	research	
The	 main	 limitation	 presented	 throughout	 our	 work	 is	 the	 restriction	 in	 number	 of	
participants	 due	 to	 the	 constraints	 of	 the	 methodology	 employed	 (for	 example,	
invasiveness,	 time	 invested,	 inclusion	 criteria)	 and	 time	 available	 (i.e.	 from	 the	 time	 of	
consent	until	the	completion	of	a	participant,	at	least	one	month	is	required).	Nevertheless,	
this	is	the	nature	of	research	in	this	area	and	the	sample	size	effect	was	reduced	by	using	
the	same	participants	in	the	different	phases	of	the	MC.		
The	findings	of	our	investigation	suggest	that	nutrition	practitioners	and	researchers	should	
bear	 in	mind	that	their	female	clients	/	participants	might	experience	fluctuations	 in	their	
energy	 demands	 and	 might	 process	 differently	 the	 food	 consumed	 depending	 on	 the	
phases	of	the	MC.	Therefore,	MC	phase	should	not	be	ignored	and	researchers	should	aim	
to	 control	 it,	 but	 also	 investigate	 it.	 Furthermore,	 the	 collection	 of	 salivary	 ovarian	
hormones	 should	 be	 encouraged	 in	 future	 research	 as	 this	 not	 only	 presents	 obvious	
benefits	related	to	their	collection	technique,	but	also	it	can	offer	a	different	and,	possibly,	
more	physiologically	meaningful	information	about	the	ovarian	hormone	concentrations.	
To	conclude,	future	areas	of	research	could	include	the	following:	
• Further	investigations	on	formulating	EIA	to	measure	salivary	P4	in	HC	users	as	the	
one	employed	in	our	project	seemed	to	cross-react	with	the	HC.	
• The	study	of	salivary	and	plasma	ovarian	hormones	along	with	the	measurement	of	
their	main	blood	carriers,	i.e.	SHBG	and	CBG,	in	NC	and	HC	users.	
• The	association	with	high	or	low-CV	in	RMR	with	long	term	BW	maintenance.	
• The	 investigation	 of	 other	 meal-appetite	 regulators	 (e.g.	 CCK)	 as	 possible	
contributors	in	the	changes	in	the	digestive	process	within	the	MC.	
• The	study	of	appetite	responses	and	food	intake	in	women	who	are	using	HC.	
• The	exploration	of	 the	parameters	 researched	 in	our	work	but	 in	a	population	of	
obese	 pre-menopausal	 women.	 Our	 studies	 have	 been	 based	 on	 samples	 of	
normal-overweight	women	and	since	states	of	obesity	can	affect	the	reproductive	
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system	it	would	not	be	sensible	to	assume	that	our	findings	will	be	transferable	in	
obese	women.	
• Similarly,	women	with	polycystic	ovary	syndrome	(PCOS)	i.e.	women	who	suffer	an	
imbalance	 in	 their	 sex	 hormone	 concentrations,	 would	 be	 a	 population	 of	 great	
interest	 to	study	since	different	 results	 to	 the	ones	observed	 in	 the	present	work	
would	be	expected	due	to	their	 inability	 to	ovulate	and	their	altered	 levels	 in	sex	
hormones.	
• Further	 conditions,	 such	 as	 women	 suffering	 from	 eating	 disorders	 would	 be	
another	 interesting	 population	 to	 study.	 Women	 with	 anorexia	 nervosa	 usually	
display	 amenorrhea	 (i.e.	 irregular	 or	 absent	menstrual	 period)	which	 is	 linked	 to	
the	inhibition	of	the	HPG	axis	as	a	consequence	of	the	starvation	state	their	bodies	
are	 exposed	 to.	 Furthermore,	 as	 previously	 exposed	 in	 the	 literature	 review,	
appetite	 regulators	 such	as	 leptin,	ghrelin	and	GLP-1	are	affected	by	 this	disease,	
therefore	it	would	be	interesting	to	study	whether	responses	to	the	same	meal	are	
kept	constant	in	women	who	still	have	their	MC	but	may	display	amenorrhea.					
	 References	
	
107	
	
References	
Adamopoulos	 DA,	 Dessypris	 A,	 Xanthopoulos	 J	 and	 Chryssicopoulos	 E	 (1982)	 Gastrin	
secretion	in	the	menstrual	cycle	and	pregnancy.	Hepato-gastroenterology	29(1):	24–6.	
Adekunle	 AO,	 Kim	 JB,	 Collins	WP	 and	Whitehead	MI	 (1989)	 Progesterone	 in	 saliva	 as	 an	
index	of	ovarian	 function.	 International	 journal	of	gynaecology	and	obstetrics:	 the	official	
organ	of	the	International	Federation	of	Gynaecology	and	Obstetrics	28(1):	45–51.	
Adrian	TE,	Ferri	GL,	Bacarese-Hamilton	AJ,	Fuessl	HS,	Polak	JM	and	Bloom	SR	(1985)	Human	
distribution	 and	 release	 of	 a	 putative	 new	 gut	 hormone,	 peptide	 YY.	 Gastroenterology	
89(5):	1070–1077.	
Ahn	RS,	Choi	 JH,	Choi	BC,	Kim	 JH,	 Lee	SH	and	Sung	SS	 (2011)	Cortisol,	 estradiol-17β,	and	
progesterone	 secretion	 within	 the	 first	 hour	 after	 awakening	 in	 women	 with	 regular	
menstrual	cycles.	The	Journal	of	endocrinology	211(3):	285–95.	
Allen	 SS,	 Hatsukami	 D,	 Christianson	 D	 and	 Brown	 S	 (2000)	 Energy	 intake	 and	 energy	
expenditure	 during	 the	 menstrual	 cycle	 in	 short-term	 smoking	 cessation.	 Addictive	
behaviors	25(4):	559–72.	
Arciero	 PJ,	Goran	MI	 and	Poehlman	 ET	 (1993)	 Resting	metabolic	 rate	 is	 lower	 in	women	
than	in	men.	Journal	of	applied	physiology	75(6):	2514–20.	
Asarian	L	and	Geary	N	(2013)	Sex	differences	in	the	physiology	of	eating.	American	journal	
of	physiology.	Regulatory,	integrative	and	comparative	physiology	305(11):	R1215–67.	
Baecke	JA,	Burema	J	and	Frijters	 JE	 (1982)	A	short	questionnaire	 for	 the	measurement	of	
habitual	 physical	 activity	 in	 epidemiological	 studies.	 The	 American	 journal	 of	 clinical	
nutrition	36(5):	936–42.	
Ballantyne	 GH	 (2006)	 Peptide	 YY(1-36)	 and	 peptide	 YY(3-36):	 Part	 II.	 Changes	 after	
gastrointestinal	surgery	and	bariatric	surgery.	Obesity	surgery	16(6):	795–803.	
Bao	 A-M,	 Liu	 R-Y,	 van	 Someren	 EJW,	Hofman	M	 a,	 Cao	 Y-X	 and	 Zhou	 J-N	 (2003)	 Diurnal	
rhythm	of	 free	 estradiol	 during	 the	menstrual	 cycle.	European	 journal	 of	 endocrinology	 /	
European	Federation	of	Endocrine	Societies	148(2):	227–32.	
Barr	 S,	 Janelle	 K	 and	 Prior	 J	 (1995)	 Energy	 intakes	 are	 higher	 during	 the	 luteal	 phase	 of	
ovulatory	menstrual	cycles.	Am	J	Clin	Nutr	61(1):	39–43.	
Barton	 M	 and	 Wiesner	 B	 (1945)	 Thermogenic	 effect	 of	 progesterone.	 The	 Lancet	
246(6378):	671–672.	
Batterham	 RL,	 Cohen	 MA,	 Ellis	 SM,	 Le	 Roux	 CW,	 Withers	 DJ,	 Frost	 GS,	 Ghatei	 MA	 and	
Bloom	SR	 (2003)	 Inhibition	of	 food	 intake	 in	 obese	 subjects	 by	peptide	 YY3-36.	The	New	
England	journal	of	medicine	349(10):	941–8.	
Bellem	 A,	 Meiyappan	 S,	 Romans	 S	 and	 Einstein	 G	 (2011)	 Measuring	 estrogens	 and	
progestagens	in	humans:	an	overview	of	methods.	Gender	medicine	8(5):	283–99.	
Bentley	 PJ	 (1980)	 Endocrine	 Pharmacology:	 Physiological	 Basis	 and	 Therapeutic	
Applications.	CUP	Archive.	
Bisdee	 JT,	 James	 WPT	 and	 Shaw	 MA	 (1989)	 Changes	 in	 energy	 expenditure	 during	 the	
	 References	
	
108	
	
menstrual	cycle.	British	Journal	of	Nutrition	61(02):	187.	
Bloom	B,	Chaikoff	IL	and	Reinhardt	WO	(1951)	Intestinal	Lymph	as	Pathway	for	Transport	of	
Absorbed	 Fatty	 Acids	 of	 Different	 Chain	 Lengths.	Am	 J	 Physiol	 --	 Legacy	 Content	 166(2):	
451–455.	
Body	Media	 (2006)	 SenseWear	 body	monitoring	 system.	 Instructions	 For	Use.	 Pittsburgh,	
USA.	
De	Boever	J,	Kohen	F	and	Vandekerckhove	D	(1986)	DirectSolid-PhaseChemiluminescence	
Immunoassay	for	Salivary	Progesterone.	32(5):	763–767.	
Bolaji	 II	(1994)	Sero-salivary	progesterone	correlation.	 International	Journal	of	Gynecology	
and	Obstetrics	45(2):	125–131.	
Bosy-Westphal	 A,	 Müller	 MJ,	 Boschmann	 M,	 Klaus	 S,	 Kreymann	 G,	 Lührmann	 PM,	
Neuhäuser-Berthold	M,	Noack	R,	Pirke	KM,	Platte	P,	Selberg	O	and	Steiniger	J	(2008)	Grade	
of	adiposity	affects	the	impact	of	fat	mass	on	resting	energy	expenditure	in	women.	British	
Journal	of	Nutrition	101(04):	466.	
Bourque	 J,	 Sulon	 J,	 Demey-Ponsart	 E,	 Sodoyez	 JC	 and	Gaspard	U	 (1986)	 A	 simple,	 direct	
radioimmunoassay	 for	 salivary	 progesterone	 determination	 during	 the	 menstrual	 cycle.	
Clinical	Chemistry	32(6):	948–951.	
Brennan	 IM,	 Feltrin	KL,	Nair	NS,	Hausken	T,	 Little	TJ,	Gentilcore	D,	Wishart	 JM,	 Jones	KL,	
Horowitz	 M	 and	 Feinle-Bisset	 C	 (2009)	 Effects	 of	 the	 phases	 of	 the	 menstrual	 cycle	 on	
gastric	 emptying,	 glycemia,	 plasma	 GLP-1	 and	 insulin,	 and	 energy	 intake	 in	 healthy	 lean	
women.	 American	 journal	 of	 physiology.	 Gastrointestinal	 and	 liver	 physiology	 297(3):	
G602–10.	
Bryant	 M,	 Truesdale	 KP	 and	 Dye	 L	 (2006)	 Modest	 changes	 in	 dietary	 intake	 across	 the	
menstrual	cycle:	implications	for	food	intake	research.	British	Journal	of	Nutrition	96(05).	
Buffenstein	 R,	 Poppitt	 SD,	 McDevitt	 RM	 and	 Prentice	 AM	 (1995)	 Food	 intake	 and	 the	
menstrual	 cycle:	 a	 retrospective	 analysis,	 with	 implications	 for	 appetite	 research.	
Physiology	&	behavior	58(6):	1067–1077.	
Cedard	 L,	 Janssens	 Y,	 Tanguy	 G	 and	 Zorn	 JR	 (1984)	 Radioimmunoassay	 of	 plasma	 and	
salivary	 progesterone	 during	 the	 menstrual	 cycle.	 Journal	 of	 Steroid	 Biochemistry	 20(1):	
487–490.	
Chung	S-C,	Bond	EF	and	Jarrett	ME	(2010)	Food	intake	changes	across	the	menstrual	cycle	
in	Taiwanese	women.	Biological	research	for	nursing	12(1):	37–46.	
Clearblue	(2013)	Clear	Blue	Advanced	Fertility	Monitor.	Geneva,	Switzerland.	
Clegg	M	 and	 Shafat	 A	 (2010)	 Energy	 and	macronutrient	 composition	 of	 breakfast	 affect	
gastric	 emptying	 of	 lunch	 and	 subsequent	 food	 intake,	 satiety	 and	 satiation.	 Appetite.	
Elsevier	Ltd	54(3):	517–23.	
Coll	AP,	Farooqi	IS	and	O’Rahilly	S	(2007)	The	hormonal	control	of	food	intake.	Cell	129(2):	
251–62.	
Compher	 C,	 Frankenfield	 D,	 Keim	 N	 and	 Roth-Yousey	 L	 (2006)	 Best	 practice	methods	 to	
apply	to	measurement	of	resting	metabolic	rate	 in	adults:	a	systematic	review.	Journal	of	
	 References	
	
109	
	
the	American	Dietetic	Association	106(6):	881–903.	
Crawley	JN	and	Corwin	RL	(1994)	Biological	actions	of	cholecystokinin.	Peptides	15(4):	731–
755.	
Curtis	 V,	 Henry	 C,	 Birch	 E	 and	 Ghusain-Choueiri	 A	 (1996)	 Intraindividual	 variation	 in	 the	
basal	metabolic	rate	of	women:	Effect	of	the	menstrual	cycle.	American	Journal	of	Human	
Biology	8(5):	631–639.	
Curtis	 V,	 Henry	 C	 and	 Ghusain-Choueiri	 A	 (1996)	 Basal	metabolic	 rate	 of	 women	 on	 the	
contraceptive	pill.	European	journal	of	clinical	nutrition	50(5):	319–22.	
Dafopoulos	 K,	 Sourlas	 D,	 Kallitsaris	 A,	 Pournaras	 S	 and	Messinis	 IE	 (2009)	 Blood	 ghrelin,	
resistin,	 and	 adiponectin	 concentrations	 during	 the	 normal	menstrual	 cycle.	 Fertility	 and	
sterility.	Elsevier	Ltd	92(4):	1389–94.	
Dalvit-McPhillips	 SP	 (1983)	 The	 effect	 of	 the	 human	menstrual	 cycle	 on	 nutrient	 intake.	
Physiology	&	behavior	31(2):	209–12.	
Day	 DS,	 Gozansky	 WS,	 Van	 Pelt	 RE,	 Schwartz	 RS	 and	 Kohrt	 WM	 (2005)	 Sex	 hormone	
suppression	 reduces	 resting	 energy	 expenditure	 and	 {beta}-adrenergic	 support	 of	 resting	
energy	expenditure.	The	Journal	of	clinical	endocrinology	and	metabolism	90(6):	3312–7.	
Deane	AM,	Nguyen	NQ,	Stevens	JE,	Fraser	RJL,	Holloway	RH,	Besanko	LK,	Burgstad	C,	Jones	
KL,	 Chapman	MJ,	 Rayner	 CK	 and	Horowitz	M	 (2010)	 Endogenous	 glucagon-like	 peptide-1	
slows	gastric	emptying	in	healthy	subjects,	attenuating	postprandial	glycemia.	The	Journal	
of	clinical	endocrinology	and	metabolism	95(1):	215–21.	
Degen	L,	Drewe	J,	Piccoli	F,	Gräni	K,	Oesch	S,	Bunea	R,	D’Amato	M	and	Beglinger	C	(2007)	
Effect	of	CCK-1	receptor	blockade	on	ghrelin	and	PYY	secretion	in	men.	American	journal	of	
physiology.	Regulatory,	integrative	and	comparative	physiology	292(4):	R1391–9.	
Delhanty	PJD,	Neggers	SJ	and	van	der	Lely	AJ	(2012)	Mechanisms	in	endocrinology:	Ghrelin:	
the	 differences	 between	 acyl-	 and	 des-acyl	 ghrelin.	 European	 journal	 of	 endocrinology	
167(5):	601–8.	
Diffey	B,	Piers	LS,	Soares	MJ	and	O’dea	K	(1997)	The	effect	of	oral	contraceptive	agents	on	
the	basal	metabolic	rate	of	young	women.	British	Journal	of	Nutrition	77(06):	853.	
Dye	L	and	Blundell	JE	(1997)	Menstrual	cycle	and	appetite	control:	implications	for	weight	
regulation.	Human	reproduction	(Oxford,	England)	12(6):	1142–51.	
EFSA	(2013)	Scientific	Opinion	on	Dietary	Reference	Values	for	energy.	EFSA	Journal	11(1):	
1–112.	
Elliott	 KJ,	 Cable	NT,	 Reilly	 T	 and	Diver	MJ	 (2003)	 Effect	 of	menstrual	 cycle	 phase	 on	 the	
concentration	 of	 bioavailable	 17-beta	 oestradiol	 and	 testosterone	 and	 muscle	 strength.	
Clinical	science	(London,	England :	1979)	105(6):	663–9.	
EMD	Millipore	Corporation	(2014)	ELISA	kit	Human	Leptin	Cat.	#	ESHL-80SK.	USA.	
Endrikat	 J,	 Blode	 H,	 Gerlinger	 C,	 Rosenbaum	 P	 and	 Kuhnz	 W	 (2002)	 A	 pharmacokinetic	
study	 with	 a	 low-dose	 oral	 contraceptive	 containing	 20	microg	 ethinylestradiol	 plus	 100	
microg	levonorgestrel.	The	European	journal	of	contraception	&	reproductive	health	care :	
the	official	journal	of	the	European	Society	of	Contraception	7(2):	79–90.	
	 References	
	
110	
	
Evans	JJ	 (1986)	Progesterone	 in	saliva	does	not	parallel	unbound	progesterone	 in	plasma.	
Clinical	chemistry	32(3):	542–4.	
Farooqi	 I,	Keogh	 J,	Kamath	S,	 Jones	S,	Gibson	W,	Trussell	R,	 Jebb	S,	 Lip	G	and	O’Rahilly	S	
(2001)	 Partial	 leptin	 deficiency	 and	 human	 adiposity.	 Nature.	 Nature	 Publishing	 Group	
414(6859):	34–5.	
Farooqi	IS	and	O’Rahilly	S	(2009)	Leptin:	a	pivotal	regulator	of	human	energy	homeostasis.	
The	American	journal	of	clinical	nutrition	89(3):	980S–984S.	
Feher	 J	 (2012)	 Quantitative	 Human	 Physiology:	 An	 Introduction	 (1st	 edition).	 Academic	
Press.	
Fehring	 RJ,	 Schneider	M	 and	 Raviele	 K	 (2006)	 Variability	 in	 the	 phases	 of	 the	menstrual	
cycle.	 Journal	 of	 obstetric,	 gynecologic,	 and	 neonatal	 nursing :	 JOGNN	 /	 NAACOG	 35(3):	
376–84.	
Ferin	M,	Jewelewicz	R	and	Warren	M	(1993)	The	menstrual	cycle.	Physiology,	Reproductive	
Disorders,	and	Infertility.	New	York:	Oxford	University	Press.	
Forman	 J,	 Miller	 W,	 Szymanski	 L	 and	 Fernhall	 B	 (1998)	 Differences	 in	 resting	 metabolic	
rates	 of	 inactive	 obese	 African-American	 and	 Caucasian	 women.	 International	 journal	 of	
obesity	and	related	metabolic	disorders	22(3):	215–21.	
FPA	 (2007)	 Contraception:	 patterns	 of	 use	 factsheet.	 .	 Available	 at:	
http://www.fpa.org.uk/factsheets/contraception-patterns-use	(accessed	06/11/15).	
Frank	TC,	Kim	GL,	Krzemien	A	and	Van	Vugt	DA	(2010)	Effect	of	menstrual	cycle	phase	on	
corticolimbic	brain	activation	by	visual	food	cues.	Brain	research.	Elsevier	B.V.	1363:	81–92.	
Frankenfield	 DC,	 Rowe	 WA,	 Smith	 JS	 and	 Cooney	 RN	 (2003)	 Validation	 of	 several	
established	equations	for	resting	metabolic	rate	in	obese	and	nonobese	people.	Journal	of	
the	American	Dietetic	Association	103(9):	1152–9.	
Frayn	KN	(1983)	Calculation	of	substrate	oxidation	rates	 in	vivo	from	gaseous	exchange.	J	
Appl	Physiol	55(2):	628–634.	
Frick	 G,	 Bremme	 K,	 Sjögren	 C,	 Lindén	 A	 and	 Uvnäs-Moberg	 K	 (1990)	 Plasma	 levels	 of	
cholecystokinin	and	gastrin	during	 the	menstrual	cycle	and	pregnancy.	Acta	obstetricia	et	
gynecologica	Scandinavica	69(4):	317–20.	
Frye	 C	 (2006)	 An	 overview	 of	 oral	 contraceptives:	mechanism	 of	 action	 and	 clinical	 use.	
Neurology	66(6	Suppl	3):	S29–36.	
Fu-Cheng	X,	Anini	Y,	Chariot	J,	Voisin	T,	Galmiche	JP	and	Rozé	C	(1995)	Peptide	YY	release	
after	intraduodenal,	intraileal,	and	intracolonic	administration	of	nutrients	in	rats.	Pflügers	
Archiv :	European	journal	of	physiology	431(1):	66–75.	
Germain	N,	Galusca	B,	 Le	Roux	CW,	Bossu	C,	Ghatei	MA,	 Lang	 F,	Bloom	SR	and	Estour	B	
(2007)	Constitutional	 thinness	and	 lean	anorexia	nervosa	display	opposite	 concentrations	
of	peptide	YY,	glucagon-like	peptide	1,	ghrelin,	and	leptin.	The	American	journal	of	clinical	
nutrition	85(4):	967–71.	
Ghoos	YF,	Maes	BD,	Geypens	BJ,	Mys	G,	Hiele	MI,	Rutgeerts	PJ	and	Vantrappen	G	 (1993)	
Measurement	of	gastric	emptying	rate	of	solids	by	means	of	a	carbon-labeled	octanoic	acid	
	 References	
	
111	
	
breath	test.	Gastroenterology	104(6):	1640–7.	
Gil	Y,	Fagundes	R,	Santos	E,	Calvo	M	and	Bernardine	 J	 (2009)	Relation	of	menstrual	cycle	
and	 alimentary	 consumption	 of	 women.	 e-SPEN,	 the	 European	 e-Journal	 of	 Clinical	
Nutrition	and	Metabolism.	Elsevier	Ltd	4(5):	e257–e260.	
Gill	 RC,	Murphy	 PD,	Hooper	HR,	 Bowes	 KL	 and	Kingma	 YJ	 (1987)	 Effect	 of	 the	menstrual	
cycle	on	gastric	emptying.	Digestion	36(3):	168–74.	
Goedecke	 JH,	 St	Clair	Gibson	A,	Grobler	 L,	 Collins	M,	Noakes	TD	and	 Lambert	 E	V	 (2000)	
Determinants	of	the	variability	in	respiratory	exchange	ratio	at	rest	and	during	exercise	in	
trained	 athletes.	 American	 journal	 of	 physiology.	 Endocrinology	 and	 metabolism	 279(6):	
E1325–34.	
Goldzieher	 JW	 and	 Stanczyk	 FZ	 (2008)	 Oral	 contraceptives	 and	 individual	 variability	 of	
circulating	levels	of	ethinyl	estradiol	and	progestins.	Contraception	78(1):	4–9.	
Gomez	 G,	 Padilla	 L,	 Udupi	 V,	 Tarasova	 N,	 Sundler	 F,	 Townsend	 CM,	 Thompson	 JC	 and	
Greeley	 GH	 (1996)	 Regulation	 of	 peptide	 YY	 homeostasis	 by	 gastric	 acid	 and	 gastrin.	
Endocrinology	137(4):	1365–9.	
Gortari	P	De	and	Joseph-Bravo	P	(2006)	Neuroendocrine	regulation	of	energy	homeostasis.	
Molecular	endocrinology	661(2):	65–85.	
Grandt	D,	Schimiczek	M,	Beglinger	C,	Layer	P,	Goebell	H,	Eysselein	VE	and	Reeve	JR	(1994)	
Two	molecular	forms	of	peptide	YY	(PYY)	are	abundant	in	human	blood:	characterization	of	
a	radioimmunoassay	recognizing	PYY	1-36	and	PYY	3-36.	Regulatory	peptides	51(2):	151–9.	
Granger	 DA,	 Hibel	 LC,	 Fortunato	 CK	 and	 Kapelewski	 CH	 (2009)	 Medication	 effects	 on	
salivary	cortisol:	 tactics	and	strategy	to	minimize	 impact	 in	behavioral	and	developmental	
science.	Psychoneuroendocrinology	34(10):	1437–48.	
Gröschl	 M	 (2008)	 Current	 status	 of	 salivary	 hormone	 analysis.	 Clinical	 chemistry	 54(11):	
1759–69.	
Guida	M,	Tommaselli	GA,	Palomba	S,	Pellicano	M,	Moccia	G,	Di	Carlo	C	and	Nappi	C	(1999)	
Efficacy	of	methods	for	determining	ovulation	in	a	natural	family	planning	program.	Fertility	
and	sterility	72(5):	900–4.	
Guo	Y,	Ma	L,	Enriori	PJ,	Koska	J,	Franks	PW,	Brookshire	T,	Cowley	MA,	Salbe	AD,	Delparigi	A	
and	 Tataranni	 PA	 (2006)	 Physiological	 evidence	 for	 the	 involvement	 of	 peptide	 YY	 in	 the	
regulation	of	energy	homeostasis	in	humans.	Obesity	(Silver	Spring,	Md.)	14(9):	1562–70.	
Hameed	 S,	 Dhillo	 WS	 and	 Bloom	 SR	 (2009)	 Gut	 hormones	 and	 appetite	 control.	 Oral	
diseases	15(1):	18–26.	
Hampson	 E	 and	 Young	 EA	 (2007)	 Sex	 Differences	 in	 the	 Brain :	 From	Genes	 to	 Behavior:	
From	Genes	to	Behavior.	USA:	Oxford	University	Press.	
Haycock	GB,	Schwartz	GJ	and	Wisotsky	DH	(1978)	Geometric	method	for	measuring	body	
surface	area:	a	height-weight	formula	validated	in	infants,	children,	and	adults.	The	Journal	
of	pediatrics	93(1):	62–6.	
Heffner	LJ	and	Schust	DJ	(2014)	Reproductive	System	at	a	Glance.	Somerset:	Wiley.	
Henry	CJK,	Hayter	J	and	Rees	DG	(1989)	The	constancy	of	basal	metabolic	rate	in	free-living	
	 References	
	
112	
	
male	subjects.	European	journal	of	clinical	nutrition	43(10):	727–31.	
Henry	 CJK,	 Lightowler	 HJ	 and	 Marchini	 J	 (2003)	 Intra-individual	 variation	 in	 resting	
metabolic	rate	during	the	menstrual	cycle.	The	British	journal	of	nutrition	89(6):	811–7.	
Hildebrand	P,	Beglinger	C,	Gyr	K,	 Jansen	 JB,	Rovati	 LC,	Zuercher	M,	 Lamers	CB,	Setnikar	 I	
and	Stalder	GA	(1990)	Effects	of	a	cholecystokinin	receptor	antagonist	on	intestinal	phase	
of	pancreatic	and	biliary	responses	in	man.	The	Journal	of	clinical	investigation	85(3):	640–
6.	
Hill	 BR,	 De	 Souza	 MJ	 and	 Williams	 NI	 (2011)	 Characterization	 of	 the	 diurnal	 rhythm	 of	
peptide	 YY	 and	 its	 association	 with	 energy	 balance	 parameters	 in	 normal-weight	
premenopausal	 women.	 American	 journal	 of	 physiology.	 Endocrinology	 and	 metabolism	
301(2):	E409–15.	
Hill	JO,	Wyatt	HR,	Reed	GW	and	Peters	JC	(2003)	Obesity	and	the	environment:	where	do	
we	go	from	here?	Science	(New	York,	N.Y.)	299(5608):	853–5.	
Hirschberg	AL	 (2012)	Sex	hormones,	appetite	and	eating	behaviour	 in	women.	Maturitas.	
Elsevier	Ireland	Ltd	71(3):	248–56.	
Hofman	LF	(2001)	Human	saliva	as	a	diagnostic	specimen.	The	Journal	of	nutrition	131(5):	
1621S–5S.	
Horowitz	M,	Maddern	GJ,	Chatterton	BE,	Collins	PJ,	Petrucco	OM,	Seamark	R	and	Shearman	
DJ	(1985)	The	normal	menstrual	cycle	has	no	effect	on	gastric	emptying.	British	journal	of	
obstetrics	and	gynaecology	92(7):	743–6.	
Horton	TJ,	Miller	EK,	Glueck	D	and	Tench	K	 (2002)	No	effect	of	menstrual	cycle	phase	on	
glucose	kinetics	and	fuel	oxidation	during	moderate-intensity	exercise.	American	journal	of	
physiology.	Endocrinology	and	metabolism	282(4):	E752–62.	
Howards	 PP,	 Schisterman	 EF,	Wactawski-Wende	 J,	 Reschke	 JE,	 Frazer	 AA	 and	 Hovey	 KM	
(2009)	Timing	clinic	visits	to	phases	of	the	menstrual	cycle	by	using	a	fertility	monitor:	the	
BioCycle	Study.	American	journal	of	epidemiology	169(1):	105–12.	
Howe	 JC,	Rumpler	W	V	and	Seale	 JL	 (1993)	Energy	expenditure	by	 indirect	calorimetry	 in	
premenopausal	 women:	 variation	 within	 one	menstrual	 cycle.	 The	 Journal	 of	 Nutritional	
Biochemistry	4(5):	268–273.	
Hu	 J,	 Zhang	 Z,	 Shen	 W-J	 and	 Azhar	 S	 (2010)	 Cellular	 cholesterol	 delivery,	 intracellular	
processing	 and	 utilization	 for	 biosynthesis	 of	 steroid	 hormones.	Nutrition	 &	 metabolism	
7(1):	47.	
Jankowski	 CM,	 Ben-Ezra	 V,	 Gozansky	 WS	 and	 Scheaffer	 SE	 (2004)	 Effects	 of	 oral	
contraceptives	on	glucoregulatory	responses	to	exercise.	Metabolism	53(3):	348–352.	
Javed	F,	He	Q,	Davidson	LE,	Thornton	JC,	Albu	J,	Boxt	L,	Krasnow	N,	Elia	M,	Kang	P,	Heshka	S	
and	Gallagher	D	(2010)	Brain	and	high	metabolic	rate	organ	mass:	contributions	to	resting	
energy	expenditure	beyond	fat-free	mass.	The	American	journal	of	clinical	nutrition	91(4):	
907–12.	
Johnson	 RK	 (2002)	 Dietary	 intake--how	 do	 we	 measure	 what	 people	 are	 really	 eating?	
Obesity	research	10	Suppl	1:	63S–68S.	
	 References	
	
113	
	
Johnson	 WG,	 Corrigan	 SA,	 Lemmon	 CR,	 Bergeron	 KB	 and	 Crusco	 AH	 (1994)	 Energy	
regulation	over	the	menstrual	cycle.	Physiology	&	behavior	56(3):	523–7.	
Karl	 JP,	 Young	 AJ,	 Rood	 JC	 and	Montain	 SJ	 (2013)	 Independent	 and	 combined	 effects	 of	
eating	 rate	 and	 energy	 density	 on	 energy	 intake,	 appetite,	 and	 gut	 hormones.	 Obesity	
(Silver	Spring,	Md.)	21(3):	E244–52.	
Kennedy	 S,	 Ryan	 L,	 Fraser	A	 and	Clegg	ME	 (2014)	 Comparison	of	 the	GEM	and	 the	 ECAL	
indirect	 calorimeters	 against	 the	 Deltatrac	 for	 measures	 of	 RMR	 and	 diet-induced	
thermogenesis.	Journal	of	Nutritional	Science.	Cambridge	University	Press	3:	e52.	
Kimm	SY,	Glynn	NW,	Aston	CE,	Poehlman	ET	and	Daniels	SR	(2001)	Effects	of	race,	cigarette	
smoking,	 and	 use	 of	 contraceptive	 medications	 on	 resting	 energy	 expenditure	 in	 young	
women.	American	journal	of	epidemiology	154(8):	718–24.	
Kissileff	 HR,	 Thornton	 JC,	 Torres	 MI,	 Pavlovich	 K,	 Mayer	 LS,	 Kalari	 V,	 Leibel	 RL	 and	
Rosenbaum	 M	 (2012)	 Leptin	 reverses	 declines	 in	 satiation	 in	 weight-reduced	 obese	
humans.	The	American	journal	of	clinical	nutrition	95(2):	309–17.	
Kjems	 LL,	 Holst	 JJ,	 Vølund	 A	 and	Madsbad	 S	 (2003)	 The	 Influence	 of	 GLP-1	 on	 Glucose-
Stimulated	Insulin	Secretion.	Diabetes	52(April	2002):	380–386.	
Kolaczynski	J,	Ohannesian	J,	Considine	R,	Marco	C	and	Caro	J	(1996)	Response	of	leptin	to	
short-term	and	prolonged	overfeeding	in	humans.	The	Journal	of	clinical	endocrinology	and	
metabolism	81(11):	4162–5.	
Konishi	 S,	 Brindle	 E,	 Guyton	 A	 and	 O’Connor	 KA	 (2012)	 Salivary	 concentration	 of	
progesterone	and	cortisol	 significantly	differs	across	 individuals	after	correcting	 for	blood	
hormone	values.	American	journal	of	physical	anthropology	149(2):	231–41.	
Kruger	J,	Galuska	DA,	Serdula	MK	and	Jones	DA	(2004)	Attempting	to	lose	weight:	specific	
practices	among	U.S.	adults.	American	journal	of	preventive	medicine	26(5):	402–6.	
Lee	 KA	 (1988)	 Circadian	 Temperature	 Rhythms	 in	 Relation	 to	 Menstrual	 Cycle	 Phase.	
Journal	of	Biological	Rhythms	3(3):	255–263.	
Lemieux	S,	Prud’homme	D,	Bouchard	C,	Tremblay	A	and	Després	JP	(1993)	Sex	differences	
in	the	relation	of	visceral	adipose	tissue	accumulation	to	total	body	fatness.	The	American	
journal	of	clinical	nutrition	58(4):	463–7.	
Li	 ET,	 Tsang	 LB	 and	 Lui	 SS	 (1999)	 Menstrual	 cycle	 and	 voluntary	 food	 intake	 in	 young	
Chinese	women.	Appetite	33(1):	109–18.	
Liao	PV	and	Dollin	 J	 (2012)	Half	 a	 century	of	 the	oral	 contraceptive	pill.	Canadian	 Family	
Physician	58:	757–760.	
Liddle	 RA,	 Goldfine	 ID,	 Rosen	 MS,	 Taplitz	 RA	 and	 Williams	 JA	 (1985)	 Cholecystokinin	
bioactivity	 in	 human	 plasma.	Molecular	 forms,	 responses	 to	 feeding,	 and	 relationship	 to	
gallbladder	contraction.	The	Journal	of	clinical	investigation	75(4):	1144–52.	
Liening	 SH,	 Stanton	 SJ,	 Saini	 EK	 and	 Schultheiss	OC	 (2010)	 Salivary	 testosterone,	 cortisol,	
and	 progesterone:	 two-week	 stability,	 interhormone	 correlations,	 and	 effects	 of	 time	 of	
day,	menstrual	cycle,	and	oral	contraceptive	use	on	steroid	hormone	 levels.	Physiology	&	
behavior.	Elsevier	Inc.	99(1):	8–16.	
	 References	
	
114	
	
Livingstone	MBE	and	Black	AE	(2003)	Markers	of	the	validity	of	reported	energy	intake.	The	
Journal	of	nutrition	133	Suppl	:	895S–920S.	
Lopez	LM,	Edelman	A,	Chen-Mok	M,	Trussell	 J	and	Helmerhorst	FM	(2011)	Progestin-only	
contraceptives:	 effects	 on	 weight.	 The	 Cochrane	 database	 of	 systematic	 reviews	 (4):	
CD008815.	
Lu	 YC,	 Bentley	GR,	 Gann	 PH,	 Hodges	 KR	 and	 Chatterton	 RT	 (1999)	 Salivary	 estradiol	 and	
progesterone	 levels	 in	 conception	 and	 nonconception	 cycles	 in	 women:	 Evaluation	 of	 a	
new	assay	for	salivary	estradiol.	Fertility	and	Sterility	71(5):	863–868.	
Lundberg	 K,	 Hilke	 S,	 Nordin	 C,	 Theodorsson	 E	 and	 Josefsson	 A	 (2010)	 Cholecystokinin	 in	
plasma	 and	 cerebrospinal	 fluid--a	 study	 in	 healthy	 young	women.	 Peptides	 31(8):	 1625–
1628.	
Lynch	NA,	Ryan	AS,	Berman	DM,	Sorkin	 JD	and	Nicklas	BJ	 (2002)	Comparison	of	VO2max	
and	 disease	 risk	 factors	 between	 perimenopausal	 and	 postmenopausal	 women.	
Menopause	9(6):	456–62.	
Lyons	PM,	Truswell	AS,	Mira	M,	Vizzard	J	and	Abraham	SF	(1989)	Reduction	of	food	intake	
in	 the	 ovulatory	 phase	 of	 the	menstrual	 cycle.	 The	 American	 journal	 of	 clinical	 nutrition	
49(6):	1164–8.	
Malagelada	 J-R	 and	Azpiroz	 F	 (2010)	Determinants	 of	 gastric	 emptying	 and	 transit	 in	 the	
small	intestine.	Hoboken,	NJ,	USA:	John	Wiley	&	Sons,	Inc.	
Mantzoros	CS,	Magkos	F,	Brinkoetter	M,	Sienkiewicz	E,	Dardeno	TA,	Kim	S-Y,	Hamnvik	O-PR	
and	Koniaris	A	(2011)	Leptin	in	human	physiology	and	pathophysiology.	American	journal	of	
physiology.	Endocrinology	and	metabolism	301(4):	E567–84.	
Margetic	S,	Gazzola	C,	Pegg	GG	and	Hill	RA	(2002)	Leptin:	a	review	of	its	peripheral	actions	
and	 interactions.	 International	 journal	of	obesity	and	related	metabolic	disorders :	 journal	
of	the	International	Association	for	the	Study	of	Obesity	26(11):	1407–33.	
Matsuo	 T,	 Saitoh	 S	 and	 Suzuki	 M	 (1998)	 Resting	 metabolic	 rate	 and	 diet-induced	
thermogenesis	during	each	phase	of	the	menstrual	cycle	in	healthy	young	women.	Journal	
of	clinical	biochemistry	and	nutrition	25(2):	97–107.	
Matsuo	 T,	 Saitoh	 S	 and	 Suzuki	 M	 (1999)	 Effects	 of	 the	 menstrual	 cycle	 on	 excess	
postexercise	oxygen	consumption	in	healthy	young	women.	Metabolism	48(3):	275–277.	
Mauras	N,	Hayes	V,	Welch	S,	Rini	A,	Helgeson	K,	Dokler	M,	Veldhuis	JD	and	Urban	RJ	(1998)	
Testosterone	deficiency	 in	young	men:	marked	alterations	 in	whole	body	protein	kinetics,	
strength,	and	adiposity.	The	Journal	of	clinical	endocrinology	and	metabolism	83(6):	1886–
92.	
Mauvais-Jarvis	F,	Clegg	DJ	and	Hevener	AL	(2013)	The	role	of	estrogens	in	control	of	energy	
balance	and	glucose	homeostasis.	Endocrine	reviews	34(3):	309–38.	
McNeil	 J	 and	 Doucet	 É	 (2012)	 Possible	 factors	 for	 altered	 energy	 balance	 across	 the	
menstrual	 cycle:	a	closer	 look	at	 the	severity	of	PMS,	 reward	driven	behaviors	and	 leptin	
variations.	European	journal	of	obstetrics,	gynecology,	and	reproductive	biology	163(1):	5–
10.	
McNeill	G,	Bruce	AC,	Ralph	A	and	 James	WP	 (1988)	 Inter-individual	differences	 in	 fasting	
	 References	
	
115	
	
nutrient	 oxidation	 and	 the	 influence	 of	 diet	 composition.	 International	 journal	 of	 obesity	
12(5):	455–63.	
Meijer	G	and	Westerterp	K	(1992)	Sleeping	metabolic	rate	in	relation	to	body	composition	
and	the	menstrual	cycle.	The	American	journal	of	clinical	nutrition.	
Melzer	K	(2011)	Carbohydrate	and	fat	utilization	during	rest	and	physical	activity.	e-SPEN,	
the	European	e-Journal	of	Clinical	Nutrition	and	Metabolism.	Elsevier	6(2):	e45–e52.	
Messini	 CI,	Dafopoulos	K,	Malandri	M,	Georgoulias	P,	Anifandis	G	and	Messinis	 IE	 (2013)	
Growth	hormone	response	to	submaximal	doses	of	ghrelin	remains	unchanged	during	the	
follicular	phase	of	the	cycle.	Reproductive	biology	and	endocrinology	11:	36.	
Moghissi	 KS	 (1976)	 Accuracy	 of	 basal	 body	 temperature	 for	 ovulation	 detection.	 Fertility	
and	sterility	27(12):	1415–21.	
Monés	J,	Carrió	I,	Calabuig	R,	Estorch	M,	Sainz	S,	Berná	L	and	Vilardell	F	(1993)	Influence	of	
the	menstrual	 cycle	 and	 of	menopause	 on	 the	 gastric	 emptying	 rate	 of	 solids	 in	 female	
volunteers.	European	Journal	of	Nuclear	Medicine	20(7).	
Monga	 AK	 and	 Dobbs	 SP	 (2011)	Gynaecology	 by	 ten	 teachers	 by	Monga,	 Ash	 K,	 Dobbs,	
Stephen	P	(19th	edition).	Taylor	&	Francis	Group.	
Moschos	S,	Chan	J	and	Mantzoros	C	(2002)	Leptin	and	reproduction:	a	review.	Fertility	and	
sterility	77(3).	
Mozaffarian	D,	Hao	T,	Rimm	EB,	Willett	WC	and	Hu	FB	(2011)	Changes	in	diet	and	lifestyle	
and	 long-term	 weight	 gain	 in	 women	 and	 men.	 The	 New	 England	 journal	 of	 medicine	
364(25):	2392–404.	
Näslund	 E	 and	 Hellström	 PM	 (2013)	 Satiation,	 Satiety	 and	 the	 Control	 of	 Food	 Intake.	
Satiation,	Satiety	and	the	Control	of	Food	Intake.	Elsevier.	
Natalucci	 G,	 Riedl	 S,	 Gleiss	 A,	 Zidek	 T	 and	 Frisch	 H	 (2005)	 Spontaneous	 24-h	 ghrelin	
secretion	 pattern	 in	 fasting	 subjects:	 maintenance	 of	 a	 meal-related	 pattern.	 European	
journal	of	endocrinology	152(6):	845–50.	
Nelson	 KM,	 Weinsier	 RL,	 Long	 CL	 and	 Schutz	 Y	 (1992)	 Prediction	 of	 resting	 energy	
expenditure	 from	 fat-free	 mass	 and	 fat	 mass.	 The	 American	 journal	 of	 clinical	 nutrition	
56(5):	848–856.	
Nieuwenhuizen	 AG,	 Hochstenbach-Waelen	 A,	 Veldhorst	 MAB,	 Westerterp	 KR,	 Engelen	
MPKJ,	 Brummer	 R-JM,	 Deutz	 NEP	 and	Westerterp-Plantenga	MS	 (2009)	 Acute	 effects	 of	
breakfasts	containing	alpha-lactalbumin,	or	gelatin	with	or	without	added	 tryptophan,	on	
hunger,	‘satiety’	hormones	and	amino	acid	profiles.	The	British	journal	of	nutrition	101(12):	
1859–66.	
Onaga	T,	Zabielski	R	and	Kato	S	 (2002)	Multiple	 regulation	of	peptide	YY	 secretion	 in	 the	
digestive	tract.	Peptides	23(2):	279–290.	
Pannacciulli	 N,	 Bunt	 JC,	 Koska	 J,	 Bogardus	 C	 and	 Krakoff	 J	 (2006)	 Higher	 fasting	 plasma	
concentrations	 of	 glucagon-like	 peptide	 1	 are	 associated	 with	 higher	 resting	 energy	
expenditure	 and	 fat	 oxidation	 rates	 in	 humans.	The	American	 journal	 of	 clinical	 nutrition	
84(3):	556–60.	
	 References	
	
116	
	
Papadimitriou	 MA,	 Krzemien	 AA,	 Hahn	 PM	 and	 Van	 Vugt	 DA	 (2007)	 Peptide	 YY(3-36)-
induced	inhibition	of	food	intake	in	female	monkeys.	Brain	research	1175:	60–5.	
Pasman	WJ,	Heimerikx	J,	Rubingh	CM,	van	den	Berg	R,	O’Shea	M,	Gambelli	L,	Hendriks	HFJ,	
Einerhand	AWC,	Scott	C,	Keizer	HG	and	Mennen	LI	(2008)	The	effect	of	Korean	pine	nut	oil	
on	 in	vitro	CCK	release,	on	appetite	sensations	and	on	gut	hormones	 in	post-menopausal	
overweight	women.	Lipids	in	health	and	disease	7:	10.	
Payne	PR	and	Waterlow	JC	(1971)	Relative	energy	requirements	for	maintenance,	growth,	
and	physical	activity.	The	Lancet	298(7717):	210–211.	
Pelkman	 CL,	 Chow	 M,	 Heinbach	 R	 a	 and	 Rolls	 BJ	 (2001)	 Short-term	 effects	 of	 a	
progestational	 contraceptive	 drug	 on	 food	 intake,	 resting	 energy	 expenditure,	 and	 body	
weight	in	young	women.	The	American	journal	of	clinical	nutrition	73(1):	19–26.	
Van	 Pelt	 RE,	 Jones	 PP,	 Davy	 KP,	 Desouza	 CA,	 Tanaka	 H,	 Davy	 BM	 and	 Seals	 DR	 (1997)	
Regular	 exercise	 and	 the	 age-related	 decline	 in	 resting	 metabolic	 rate	 in	 women.	 The	
Journal	of	clinical	endocrinology	and	metabolism	82(10):	3208–12.	
Perri	 F,	 Pastore	 MR	 and	 Annese	 V	 (2006)	 13C-octanoic	 acid	 breath	 test	 for	 measuring	
gastric	emptying	of	solids.	European	review	for	medical	and	pharmacological	 sciences	9(5	
Suppl	1):	3–8.	
Piers	 LS,	 Diggavi	 SN,	 Rijskamp	 J,	 van	 Raaij	 JM,	 Shetty	 PS	 and	Hautvast	 JG	 (1995)	 Resting	
metabolic	 rate	 and	 thermic	 effect	 of	 a	 meal	 in	 the	 follicular	 and	 luteal	 phases	 of	 the	
menstrual	cycle	in	well-nourished	Indian	women.	The	American	journal	of	clinical	nutrition	
61(2):	296–302.	
PubChem	 (	 (n.d.))	 Octanoic	 acid.	 .	 Available	 at:	
http://pubchem.ncbi.nlm.nih.gov/compound/octanoic_acid#section=Top	 (accessed	
17/09/15).	
R&D	Systems	(	(n.d.))	ELISA	Development	Guide.	.	
Ravussin	E,	Burnand	B,	Schutz	Y	and	Jéquier	E	(1982)	Twenty-four-hour	energy	expenditure	
and	resting	metabolic	rate	in	obese,	moderately	obese,	and	control	subjects.	The	American	
journal	of	clinical	nutrition	35(3):	566–73.	
Riad-Gabriel	M,	Jinagouda	S,	Sharma	A,	Boyadjian	R	and	Saad	M	(1998)	Changes	in	plasma	
leptin	during	the	menstrual	cycle.	European	Journal	of	Endocrinology	139(5):	528–531.	
Roche	(2009a)	Elecys	Oestradiol	II	Cobas	-	3000079122	(V	15.).	.	
Roche	(2009b)	Elecys	Progesterone	II	Cobas	-	12145383122	(V	12.).	.	
Rosenbaum	M	and	Leibel	RL	(2014)	20	years	of	leptin:	role	of	leptin	in	energy	homeostasis	
in	humans.	The	Journal	of	endocrinology	223(1):	T83–96.	
Rothman	MS,	 Carlson	NE,	 Xu	M,	Wang	C,	 Swerdloff	 R,	 Lee	 P,	Goh	VHH,	 Ridgway	 EC	 and	
Wierman	 ME	 (2011)	 Reexamination	 of	 testosterone,	 dihydrotestosterone,	 estradiol	 and	
estrone	 levels	 across	 the	 menstrual	 cycle	 and	 in	 postmenopausal	 women	 measured	 by	
liquid	chromatography-tandem	mass	spectrometry.	Steroids	76(1-2):	177–82.	
Salimetrics	 (2008)	 Collecting	 unstimulated	 whole	 saliva	 samples	 by	 passive	 drool	 from	
human	subjects	(ages	5+).	USA.	
	 References	
	
117	
	
Salimetrics	(2012a)	Salivary	17β-Estradiol	Enzyme	Immunoassay	Kit	(Item	No.	1-3702).	.	
Salimetrics	 (2012b)	 Salivary	 Progesterone	 Enzyme	 Immunoassay	 Kit	 (Item	 No.	 1-1502).	
Suffolk,	UK.	
Schommartz	B,	Ziegler	D	and	Schadewaldt	P	(1997)	Significance	of	diagnostic	parameters	in	
[(13)c]octanoic	 Acid	 gastric	 emptying	 breath	 tests.	 Isotopes	 in	 environmental	 and	 health	
studies.	Taylor	&	Francis	Group	33(1-2):	135–43.	
Schultheiss	 OC,	 Dargel	 A	 and	 Rohde	 W	 (2003)	 Implicit	 motives	 and	 gonadal	 steroid	
hormones:	effects	of	menstrual	cycle	phase,	oral	contraceptive	use,	and	relationship	status.	
Hormones	and	Behavior	43(2):	293–301.	
Schwartz	MW,	Woods	SC,	Porte	D,	Seeley	RJ	and	Baskin	DG	(2000)	Central	nervous	system	
control	of	food	intake.	Nature	404(6778):	661–71.	
Shi	 H,	 Seeley	 RJ	 and	 Clegg	 DJ	 (2009)	 Sexual	 differences	 in	 the	 control	 of	 energy	
homeostasis.	Frontiers	in	neuroendocrinology.	Elsevier	Inc.	30(3):	396–404.	
Shreeve	 WW,	 Cerasi	 E	 and	 Luft	 R	 (1970)	 Metabolism	 of	 [2-14c]	 pyruvate	 in	 normal,	
acromegalic	 and	 HGH-treated	 human	 subjects.	 European	 Journal	 of	 Endocrinology	 65(1):	
155–169.	
Sino	 Biological	 Inc.	 (	 (n.d.))	 Competitive	 ELISA:	 Basic	 principles.	 .	 Available	 at:	
http://www.elisa-antibody.com/ELISA-Introduction/ELISA-types/competitive-elisa	
(accessed	13/10/15).	
Smolin	LA	and	Grosvenor	MB	(1994)	Nutrition:	science	and	applications.	Saunders	College	
Publishing.	
Soares	MJ	and	Shetty	PS	(1987)	Long-term	stability	of	metabolic	rates	in	young	adult	males.	
Human	nutrition.	Clinical	nutrition	41(4):	287–90.	
Solomon	S,	Kurzer	M	and	Calloway	D	 (1982)	Menstrual	 cycle	and	basal	metabolic	 rate	 in	
women.	The	American	journal	of	clinical	nutrition	36(4):	611–616.	
Speakman	 JR	 and	Westerterp	 KR	 (2010)	 Associations	 between	 energy	 demands,	 physical	
activity,	and	body	composition	in	adult	humans	between	18	and	96	y	of	age.	The	American	
journal	of	clinical	nutrition	92(4):	826–34.	
St-Onge	M,	Mignault	 D,	 Allison	 DB	 and	 Rabasa-Lhoret	 R	 (2007)	 Evaluation	 of	 a	 portable	
device	to	measure	daily	energy	expenditure	in	free-living	adults.	Am	J	Clin	Nutr	85(3):	742–
749.	
Steiner	M,	Macdougall	M	and	Brown	E	(2003)	The	premenstrual	symptoms	screening	tool	
(PSST)	for	clinicians.	Archives	of	Women’s	Mental	Health	6(3):	203–209.	
Stewart	AA,	Marfell-Jones	M	and	Olds	T	(2011)	International	standards	for	anthropometric	
assessment.	 Lower	 Hutt,	 New	 Zealand:	 International	 Society	 for	 the	 Advancement	 of	
Kinanthropometry.	
Stoeckel	LE,	Weller	RE,	Giddings	M	and	Cox	JE	(2008)	Peptide	YY	levels	are	associated	with	
appetite	suppression	 in	response	to	 long-chain	fatty	acids.	Physiology	&	behavior	93(1-2):	
289–95.	
van	 Strien	 T,	 Frijters	 JER,	 Bergers	GPA	 and	Defares	 PB	 (1986)	 The	Dutch	 Eating	 Behavior	
	 References	
	
118	
	
Questionnaire	 (DEBQ)	 for	 assessment	 of	 restrained,	 emotional,	 and	 external	 eating	
behavior.	International	Journal	of	Eating	Disorders	5(2):	295–315.	
Stubbs	RJ,	Johnstone	AM,	O’Reilly	LM	and	Poppitt	SD	(1998)	Methodological	issues	relating	
to	 the	 measurement	 of	 food,	 energy	 and	 nutrient	 intake	 in	 human	 laboratory-based	
studies.	The	Proceedings	of	the	Nutrition	Society	57(3):	357–72.	
Stunkard	AJ	and	Messick	S	(1985)	The	three-factor	eating	questionnaire	to	measure	dietary	
restraint,	disinhibition	and	hunger.	Journal	of	Psychosomatic	Research	29(1):	71–83.	
Suh	 S-H,	 Casazza	 GA,	 Horning	 MA,	 Miller	 BF	 and	 Brooks	 GA	 (2003)	 Effects	 of	 oral	
contraceptives	 on	 glucose	 flux	 and	 substrate	 oxidation	 rates	 during	 rest	 and	 exercise.	
Journal	of	applied	physiology	94(1):	285–94.	
Tenovuo	JO	(1989)	Human	Saliva,	Volumen	2.	USA:	CRC	Press,	Inc.	
Tschop	 M,	 Weyer	 C,	 Tataranni	 PA,	 Devanarayan	 V,	 Ravussin	 E	 and	 Heiman	 ML	 (2001)	
Circulating	ghrelin	levels	are	decreased	in	human	obesity.	Diabetes	50(4):	707–709.	
Uvnäs-Msoberg	K,	Sjögren	C,	Westlin	L,	Anderson	PO	and	Stock	S	(1989)	Plasma	Levels	of	
Gastrin,	 Somatostatin,	 VIP,	 Insulin	 and	 Oxytocin	 During	 the	 Menstrual	 Cycle	 in	 Women	
(With	 and	 Without	 Oral	 Contraceptives).	 Acta	 Obstetricia	 et	 Gynecologica	 Scandinavica	
68(2):	165–169.	
de	Vries	J,	Zock	P,	Mensink	R	and	Katan	M	(1994)	Underestimation	of	energy	intake	by	3-d	
records	compared	with	energy	intake	to	maintain	body	weight	in	269	nonobese	adults.	Am	
J	Clin	Nutr	60(6):	855–860.	
Van	Vugt	D	 a	 (2010)	 Brain	 imaging	 studies	 of	 appetite	 in	 the	 context	 of	 obesity	 and	 the	
menstrual	cycle.	Human	reproduction	update	16(3):	276–92.	
Walker	RF,	Read	GF	and	Riad-fahmy	D	(1979)	Radioimmunoassay	of	Progesterone	in	Saliva :	
Application	to	the	Assessment	of	Ovarian	Function.	2033:	2030–2033.	
Wallace	M,	Hashim	YZH-Y,	Wingfield	M,	Culliton	M,	McAuliffe	F,	Gibney	MJ	and	Brennan	L	
(2010)	Effects	of	menstrual	cycle	phase	on	metabolomic	profiles	in	premenopausal	women.	
Human	reproduction	(Oxford,	England)	25(4):	949–56.	
Wang	 Z,	 Heshka	 S,	 Zhang	 K,	 Boozer	 CN	 and	 Heymsfield	 SB	 (2001)	 Resting	 energy	
expenditure:	systematic	organization	and	critique	of	prediction	methods.	Obesity	research	
9(5):	331–6.	
Webb	P	(1986)	24-hour	energy	expenditure	and	the	menstrual	cycle.	The	American	journal	
of	clinical	nutrition	44(5):	614–9.	
Weijs	 PJM	 and	 Vansant	 GAAM	 (2010)	 Validity	 of	 predictive	 equations	 for	 resting	 energy	
expenditure	 in	 Belgian	 normal	 weight	 to	 morbid	 obese	 women.	 Clinical	 nutrition	
(Edinburgh,	Scotland)	29(3):	347–51.	
Weir	JB	de	V.	(1949)	New	methods	for	calculating	metabolic	rate	with	special	reference	to	
protein	metabolism.	The	Journal	of	physiology	109(1-2):	1–9.	
WHO	(2015)	Obesity	and	overweight.	World	Health	Organization.	
Willett	W	(2012)	Nutritional	Epidemiology.	.	
	 References	
	
119	
	
Worthman	 CM,	 Stallings	 JF	 and	 Hofman	 LF	 (1990)	 Sensitive	 salivary	 estradiol	 assay	 for	
monitoring	ovarian	function.	Clinical	Chemistry	36(10):	1769–1773.	
Yach	D,	Stuckler	D	and	Brownell	KD	 (2006)	Epidemiologic	and	economic	consequences	of	
the	 global	 epidemics	 of	 obesity	 and	 diabetes.	Nature	medicine.	 Nature	 Publishing	Group	
12(1):	62–6.	
Yin	 X,	 Li	 Y,	 Xu	 G,	 An	 W	 and	 Zhang	 W	 (2009)	 Ghrelin	 fluctuation,	 what	 determines	 its	
production?	Acta	Biochimica	et	Biophysica	Sinica	41(3):	188–197.	
Zimmerman	 Y,	 Eijkemans	MJC,	 Coelingh	Bennink	HJT,	 Blankenstein	MA	and	 Fauser	 BCJM	
(2014)	The	effect	of	combined	oral	contraception	on	testosterone	levels	in	healthy	women:	
a	systematic	review	and	meta-analysis.	Human	reproduction	update	20(1):	76–105.	
	 Appendices	
	
120	
	
Appendices	
• UREC	Ethical	approvals	
• Consent	forms	
• Participant	information	sheets	
• Screening	questionnaires	
• Life-style	questionnaire	(includes:	PAQ,	PSST,	TFEQ	FI,	DEBQ)	
• VAS	
• 3-day	food	diary	

 
Dr Helen Lightowler 
Director of Studies 
Department of Sport and Health Sciences 
Faculty of Health and Life Sciences 
Oxford Brookes University 
Gipsy Lane 
Headington 
 
16 October 2014 
 
Dear Dr Lightowler 
 
UREC Registration No: 140854 
Appetite hormone response in different phases on the menstrual cycle 
 
Thank you for the email of 14 October 2014 outlining your response to the points raised in my previous letter about 
the PhD study of your research student Marta Campolier, and attaching the revised documents. I am pleased to 
inform you that, on this basis, I have given Chair’s Approval for the study to begin.   
 
The UREC approval period for this study is two years from the date of this letter, so 16 October 2016. If you need 
the approval to be extended please do contact me nearer the time of expiry. 
 
Should the recruitment, methodology or data storage change from your original plans, or should any study 
participants experience adverse physical, psychological, social, legal or economic effects from the research, please 
inform me with full details as soon as possible. 
 
Yours sincerely 
 
 
 
 
Hazel Abbott 
Chair of the University Research Ethics Committee 
 
cc   Dr Sangeetha Thondre, Co-investigator 
       Marta Campolier, Research Student 
       Dido Green, Research Ethics Officer 
       Jill Organ, Research Degrees Team 
       Louise Wood, UREC Administrator 
UNIVERSITY RESEARCH ETHICS 
COMMITTEE, FACULTY OF HEALTH AND 
LIFE SCIENCES 
 
Headington Campus   Gipsy Lane 
Oxford   OX3 0BP   UK 
 
Tel: 01865 482639 
heabbott@brookes.ac.uk 
 
CONSENT FORM 
 
Resting metabolic rate and hormone levels in saliva and blood during the 
different phases of the menstrual cycle 
 
 
Marta Campolier (PhD researcher) 
Department of Sport and Health Sciences 
Faculty of Health and Life Sciences 
Oxford Brookes University 
Gipsy Lane Campus 
Headington 
Oxford OX3 0BP 
marta.campolier-2012@brookes.ac.uk 
 
 
 
 Please initial box 
I confirm that I have read and understand the information sheet for the above 
research project and have had the opportunity to ask questions. 
 
 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving reason. 
 
 
I agree to take part in the above study. 
 
 
 
 
I understand that my data gathered in this study may be stored (after it has 
been anonymised) in a specialist data centre and may be used for future 
research. 
 
 
 
 
. 
 
 
Name of Participant Date Signature 
 
 
 
 
Name of Researcher Date Signature 
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Mrs Marta Campolier 
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S4.07 Functional Food Centre 
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Gipsy Lane, Oxford 
OX3 0BP 
marta.campolier-
2012@brookes.ac.uk 
Phone: +44 1865 48 3283 
 
Dr Helen Lightowler 
Senior Lecturer 
S4.06a Functional Food Centre 
School of Life Sciences 
Oxford Brookes University 
Gipsy Lane, Oxford 
OX3 0BP 
 
hlightowler@brookes.ac.uk 
Phone: +44 1865 48 3245 
 
Dr P Sangeetha Thondre  
Research Fellow 
S4.06a Functional Food Centre 
School of Life Sciences 
Oxford Brookes University 
Gipsy Lane, Oxford 
OX3 0BP 
 
pthondre@brookes.ac.uk 
Phone: +44 1865 48 3988 
 
 
 
 
 
 Please initial box 
I confirm that I have read and understand the information sheet for the above 
research project and have had the opportunity to ask questions. 
 
 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving reason. 
 
 
I agree to take part in the above study. 
 
 
 
 
I understand that my data gathered in this study may be stored (after it has 
been anonymised) in a specialist data centre and may be used for future 
research. 
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Department of Sport and Health Sciences 
Oxford Brookes University, Gipsy Lane, Oxford, OX3 0BP, UK 
 
Marta Campolier  
Email: marta.campolier-2012@brookes.ac.uk   Phone: +44 (0) 1865 48 3283 
 
INFORMATION SHEET 
 
Full title of Project: Resting metabolic rate and hormone levels in saliva and blood during 
different phases of the menstrual cycle 
 
You are being invited to take part in a research study. Before you decide whether or not to 
take part, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. 
 
What is the purpose of the study? 
Energy balance (energy input = energy output) is key to maintaining body weight. In 
contrast, continuous imbalances between what is ingested and “burnt” can induce changes 
in weight and body composition. Resting metabolic rate (RMR) is the most important 
component of total energy expenditure. Differences in RMR account for several features e.g. 
age, gender and body mass index (BMI). While there is a low variation in RMR in men, 
previous studies have shown wide differences in the variation in RMR in women during the 
menstrual cycle. These differences may be due to changes in estrogen and progesterone 
levels during the menstrual cycle. However, limited studies have monitored RMR and 
hormone levels during the menstrual cycle to fully describe this phenomenon. 
 
Although overweight and obese women have shown to have a higher RMR than lean 
counterparts, there are no data on RMR throughout phases of the menstrual cycle 
specifically in this population. Similarly, the use of hormonal contraceptives (HC) and their 
potential effects on energy metabolism are still ambiguous.  
 
Although blood collection has been usually used in research for measuring hormone levels, 
saliva samples have become more common to measure and monitor levels of hormones 
such as cortisol and sex steroids due to being non-invasive, stress-free and easy to collect 
and store. Although saliva levels have been shown to compare well with hormone levels 
measured in blood, the ratio between the two specimens seems to be altered between 
individuals and phases of the menstrual cycle; therefore further research is required.  
 
The aim of this study is to investigate RMR along with ovarian hormone levels during the 
different phases of the menstrual cycle in healthy women.        
 
Why have I been invited to participate? 
We are inviting healthy women volunteers: 
x Aged 18-40 years 
x With a regular (i.e. cycle length of 25-35 days) and natural or artificial (i.e. induced by 
hormonal contraceptives) menstrual cycle 
x Not pregnant or lactating 
x Not having any metabolic/genetic diseases or taking any medications known to interfere 
with metabolism 
 
Should you agree to participate, and after signing consent, you will then be asked to 
complete a basic health questionnaire to make sure that you are eligible to participate in the 
study.  
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Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason. If you are a 
student by choosing to either take part or not take part in the study or to withdraw at any time 
will have no impact on your marks, assessments or future studies. 
 
What will happen to me if I take part? 
After reading this information sheet, we will discuss any queries you may have about the 
study. Should you then agree to participate, you will be asked to sign a consent form to 
participate. On an agreed day, you will be asked to come to the Functional Food Centre to 
complete a screening questionnaire that will give us an indication of your health status, the 
characteristics of your period and whether you are on any medication that may affect the 
parameters that we are measuring, thus showing us whether you are eligible for our study.  
 
The general body health profile and menstrual cycle characteristics is for screening 
purposes only and is not a health check; however this information will be shared with you.  
The research team may recommend that you see your GP if the information indicates 
anything unusual about the information collected. They will not be expressing a medical 
opinion but are indicating that it may be advisable to have a health check with your GP.   
  
Following this screening, if you are eligible to participate we will arrange for you to come to 
the Functional Food Centre in the mornings for the testing days between 7-10am depending 
on your convenience. 
 
On the evening before each test day, you will be asked to avoid: 
x the consumption of caffeine, alcohol and nicotine 
x unusual strenuous exercise that you would not usually undertake as part of your 
normal ‘daily lifestyle’. 
You will also have to fast overnight (from 10-12 hours before the testing time). 
 
You will be asked to come to the Functional Food Centre three times a week (e.g. Monday, 
Wednesday and Friday) for testing for one complete menstrual cycle for a total of ~12 visits 
(in addition to the initial screening). Optionally, you could participate for an extra menstrual 
cycle later on. 
 
The following measurements will be taken during each test day after having rested for 20-30 
minutes: 
x Resting metabolic rate (RMR) – Energy expenditure will be measured while you are 
lying still under a hood system. The 
hood is see-through plastic, similar 
to a hairdryer hood. An image of it 
can be seen here. The oxygen and 
carbon dioxide in your breath will be 
measured and can be used to 
calculate energy expenditure. You 
will be asked to lie completely still 
during the measurement for 30 
minutes and the average energy 
expenditure will be calculated. 
During this time you can listen to music or watch DVDs on a laptop. 
 
x Body composition - Weight and body composition will be measured by a digital scale 
(Tanita). Moreover, on the first testing day height will be assessed. 
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x Saliva hormones – 5 ml of unstimulated saliva will be collected by 
passive drool after having rinsed thoroughly the mouth with water 
10 minutes before the sample is collected. 
 
x Blood hormones – Forearm blood samples will be taken following 
the other tests. Each measurement requires only 6ml of blood, 
therefore we would insert a small needle into a large vein on the 
under side of the elbow (anti-cubital fosse), it has a tube attached to it which means we 
can collect blood. After the measurement the needle will be removed and a cotton wool 
pad will be administered with pressure to prevent any bleeding. All of the procedures will 
be carried out by a fully trained phlebotomist and be observed by another trained 
phlebotomist, in addition a first aider will be present, in order to minimise the risk of pain 
or bleeding, but you should be aware of this risk before deciding to participate. 
 
x Finally on the first testing day in addition to the previously mentioned we will also ask you 
to fill in a life style questionnaire. 
 
What are the possible disadvantages and risks of taking part?  
There are no major risks. The only risks will be sometimes a slight bruising where the blood 
has been taken. That should disappear within days and both arms will be used alternatively 
to minimise the bruising. Moreover, it will not prevent you from doing your regular daily 
activity. Moreover, the participant will be advised to tell any person taking blood in the future 
that they had fainted as a result of the procedure. In case of repeated severe adverse 
effects, the participant will be encouraged to withdraw from the study. 
 
The study is quite time consuming as it consists of health and menstrual profile on the 
preliminary visit as well as the testing days of up to 1½ hours, three times a week during the  
menstrual cycle; however, as outlined above, you can read, listen to music and watch DVDs 
during this time. 
 
What are the possible benefits of taking part? 
After each testing day you will be provided with a free breakfast once the testing procedures 
are completed. You will receive £50 per menstrual cycle in Amazon Vouchers and you will 
also get information from your body composition and menstrual cycle profile. Finally, you will 
also contribute in furthering our understanding on the topic.  
 
Will what I say in this study be kept confidential? 
All information collected about you will be kept strictly confidential (subject to legal 
limitations). Access to the data will be by the researcher working on this study only. Access 
to computer files will be by password only and data and the codes and identifying 
information will be kept in separately in locked filing cabinets. 
 
Data generated by the study must be retained in accordance with the University's policy on 
Academic Integrity. The data generated in the course of the research must be kept securely 
in paper or electronic form for a period of ten years after the completion of a research 
project. Due to the small number of volunteers taking part in this study it may be difficult to 
maintain anonymity of the volunteers as participants may overlap with their sessions. 
However all data will be de-identified. Results from the research would be published in a way 
that looks at the group responses to the questionnaires, so that no individuals would be able 
to be identified or recognised.  
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What should I do if I want to take part? 
If you would like to take part in this research study you can do so by contacting the 
researchers at the address, phone number or email address given below.   
 
What will happen to the results of the research study? 
The results of this research will be published in a research journal. Your name or identity will 
not be recognisable from this. If you wish to obtain a copy of the published research you can 
do so by contacting the researchers at the address, phone number or email address given 
below following completion of the study. Furthermore, a summary of your personal results 
will be available to you, if interested. 
 
Who is organising and funding the research? 
I am conducting the research as a PhD researcher at Oxford Brookes University under the 
supervision of Dr Helen Lightowler and Dr Sangeetha Thondre. This research is being 
completed and funded by the Faculty of Health and Life Science at Oxford Brookes 
University.  
 
Who has reviewed the study? 
This research has been approved by the University Research Ethics Committee at Oxford 
Brookes University. 
 
Contact for Further Information 
Miss Marta Campolier 
PhD Researcher 
S4.07 Functional Food Centre 
School of Life Sciences 
Oxford Brookes University 
Gipsy Lane, Oxford 
OX3 0BP 
marta.campolier-
2012@brookes.ac.uk 
Phone: +44 1865 48 3283 
 
Dr Helen Lightowler 
Senior Lecturer 
S4.06a Functional Food Centre 
School of Life Sciences 
Oxford Brookes University 
Gipsy Lane, Oxford 
OX3 0BP 
 
hlightowler@brookes.ac.uk 
Phone: +44 1865 48 3245 
 
Dr P Sangeetha Thondre  
Research Fellow 
S4.07 Functional Food Centre 
School of Life Sciences 
Oxford Brookes University 
Gipsy Lane, Oxford 
OX3 0BP 
 
pthondre@brookes.ac.uk 
Phone: +44 1865 48 3988 
If you have any concerns about the way in which the study has been conducted, you should 
contact the Chair of the University Research Ethics Committee on ethics@brookes.ac.uk. 
 
 
Thank you for taking time to read this information sheet. 
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Functional Food Centre 
Department of Sport and Health Sciences 
Oxford Brookes University, Gipsy Lane, Oxford, OX3 0BP, UK 
 
Marta Campolier Email: marta.campolier-2012@brookes.ac.uk Phone: +44 (0) 1865 483283 
 
INFORMATION SHEET 
 
Full title of Project: Appetite hormone response in different phases of the menstrual cycle 
 
You are being invited to take part in a research study. Before you decide whether or not to take part, it 
is important for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully. 
 
What is the purpose of the study? 
Energy balance (energy input = energy output) is key to maintaining body weight. In contrast, 
continuous imbalances between what is ingested and “burnt” can induce changes in weight and body 
composition.  
 
We have observed that some women show modest changes in their energy expenditure, across their 
menstrual cycle. Moreover, previous research has shown that women might also display different food 
patterns amongst phases of the menstrual cycle. Nevertheless, little is known regarding what is 
underpinning these changes. Although the cyclical variations in the sex hormones estrogen and 
progesterone have been claimed to be responsible for these changes in both sites of the energy 
balance equation, how these can ultimately induce modifications in the energy consumed and 
expended still unknown. 
 
Although there are few reports looking at appetite hormones in a fasted state throughout the 
menstrual cycle, how these may respond to the same breakfast in the different menstrual cycle 
phases is still uncertain. Previous studies have observed that changes in the emptying rate of foods in 
the stomach might also be related to changes in appetite hormones.  
 
The aim of this study is to investigate whether appetite hormones and feelings of hunger change at 
the different phases of the menstrual cycle in healthy women.        
 
Why have I been invited to participate? 
We are inviting healthy women volunteers: 
x Aged 18-40 years 
x With a body mass index (BMI) between 18-30 kg/m2   
x With regular (i.e. cycle length of 25-35 days) and natural (i.e. not taking hormonal contraceptives) 
menstrual cycles 
x Not pregnant or lactating 
x Not anaemic  
x Not having any metabolic/genetic diseases or taking any medications known to interfere with 
metabolism or appetite 
x Not suffering from any eating disorders 
x Not following any diet with the attempt to lose weight 
x Non-smoking 
x Not highly physically active i.e. training more than 5 hours a week, and involved in endurance 
sports at competitive levels 
x Not allergic/intolerant to any of the foods presented in the study 
x Habitually consume breakfast and lunch 
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Should you agree to participate, and after signing the consent form, you wil be asked to complete a 
health questionnaire to make sure that you are eligible to participate in the study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you wil be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part you are stil 
free to  withdraw  at any time and  without giving a reason. If  you are  a student  by  choosing to  either 
take part or not take part in the study or to withdraw at any time wil have no impact on your marks, 
assessments or future studies. If you are a member of staf by choosing to take or not to take part in 
the study or to withdraw at any time wil have no impact on your employment status at the university. 
 
What wil happen to me if I take part? 
After reading this information  sheet  and  having  had  at least  24  hours for  you to  consider  your 
participation,  we  wil  discuss  any  queries  you  may  have  about the  study.  Should  you then  agree to 
participate, you wil be asked to sign a consent form to participate. 
 
On an agreed day, you wil be asked to come to the Functional Food Centre to complete a screening 
and a life style questionnaire with measurements of your body weight that wil give us an indication of 
your  health  status, the  characteristics  of  your  period  and  whether  you  are  on  any  medication  or 
condition that  may  afect the  parameters that  we  are  measuring, thus  showing  us  whether  you  are 
eligible for  our  study.  The  general  body  health  profile  and  menstrual  cycle  characteristics is for 
screening purposes only and is not a health check; however this information wil be shared with you. 
The research team  may recommend that  you  see  your  GP if the information indicates  anything 
unusual  about the information  colected.  They  wil  not  be  expressing  a  medical  opinion  but  are 
indicating that it  may  be  advisable to  have  a  health  check  with  your  GP. If  you  are  eligible to 
participate  we  wil  provide  you  with  a fertility  monitor that  wil  help  us to schedule the  visits to the 
Functional  Food  Centre  according to the  phases  of  your  menstrual  cycle. It is  estimated that this 
screening session wil last up to 1 hour. 
 
For each cycle phase i.e. menstrual, folicular and luteal, three consecutive days according to the 
fertility monitor readings and the usual length of your menstrual cycle (e.g. days 2 to 4, 12 to 14 and 
26 to  28  of  your  cycle for  menstrual, folicular  and luteal  phases, respectively), wil  be  selected in 
which you wil be asked to keep record of your food intake and wear a body monitoring system 
that measures your physical activity. (See example of timeline below) 
 
 Notifications between participant 
& researcher 
Food diary 
Physical Activity monitor 
 
Fertility test 
Testing day at the FFC 
Folicular Phase Luteal Phase Menstrual Phase 
 
+ 
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x Food diary - you will be asked to weigh and record your food intake in a 
food diary; during the screening session, you will be provided with food 
weighing scales to weigh food and beverages and any food waste.  
 
x Body monitoring system (SenseWear®) - this consists of an armband that 
assesses your physical activity throughout the day; you do not need to 
worry about anything else other than wearing it all times except when you 
are in constant contact with water e.g. showering, swimming. During the 
screening session, the SenseWear will be given to you with instructions on 
how to put it on and use. 
 
The visit to the Functional Food Centre will happen on the second of the three selected days in 
each phase and therefore there will be a total of three visits to the lab for testing for this study. On 
these visits you will attend the Functional Food Centre after an overnight fast at any time agreed with 
the researcher between 07:30-09:30 for a total of 5 hours. Each visit will involve the following: 
x Body composition - Weight and body composition will be measured by a digital scale (Tanita). 
Moreover, on the first testing day height will be assessed. 
 
x Breakfast – You will be provided with a standardized breakfast consisting of: two slices of 
wholemeal bread toasted with scrambled eggs, a pot of pineapple and tea/coffee.  
 
x Satiety ratings – Every 15 minutes for the first hour and every 30 minutes for the following four 
hours after the breakfast you will be asked to rate on a scale how hungry you are feeling. 
 
x Gastric emptying – Breath samples for the measurement of gastric emptying will be taken by 
blowing into a small glass tube through a straw every 15 minutes for 4 hours after breakfast. 
Gastric emptying rate will be assessed by the 100 mg of 13C sodium acetate added into your 
breakfast. 13C is a naturally abundant stable isotope of carbon that is completely safe and that is 
regularly used in the food industry as seasoning.  
 
x Appetite hormones response – Forearm blood samples will be taken at 0, 15, 30, 45, 60, 90, 
120, 150,180, 210 and 240 minutes following breakfast. Each measurement requires only 4ml of 
blood (except at minute 0 which will be 6ml), therefore a total of 46ml of blood in 11 samples will 
be collected over 4 hours. This may seem a lot but if you were to donate blood, you would give 
470ml in 10-15min, therefore the amount drawn for this study is minimal and during a longer 
period of time. To do this, we will insert a small needle with a cannula into a large vein of your 
arm and once in place, the needle will be removed so that the only piece left is a small flelxible 
plastic in your arm. a tube will be attached to collect the blood at 
the abovementioned timings. Moreover, there will be minimal 
discomfort because after the insertion of the cannula for the first 
measurement, all further samples do not require the insertion of 
any needle for their collection. All of the procedures will be 
carried out by a fully trained phlebotomist. In addition a first 
aider will be in the area in order to manage any possible 
adverse event.  
 
x Sex hormones – from the first sample drawn before your breakfast, oestrogen and progesterone 
levels will be also measured to confirm the phase of your menstrual cycle. 
 
x Buffet lunch – After the four hours of testing, a buffet lunch will be provided after which you will 
be free to leave. Foods included in the buffet will range from sandwiches, pizza slices, salads, 
yogurts, biscuits and fruit, as well as a range of beverages. 
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Between measurements you will be remain in the lab during the entire testing period and you will be 
allowed to work on your laptop, read or listen to music in a designated area provided for your use. 
Finally, on the evening before each test day, you will be asked to avoid: 
x the consumption of caffeine and alcohol 
x unusual strenuous exercise that you would not usually do as part of your normal ‘daily lifestyle’. 
 
What are the possible disadvantages and risks of taking part?  
There are no potential risks to you associated with the proposed research. You will be carefully 
screened for allergies and intolerances before inclusion in the study. All the foods will be prepared 
under strict hygiene conditions in a well-managed purpose-built test kitchen. The food ingredients will 
be carefully monitored for quality and expiry dates. In case of any allergic reaction to the foodstuffs 
after the testing days, please refer to the NHS or Allergy UK websites given below: 
http://www.nhs.uk/conditions/food-allergy/pages/intro1.aspx  
http://www.allergyuk.org/corporate.aspx or dial Allergy UK helpline at 01322 619898. 
 
The cannulation procedure can feel a bit uncomfortable during the insertion of the cannula however, 
that should not hurt you during the 4 hours that you will be wearing it, nor during the collection of each 
blood sample. In case of an unsuccessful cannulation, the researcher will consider seeking 
assistance/advice from a more experienced member of staff. No more than a total of four attempts will 
be made and only with your full consent before each attempt. In case of having fainted during the 
procedure, you will be advised to tell the person taking blood in the future and if repeated adverse 
effects occur you will be encouraged to withdraw from the study. Hygiene and good practice 
guidelines will be followed at all times to reduce any little chance of getting your vein infected or 
inflamed. Under the unexpected occurrence of any of these, the cannula will be removed immediately 
and you will be advised to see your GP. 
 
The study is quite time consuming as it consists of health and menstrual profile on the preliminary visit 
as well as the three testing days of up to 5 hours; however, as outlined above, you can read, work on 
your laptop, listen to music and watch DVDs during this time. 
 
What are the possible benefits of taking part? 
For every testing day you will have a free breakfast and lunch. Moreover, you will be able to get 
information about your menstrual cycle and body composition and you will receive £50 Amazon 
Voucher after the completion of the study. Finally, you will also contribute in furthering our 
understanding on the topic.  
 
Will what I say in this study be kept confidential? 
All information collected about you will be kept strictly confidential (subject to legal limitations). Access 
to the data will be by the researcher working on this study only. Access to computer files will be by 
password only and data and the codes and identifying information will be kept in separately in locked 
filing cabinets. 
 
Data generated by the study must be retained in accordance with the University's policy on Academic 
Integrity. The data generated in the course of the research must be kept securely in paper or 
electronic form for a period of ten years after the completion of a research project. Due to the small 
number of volunteers taking part in this study it may be difficult to maintain anonymity of the 
volunteers as participants may overlap with their sessions. However all data will be de-identified, i.e. a 
reversible process in which your name will be removed and replaced by a code that will be used by 
those handling your data. If necessary, it will be possible to link the code to the original identifiers and 
identify your data but these will be kept separately and securely with only access to the researcher. 
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Results from the research would be published in a way that looks at the group responses to the 
questionnaires, so that no individuals would be able to be identified or recognised. Moreover, plasma 
samples stored (after having been anonymised) may be used for future research. 
 
What should I do if I want to take part? 
If you would like to take part in this research study you can do so by contacting the researchers at the 
address, phone number or email address given below.   
 
What will happen to the results of the research study? 
The results of this research will be published in a research journal. Your name or identity will not be 
recognisable from this. If you wish to obtain a copy of the published research you can do so by 
contacting the researchers at the address, phone number or email address given below following 
completion of the study. Furthermore, a summary of your personal results will be available to you, if 
interested. 
 
Who is organising and funding the research? 
I am conducting the research as a PhD researcher at Oxford Brookes University under the 
supervision of Dr Helen Lightowler and Dr Sangeetha Thondre. This research is being completed and 
funded by the Faculty of Health and Life Science at Oxford Brookes University.  
 
Who has reviewed the study? 
This research has been approved by the University Research Ethics Committee at Oxford Brookes 
University. If you have any concerns about the conduct of this research project you can contact the 
Chair of the University Research Ethics Committee at Oxford Brookes University, at the e-mail 
address: ethics@brookes.ac.uk  
 
Contact for Further Information 
Miss Marta Campolier 
PhD Researcher 
S4.07 Functional Food 
Centre 
School of Life Sciences 
Oxford Brookes University 
Gipsy Lane, Oxford 
OX3 0BP 
marta.campolier-
2012@brookes.ac.uk 
Phone: +44 1865 48 3283 
 
Dr Helen Lightowler 
Senior Lecturer 
S4.06a Functional Food 
Centre 
School of Life Sciences 
Oxford Brookes University 
Gipsy Lane, Oxford 
OX3 0BP 
 
hlightowler@brookes.ac.uk 
Phone: +44 1865 48 3245 
 
Dr P Sangeetha Thondre  
Research Fellow 
S4.06a Functional Food 
Centre 
School of Life Sciences 
Oxford Brookes University 
Gipsy Lane, Oxford 
OX3 0BP 
 
pthondre@brookes.ac.uk 
Phone: +44 1865 48 3988 
If you have any concerns about the way in which the study has been conducted, you should contact 
the Chair of the University Research Ethics Committee on ethics@brookes.ac.uk. 
 
 
Thank you for taking time to read this information sheet. 
 
Date: ____ /____ /_______  ID: ______ 
 
Screening Questionnaire 
Please answer all questions with a circle or as appropriate. If you have a problems with this questionnaire 
please ask.  
General Health  
1. When were you born?  _____ / _____ / ______ (DD/MM/YYYY) 
2. Are you allergic to any foods?  Yes  No 
If yes which one(s)? _____________________________________________________________ 
3.    Do you have a genetic or metabolic disease?  Yes   No 
If yes which one(s)? _____________________________________________________________ 
4.    Do you suffer from anaemia?  Yes   No 
5.    Are you taking any medication including herbal?  Yes  No 
    If yes, which one(s)? ______________________________________________________________ 
6.  Are you a smoker?     Yes  No 
    If yes, how many a day? ______cigarettes/day  
 
 
When you have finished please hand back to the researcher. 
THANK YOU FOR YOUR TIME 
------------------------------------------------------------------------------------- ---------------------------------------------------------- 
Official use only 
Breakfast: Cereals                     Bread      Self-provided   
Next expected period:  __________________________    Testing time slot: _____ : _____ 
Menstrual Cycle  
1. What is the average length of your menstrual cycle? (i.e. from beginning of 
one menstruation to the beginning of the next)  
 
________ days 
2. What is the average length of your menstruation? (i.e. bleeding days)  ________ days 
3. Number of days since the start of your last menstruation? ________ days 
4. Have you experienced regular menstrual cycles for the previous 3 cycles? Yes   No 
5. Do you use any hormonal contraceptive?  Yes  No 
If yes, which kind of? (e.g. type, brand) _______________________________________________ 
And for how long have you been using them? _________________________________________ 
6. Have you given birth within the last 2 years?   Yes   No 
If yes, are you still lactating / breastfeeding? 
If not, when did you stop? ___________________ 
Yes  No 
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Date: ____ /____ /_______  ID: ______ 
 
Screening Questionnaire 
Please answer all questions with a circle or as appropriate. If you have a problems with this questionnaire 
please ask.  
General Health  
1. When were you born?  _____ / _____ / ______ (DD/MM/YYYY) 
2. Are you allergic to any foods?  Yes No 
If yes which one(s)? _____________________________________________________________ 
3. Are you following a diet with the aim to put on or lose weight? Yes No 
4. Do you habitually consume breakfast and lunch? Yes No 
5. Do you have a genetic or metabolic disease?  Yes No 
If yes which one(s)? _____________________________________________________________ 
6. Do you suffer from anaemia?  Yes No 
7. Are you taking any medication including herbal?  Yes No 
    If yes, which one(s)? ______________________________________________________________ 
8. Are you a smoker?     Yes No 
  
 
 
When you have finished please hand back to the researcher. 
THANK YOU FOR YOUR TIME 
Menstrual Cycle  
1. What is the average length of your menstrual cycle? (i.e. from beginning of 
one menstruation to the beginning of the next)  
 
________ days 
2. What is the average length of your menstruation? (i.e. bleeding days)  ________ days 
3. What date did your last menstruation start? ____ / ____ / ____ 
4. Have you experienced regular menstrual cycles for the previous 3 cycles? Yes   No 
5. Do you use any hormonal contraceptive?  Yes  No 
6. Have you given birth within the last 2 years?   Yes   No 
If yes, are you still lactating / breastfeeding? 
If not, when did you stop? ___________________ 
Yes  No 
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Body Composition  
Height  
Weight  
Tanita:  
x BMI  
x % Fat Mass  
x Fat Mass (kg)  
x Fat Free Mass  
x Total Body Water  
Waist (cm)  
Hip (cm)  
WHR  
 
Equipment Provided  
Food Scales  
PA Monitor  
Fertility Monitor  
 
Breakfast Details  
Coffee Milk 
Tea Sugar 
Water  
Time  
 
Menstrual Cycle Dates Date Cycle Day  
Start Cycle    
End Menses    
High Phase    
Peak Days    
Testing Days MPh   
 FPh   
 LPh   
End Cycle    
 
Cannula Site  
Screening  
MPh  
FPh  
LPh  
 
P ____  Ph ____ (D ____ _) Date: _____ / _____ / _____   MC – Study 02 
1 
 
0:00 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all 
 
0:15 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all 
      
0:30 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all
(min 0) 
(min 15) 
(min 30) 
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0:45 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all 
 
1:00 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all 
 
1:30 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all 
(min 45) 
(min 60) 
(min 90) 
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2:00 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all 
 
2:30 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all 
 
3:00 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all 
(min 120) 
(min 150) 
(min 180) 
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3:30 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all 
 
4:00 
 
How hungry do you feel? 
 
Not at all hungry                         Extremely hungry 
How full do you feel? 
 
         
 Not at all full               Extremely full 
How strong is your desire to eat?  
 
 
Not at all strong               Extremely strong 
 
         How much food do you think you can eat? 
 
 
A large amount             Nothing at all 
 
 
 
(min 210) 
(min 240) 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Food Diary 
Participant ID:  ____________ 
 
 
Days Recorded: 
 
1.  ______ / ______ / ______  Cycle day:  ______ 
2.  ______ / ______ / ______  Cycle day:  ______ 
3.  ______ / ______ / ______  Cycle day:  ______ 
Food Diary   
 
We would like you to keep a diary of everything you eat and drink over 3 
days. Please read carefuly the instructions below before starting to fil in 
the diary. 
 
It is important to record everything you eat and drink, no matter how 
smal the amount. 
 
 Each day is marked in 6 sections, beginning with the first thing in the 
morning and ending with bedtime. For each part of the day, write down 
al food and drink consumed. If nothing is consumed during a part of the 
day draw a line through that section. 
 
 Give as much information as possible about the foods and drinks you 
eat. It is very useful if you include: 
- Brand name e.g. Branston pickle, 
- How the food was cooked, e.g. baked, griled, raw, etc. 
- Extra ingredients, e.g. teaspoon of grated parmesan on pasta or 
dressings/sauces added to salads 
 
 Estimating the amount eaten: 
- Use the scale provided to record food weights when possible 
- Look at the details on the packaging of some foods 
- Household measures may help; 
- A general recording of whether portions are smal, medium or 
large is also helpful. 
 
 Remembering later is often more dificult than we initialy predict, so it 
is often easier to try to record as you go through the day, where 
possible. 
 
 Please start each day on a new sheet 
 
 See the example on the folowing page 
 
 
 
DATE Day of the week:  
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
___ : ___    
   
   
   
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
07 : 30 
Cornflakes Kellogg’s, Special K 1 Bowl 
Milk Whole (Cravendale) 200 g 
Sugar Siucra 15 g 
   
   
MID-MORNING (between breakfast and lunch) 
Time Food/Drink Description & Preparation Amount 
10 : 45 
Toast White, Warburton’s  1 slice 
 Crusty, thick  
Butter Anchor 50 g 
LUNCH 
Time Food/Drink Description & Preparation Amount 
13 : 30 
Bread roll French style baguette 1 plate 
Butter Anchor 50 g 
Chicken Breast pieces grilled 250 g 
Lettuce Iceberg 30 g 
Tomato Cherry 3 small 
   
Wednesday 1 4 1 2 0 3 
Food Diary   
 
 
DATE Day of the week:  
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
   
   
   
   
   
MID-MORNING (between breakfast and lunch) 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
LUNCH 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
Time Food/Drink Description & Preparation Amount 
 
   
   
   
   
   
   
TEA (between lunch and evening meal) 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
   
   
   
   
   
AFTER EVENING MEAL (between evening meal and bedtime) 
Time Food/Drink Description & Preparation Amount 
___ : ___       
       
Food Diary   
 
  
DATE Day of the week:  
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
   
   
   
   
   
MID-MORNING (between breakfast and lunch) 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
LUNCH 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
   
   
TEA (between lunch and evening meal) 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
   
   
   
   
   
AFTER EVENING MEAL (between evening meal and bedtime) 
Time Food/Drink Description & Preparation Amount 
___ : ___       
       
Food Diary   
 
 
DATE Day of the week:  
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
   
   
   
   
   
MID-MORNING (between breakfast and lunch) 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
LUNCH 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
Time Food/Drink Description & Preparation Amount 
 
   
   
   
   
   
   
TEA (between lunch and evening meal) 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
___ : ___ 
   
   
   
   
   
   
   
   
   
AFTER EVENING MEAL (between evening meal and bedtime) 
Time Food/Drink Description & Preparation Amount 
___ : ___       
       
